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CHAPTER 1
General Introduction
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The ABCs of multidrug resistance in malaria
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MALARIA
Malaria is one of the major global health problems that was estimated to cause 207 million new 
cases and 584.000 casualties in 2014 mainly in children under five in (sub)tropical regions (Figure 
1A)1. These mortality figures are almost exclusively caused by infections with the most virulent 
Plasmodium parasite; Plasmodium falciparum (P. falciparum). This versatile parasite is injected into the 
skin of soon-to-be patients through the bite of an infected female Anopheles mosquito, after which 
sporozoites travel through the bloodstream, and infect liver cells. The liver stage of P. falciparum 
parasites lasts for approximately seven days, during which intracellular multiplication generates 
presumably tens of thousands of merozoites. Bursting of liver cells releases these parasites into the 
blood stream, where they can infect red blood cells. During the red blood cell cycle, newly invaded 
parasites form the typical ring stages that can be observed in the peripheral blood, after which 
they develop into trophozoites and schizonts, that are sequestered in microvasculature of various 
organs2. Fully matured schizonts mostly consist of 14-20 merozoites3, that upon rupturing of the 
infected red blood cell infect new cells. This is the stage of the P. falciparum life cycle that causes 
the well-known malaria symptoms; intermittent high fever, muscle ache, headache, vomiting. Not 
only the steep reduction in red blood cells, which leads to low hematocrite values, but also the 
tendency of infected red blood cells to adhere to endothelium of capillaries, and thereby blocking 
hem, contributes to the severity of the disease4. In case of cerebral malaria, when oxygen supply to 
the brain critically inhibited, surviving patients may suffer from permanent cognitive impairment5. 
During the blood stage cycle, a small proportion of the parasites switch to gametocyte formation. 
Gametocytes, both male and female, can be taken up by a mosquito, and during a short diploid 
stage in which genomic exchange is realized, these gametes form ookinetes that traverse the 
mosquito midgut wall, where the oocysts mature, and after approximately 14 days, sporozoites 
can be detected in the mosquito salivary glands (Figure 1B).
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Figure 1. P. falciparum characteristics. 
A Geographical dissemination of P. falciparum malaria, indicating specifically high incidence in sub-Sahara 
Africa. B Overview of the parasite life cycle, including the vector stage, liver stage, asexual and sexual blood 
stages.
MULTIDRUG RESISTANCE IN MALARIA
During the last few decades, many efforts have been made to create a safe and effective vaccine 
with the objective of malaria eradication; however, the complicated parasite life cycle and unravelled 
immune response mechanisms have been hampering these attempts, and clinical trials of the most 
promising vaccine have not resulted in an efficacy above 65%6,7. The development of a vaccine will 
most likely take many more years, and accessibility for people at risk as well as the efficacy of the 
product will remain a major challenge. In the meantime, conventional treatment of malaria infections 
has become increasingly problematic as resistance against long-term first-line antimalarials such as 
chloroquine, sulfadoxine-pyrimethamine, and mefloquine is broadly spread. Only a limited number of 
effective antimalarials are still available, which has led the World Health Organization to recommend 
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artemisinin-based combination therapies to ensure effective treatment and prevent further resistance 
acquisition. Nonetheless, a long-feared reduced in vivo susceptibility for artemisinin was reported in the 
Thai-Cambodian border and Western Cambodia in 20098, and although the K13-propellor domain was 
identified as a molecular marker9, additional mutations contributing to resistance acquisition remain to 
be identified. In the case of quinoline resistance, active extrusion from the digestive vacuole by a mutated 
chloroquine resistance transporter (PfCRT) gene inhibits accumulation at its target site10. Yet, mutations 
in Pfcrt alone cannot account for the variability in response to chloroquine treatment of different parasite 
clones11. Most likely other mechanisms contribute to resistance acquisition by decreasing drug pressure 
and creating a window for selection of resistant parasites, possibly by increased export of antimalarial 
compounds. Indeed, the ATP-binding cassette (ABC) transporter family member, multidrug resistance 
protein 1 (Pfmdr1), also named P-glycoprotein homologue (Pgh), has been associated with chloroquine 
and artemsinin resistance in vitro12. In the last two decades, many studies have concluded that mutations 
in Pfmdr1 and an increased copy number of the Pfmdr1 gene are indeed related to resistance against 
several types of drugs12,13. Likewise, single nucleotide polymorphisms in an ABC family member, 
multidrug resistance-associated protein 1 (Pfmrp1), have been linked with reduced drug response in 
malaria11. The role of many other ABC transport proteins has not yet been subject of investigation. 
The ABC transport family 
Many ABC transporters actively pump out a wide range of structurally and functionally diverse 
drugs, thereby decreasing intracellular drug accumulation, ultimately resulting in drug resistance14. 
The P. falciparum ABC family consists of 16 ABC members15-17 that have been categorized into 
subfamilies (A through I) according to phylogenetic analysis of the primary or secondary structures 
of the conserved NBDs17-19. The structure of a typical ABC transporter is composed of two trans-
membrane domains (TMDs), each consisting of 6 trans-membrane helices (TM), and two cytosolic 
nucleotide-binding domains (NBDs). ABC transporters are either encoded as full transporters 
(TMD-NBD-TMD-NBD) or as half transporters (TMD-NBD) that upon translation combine to form a 
functional unit. The TMDs contain one or more substrate-binding sites. ABC transporters, present 
in the plasma membrane in the inward-facing configuration, allow substrates to enter the putative 
substrate-binding chamber from the membrane or the cytoplasm (Figure 2A)20. Translocation of 
substrate across the membrane is achieved by rearrangement of the TM helices, physically closing 
them to the substrate delivery side and opening them on the opposite side of the membrane 
(Figure 2B). This mechanism is induced by the binding of ATP and the subsequent dimerization 
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of the NBDs. ATP hydrolysis drives the NBDs apart, flipping the TMDs from the outward-facing to 
the inward-facing conformation to reset the cycle20. Our knowledge of the drug-binding sites is 
still rudimentary. For example, we lack detailed knowledge of the architecture of the drug-binding 
site, nor do we know how many sites an ABC transporter possesses, or how the hydrolysis of ATP is 
coupled to the binding and translocation of drugs across the membrane14. 
Figure 2. Crystal structures of ABC full transporters. 
The transporter is composed of TMDs, each consisting of 6 TMs, and two cytosolic NBDs. A Front view of the 
nucleotide-free mouse multidrug exporter Mdr1A (3G5U.pdb) in the inward-facing conformation. B Side view 
of the nucleotide-bound Sav1866 multidrug exporter from Staphylococcus aureus (2HYD.pdb) in the outward-
facing conformation. The structural figures were prepared using the program Yasara (www.yasara.org).
Figure 3. Phylogram of the P. falciparum 
ABC superfamily based on the NBD 
alignment. 
The NBDs (30 amino acids before Walker 
A until Walker B) of the Plasmodium 
falciparum ABC proteins (Table 1) 
were aligned with ClustalW221 and the 
phylogenetic data were imported in 
TreeView (Page, 1996). In combination 
with blast searches the ABC transport 
proteins were categorized in subfamilies, 
as has been described previously17.
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In the Plasmodium parasite the ABC A subfamily is missing (Figure 3), as is the case in all Apicom-
plexa. Seven members are present in the B subfamily, of which only PfMDR1 is a full transporter. The 
C subfamily encodes two full transporters, whereas the G subfamily only contains one half trans-
porter. Besides these proteins, there is one additional member in the ABC I subfamily that also en-
codes a TMD. Five ABC proteins do not contain TMDs and are members of the E, F, and I subfamily. 
Pfmdr1 in multidrug resistance
PfMDR1 is localized predominantly to the parasite’s digestive vacuole membrane and to a lesser 
extent to the plasma membrane22. Indeed, it was demonstrated that PfMDR1 transports the 
fluorescent compound Fluo-4 into the digestive vacuole23. 
In 1989 the Pfmdr1 gene was shown to be amplified in some chloroquine-resistant parasites, 
indicating that it might be associated with P. falciparum chloroquine resistance24. However, when 
one of the two Pfmdr1 copies of a drug-resistant strain were genetically disrupted, no change 
in chloroquine sensitivity was shown, but an increased in vitro susceptibility to mefloquine, 
lumefantrine, halofantrine, quinin and artemisinin was observed25. Analysis of Pfmdr1 expression 
showed that the expression level is consistent with the gene copy number, but not associated 
with chloroquine sensitivity25,26. A genetic cross between chloroquine-resistant and -susceptible 
clones underlined that Pfmdr1 amplification is not related to chloroquine resistance27. In fact, de-
amplification of the Pfmdr1 gene occurred after chloroquine pressure selection28. Meta-analysis of 
published data showed that an increased Pfmdr1 copy number was correlated with mefloquine 
treatment failure29. Furthermore, three or more copies of Pfmdr1 were also associated with 
recrudescence in patients treated with artesunate-mefloquine30. Indeed, in a culture adapted P. 
falciparum isolate, containing the Pfmdr1 gene, copy numbers increased after stepwise increasing 
concentrations of mefloquine31. It was demonstrated that this event occurred frequently and can 
be expected to occur in most clinical cases. Parasites with multiple copies of the Pfmdr1 gene, 
however, have decreased survival fitness in the absence of drug pressure31. 
Several Pfmdr1 point mutations (N86Y, Y184F, S1034C, N1042D, and D1246Y) were demonstrated 
to be linked to decreased drug sensitivity32. The relationship between the Pfmdr1 N86Y 
polymorphism and drug resistance has been investigated in more than 40 publications29. 
Systematic review and meta-analysis of published data showed that the Pfmdr1 polymorphism 
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was associated with chloroquine and amodiaquine therapeutic failure29. In isolates from Thailand, 
artemether- lumefantrine pressure selects for the N86Y polymorphism33. In Tanzania, amodiaquine 
monotherapy can select for the N86Y/F184Y/D1246Y haplotype, whereas artemether- lumefantrine 
selects for the opposite haplotype34. Moreover, allelic replacement of the Pfmdr1 gene provided 
proof that mutations S1034C, N1042D, and D1246Y can contribute to increased in vitro sensitivity 
for mefloquine, halofantrine, and artemisinin, whereas they confer resistance to quinine12,13. In 
addition, removal of these mutations can result in increased sensitivity towards chloroquine in a 
strain-specific manner35. In the absence of selective pressure, these mutations in the Pfmdr1 gene 
also gave rise to a substantial fitness cost in the intraerythrocytic asexual stage of the parasite36. 
These polymorphisms are localized in different positions within the PfMDR1 protein. N86Y is 
located in the first loop between TM1 and TM2; Y184F at the edge of TM3; S1034C and N1042D in 
TM11, whereas D1246Y is located in the C-terminal end of the protein. 
Only very few multiple membrane spanning Plasmodium proteins have been expressed 
heterologously. Most likely the expression is rather difficult due to the A/T richness of the genes 
and the specific codon usage. P. falciparum genes that have been expressed successfully, usually 
encode for small soluble proteins or peptides37. Today, Pfmdr1 is the only ABC transporter that 
has been functionally expressed. In 1994, Pfmdr1 was first expressed in mammalian cells, and 
immunofluorescence revealed an intracellular localization of the transporter38. The authors 
demonstrated that wild-type Pfmdr1 could mediate an increased intracellular accumulation 
of chloroquine and that this function is impaired in chloroquine-resistant mutants (S1034C and 
N1042D) of the protein. A follow-up study showed that PfMDR1 does not transport chloroquine, 
but instead influences chloroquine accumulation by modulating the pH of acidic organelles, and it 
was speculated that the Pfmdr1 gene encodes a vacuolar chloride channel39. Soon thereafter it was 
demonstrated that Pfmdr1 expressed in yeast functions as a transport protein and complements 
a mutation in ste6, a gene encoding an ABC transporter that exports the mating pheromone 
a-factor40. Furthermore, Pfmdr1 containing S1034C and N1042D appeared to abolish this mating 
phenotype, indicating that these polymorphisms reverse its transport function. 
More than a decade later, chloroquine-sensitive PfMDR1 ATPase activity was determined after 
heterologous expression of codon-optimized Pfmdr1 in Pichia pastoris41. The single S1034C 
mutation was found to ablate drug stimulation of PfMDR1 ATPase activity by quinine, mefloquine, 
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and chloroquine42. Recently, the functional expression was reported of Pfmdr1 variants in Xenopus 
laevis oocytes43. This approach has led to the first direct evidence of antimalarial drug transport by 
PfMDR1. Chloroquine, quinine and vinblastine, but not halofantrine, were found to be substrates 
of the wild-type (N86/Y184/S1034/N1042/D1246) PfMDR1 transporter. By contrast, chloroquine 
and quinine were not transported by polymorphic Pfmdr1 variants, whereas halofantrine 
and vinblastine were. Altered substrate specificity for mutated Pfmdr1 transporters was thus 
demonstrated. Heterologous expression of Plasmodium transport proteins is an important tool 
that can identify substrates and effects of mutations on drug transport, which can be translated 
to drug resistance phenotypes. However, experiments in heterologous expression systems should 
be interpreted with caution when extrapolating conclusions from the model system towards the 
organisms under focus. 
DRUG BINDING OF PfMDR1
The x-ray structure of mouse MDR1 in a drug-binding-competent state was described 
recently. This protein has 27% amino acid identity with PfMDR1 and therefore can be used 
to generate a homology model in which the polymorphisms can be visualized and related 
to specific protein functions. The multiple substrate binding sites that were visualized in the 
crystal structure show that it is difficult to predict at which position in the pocket drugs will 
bind. Combining the homology model with drug-interaction, mutagenesis, and docking 
studies can indicate the precise location of drug binding. This strategy can also be applied 
to other PfABC family members involved in multidrug resistance. Development of new 
antimalarials might benefit from these new developments.
 
Combining the various transport and drug sensitivity data directs towards a more or less plausible 
mechanism of multidrug resistance by Pfmdr1. Wild-type Pfmdr1 expressed in Xenopus laevis 
oocytes readily effluxes chloroquine and quinine, whereas polymorphisms can abolish this 
transport43. The opposite is true for halofantrine; wild-type PfMDR1 does not transport the drug, 
whereas introduction of specific polymorphisms creates a halofantrine-transporting PfMDR1. This 
is in agreement with the observation that wild-type Pfmdr1 stimulates intracellular accumulation 
of chloroquine and that this process is inhibited by the introduction of specific single nucleotide 
polymorphisms38. These polymorphisms also affect the interaction of chloroquine with the 
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ATPase activity of PfMDR142. Furthermore, the main localization of PfMDR1 in the membrane 
of the digestive vacuole indicates that it could transport antimalarials from the cytosol of the 
parasite into this vacuole, where the drug target of the quinoline antimalarials is assumed to be 
situated. As expected from these characteristics, the introduction of the polymorphisms results 
in a chloroquine- and quinine-resistant, but halofantrine-sensitive, parasite12,13,35.  Moreover, in 
chloroquine-resistant strains, wild-type Pfmdr1 might be down-regulated28, and up-regulation of 
wild type PfMDR1 does not lead to resistance against chloroquine, whereas mefloquine resistance 
was observed29. These facts imply that the transporter has a crucial role in uptake of chloroquine 
and possibly quinine into the digestive vacuole, which may herald a shift in the wide-spread 
assumption that quinolines adequately enter the digestive vacuole through simple diffusion44. 
Apart from the parasite strain, substrate specificity, drug dosing, rate of efflux, drug interactions 
and competition are complex processes that could explain some paradoxical results reported 
in literature. Also the translation from ATPase activity to the actual translocation of a substrate 
complicates clear conclusions towards substrate identification. Moreover, the physiological role of 
PfMDR1 is not known, and drugs might inhibit PfMDR1 transport activity, thereby reducing uptake 
of other substrates required in the digestive vacuole for survival of the parasite. 
OTHER PfMDR TRANSPORTERS
Of the 11 P. falciparum ABC family members that contain a TMD, the ABC B subfamily is the 
largest with seven members (Table 1). Only PfMDR1 is a full transporter, whereas the other six 
are half transporters. PfMDR2 is localized in both the plasma membrane45 and the digestive 
vacuole membrane46 of the parasite. Initially, PfMDR2 was assumed to be involved in chloroquine 
resistance47, but in a later study that showed equal protein levels of PfMDR2 in chloroquine-
resistant and -sensitive parasites, this suggestion was dismissed45. PfMDR2 is probably not involved 
in drug sensitivity, but seems to be an efflux pump of heavy metals. Rosenberg et al. developed 
a P. falciparum line resistant against the heavy metals cadmium and lead48. When exposed to 
these metals no accumulation was observed in this line, whereas a sensitive line did accumulate 
the metals. It was shown that this sensitive line harboured a truncated inactive PfMDR2 protein, 
and the resistant line a full-length active protein. Also in a study employing fluorescently labelled 
cadmium, cadmium accumulation was significantly decreased in the resistant line49. These 
findings strongly suggest that the PfMDR2 protein acts as an efflux pump of cadmium and lead. 
Furthermore, the F423Y polymorphism in Pfmdr2 has been associated with in vitro pyrimethamine 
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resistance50. For Pfmdr5, only the plasma membrane expression in all asexual stages of P. falciparum 
has been reported17.
A trinucleotide insertion in Pfmdr6 showed a significant association with decreased sensitivity to 
chloroquine11, which was later also confirmed for artesunate51. Recently, length variations in simple 
repeats of Pfmdr6 have been associated to altered sensitivity towards dihydroartemisinin in vitro52. 
In another study on polymorphic repeats, an association with piperaquine and lumefantrine 
sensitivity was found53.
To our knowledge, no results have been published on the characteristics of Pfmdr3, Pfmdr4, or 
Pfmdr7. It would be worthwhile to investigate the Pfmdrs in more detail, as these transporters are 
candidate drug transporters. 
PfMRPS IN MULTIDRUG RESISTANCE
The P. falciparum parasite encodes for two MRP transport proteins, which are both full transporters. 
A few years ago, single nucleotide polymorphisms in Pfmrp1 were linked to decreased sensitivity to 
chloroquine and quinine in P. falciparum11. Also Pfmrp2 was associated with drug sensitivity more 
recently (Table 1). 
Whereas PfMDR1 is localized mainly in the membrane of the digestive vacuole22, plasma membrane 
expression of PfMRP1 and PfMRP2 in all asexual stages of the parasite was demonstrated17,54. 
Expression of Pfmrp1 and Pfmrp2 was up-regulated by mefloquine and chloroquine in laboratory 
cultures of both drug-sensitive and -resistant strains55, and alterations in expression profiles for 
both Pfmrp1 and Pfmrp2 were observed upon exposure to different dosages of mefloquine56.
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Table 1. The Plasmodium ABC superfamily
Family Name P.falciparum P. vivax P. knowlesi P. berghei P. yoelli P. chabaudi
ABCB
ABCB1 Pfmdr1 PF3D7_0523000 PVX_080100 PKH_100920 PBANKA_123780 PY00245 PCAS_123820
ABCB2 Pfmdr2 PF3D7_1447900 PVX_118100 PKH_125840 PBANKA_131170 PY06054 PCAS_131500
ABCB3 Pfmdr3 PF3D7_1145500 PVX_092880 PKH_094310 PBANKA_090350 PY06546 PCAS_070470
ABCB4 Pfmdr4 PF3D7_0302600 PVX_119255 PKH_083760 PBANKA_040120 PY03961 PCAS_040210
ABCB5 Pfmdr5 PF3D7_1339900 PVX_082915 PKH_121420 PBANKA_135330 PY02551 PCAS_135790
ABCB6 Pfmdr6 PF3D7_1352100 PVX_083495 PKH_120190 PBANKA_136480 PY07089 PCAS_136940
ABCB7 Pfmdr7 PF3D7_1209900 PVX_084520 PKH_130880 PBANKA_060830 PY01826 PCAS_060890
ABCC
ABCC1 Pfmrp1 PF3D7_0112200 PVX_097025 PY05035 PCAS_144600
ABCC2 Pfmrp2 PF3D7_1229100 PVX_124085 PKH_144590 PBANKA_144380
ABCE
ABCE1 PF3D7_1368200 PVX_115370 PKH_110230 PBANKA_114410 PY04219 PCAS_114360
ABCF
ABCF1 PF3D7_0813700 PVX_123085 PKH_142470 PBANKA_142380 PCAS_142560
ABCF2 PF3D7_1121700 PVX_091705 PKH_091910 PBANKA_092660 PCAS_091770
ABCG
ABCG1 PF3D7_1426500 PVX_085205 PKH_132390 PBANKA_101810 PY00207 PCAS_101790
ABCI
ABCI1 PF3D7_0319700 PVX_095250 PKH_082130 PY00170 PCAS_121950
ABCI2 PF3D7_1434000 PVX_084835 PKH_131530 PBANKA_101080 PY06911 PCAS_101070
ABCX
ABCX1 PF3D7_1413500 PVX_085775 PKH_133410 PBANKA_102920 PCAS_102900
A number of polymorphisms of Pfmrp1 were related with altered antimalarial sensitivity; the K1466R 
and the I876V polymorphisms in Pfmrp1 were selected among parasites in recrudescent infections 
after sulfadoxine-pyrimethamine and artemether-lumefantrine treatment, respectively57,58. 
Furthermore, the F1390I SNP was associated with artemisinin, mefloquine and lumefantrine 
sensitivity in vitro59, the I876V polymorphism was related to reduced chloroquine sensitivity in 
samples isolated at the China-Myanmar border60 and 191Y and 1390I SNPs were associated with 
increased sensitivity towards chloroquine and quinine61. Furthermore, Pfmrp1 polymorphisms 
in parasite isolates from North-East Myanmar showed reduced in vitro susceptibility towards 
chloroquine, mefloquine, pyronaridine and lumefantrine62, and decreased sensitivity towards 
mefloquine and artesunate was found for a number of polymorphisms in this gene63. Combined, 
these data indicate that PfMRP1 is involved in P. falciparum drug sensitivity. 
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Pfmrp1 disruption in a P. falciparum chloroquine-resistant line showed that under normal culture 
conditions these parasites could not grow to a parasitemia higher than 5%, possibly because of 
lower efficiency in removing toxic metabolites64. The disrupted parasite also accumulated more 
radiolabeled glutathione, chloroquine, and quinine. Moreover, they became more sensitive 
to multiple antimalarial drugs, including chloroquine, quinine, artemisinin, piperaquine, and 
primaquine. This suggests that PfMRP1 plays a role in the efflux of glutathione, chloroquine, and 
quinine. 
For the Pfmrp2 gene, repeat polymorphisms were associated to altered lumefantrine sensitivity53. 
A deletion in the upstream region of the gene which induces PfMRP2 expression was associated 
with increased resistance against quinoline antimalarials65. A study of Veiga et al. showed a high 
diversity in Pfmrp2 polymorphisms, of which a number was related to decreased sensitivity of again 
quinoline antimalarials66.
OTHER PLASMODIUM ABC TRANSPORTERS IN MULTIDRUG RESISTANCE
The location of the Plasmodium ABC transport proteins within the parasite are depicted in Figure 4. 
In addition to the seven ABC B and two ABC C subfamily members, there are seven other ABC members 
(Table 1). Two of these, ABCG1 (PF3D7_1426500) and ABCI1 (PF3D7_0319700), contain a TMD and 
thus most likely are transport proteins. 
The role of the Plasmodium ABCG1 in multidrug resistance has not yet been investigated. The human 
G family member, breast cancer resistance protein (BCRP/ABCG2), can actively extrude a broad 
range of endogenous and exogenous substrates (e.g. cytostatics) across biological membranes67. 
The orthology of the Plasmodium ABCG1 transport protein and the human BCRP makes it an 
interesting candidate drug transporter. Pfabcg1 (indicated as Pfabcg2 in67) was disrupted in a 
quest for novel transmission-blocking antimalarial compounds68. The resulting parasite developed 
normally during asexual replication, however, gametocyte formation was strongly reduced. 
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ABCI3 is an atypical ABC family member that does not possess a clear ABC signature motif, but 
according to a Pfam search, ABCI3 belongs to the ABC family69. In conclusion, next to the P. 
falciparum B and C subfamily members there is another good candidate drug transporter in the G 
subfamily, and in the I subfamily a possible transport protein with little homology to mammalian 
transporters. 
  
Figure 4. Schematic representation of the localisation of the P. falciparum ABC transporters 
in the parasite. 
The PfABC transport proteins are indicated on the parasite plasma membrane and digestive vacuole membrane. 
In addition the known substrates are depicted.
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ABC TRANSPORTERS IN OTHER PLASMODIUM SPECIES 
Of the four human malaria parasites, P. falciparum is the most virulent species. Outside Africa P. 
vivax is very frequent and represents a major threat to health70. P. ovale and P. malariae generally 
give mild infections71. There is little information about ABC transporters in P. vivax and to our 
knowledge no information about these proteins in P. ovale, P. malariae and P. knowlesi. In Table 
1, the ABC family members of the human malaria parasite P. vivax, the primate malaria parasite 
P. knowlesi and the rodent malaria parasites P. berghei, P. yoelii, P. chabaudi are compared with P. 
falciparum. In general the same family members are present, however, in the MRP family, rodent 
species encode only one MRP orthologue. 
The mdr1 gene was also identified in the human malaria parasite P. vivax, but initially no correlation 
was found between chloroquine resistance and specific mutations72. A few years later, the Y976F 
mutation of Pvmdr1 was associated with reduced susceptibility to chloroquine73, but greater 
susceptibility to arsenate and mefloquine74. However, in Madagascar this mutation was already 
fixed in the P. vivax population and no significant correlation between the Pvmdr1 Y976F mutation 
and chloroquine treatment outcome was observed75. Furthermore, the supposedly selective 
pressure on this mutation was investigated in multiple malaria endemic settings, however, no 
direct effect on chloroquine sensitivity could be identified76-81. Also for the F1076L mutation a 
resistance mechanism was not observed77,82,83. Interestingly, the single nucleotide polymorphisms 
found in P. vivax differed from those present in P. falciparum, indicating that differences other than 
mutations may be implicated in chloroquine resistance in these two malaria parasite species84,85. 
Increased Pvmdr1 gene copy number has been detected79,81, which was not associated with 
chloroquine resistance73,77, but was associated with a reduced susceptibility to mefloquine74,80. 
Pvmdr1 gene amplification appeared significantly more common in an area where mefloquine 
pressure has been intense compared to areas where there has been less exposure of parasites 
to mefloquine84. Furthermore, increased transcript levels were found in a patient with severe P. 
vivax malaria as compared to patients with mild malaria86. These first studies on PvMDR1 indicate 
that this transporter is involved in drug transport and susceptibility of the parasite. More research 
on PvMDR1 and the other PvABC transport proteins is required to value the importance of these 
transporters in P. vivax multidrug resistance, and to determine their physiological functions.  
Manuscript_SR_DEF.indd   18 21-04-16   07:57
19
General Introduction
AIM AND OUTLINE OF THIS THESIS
In this thesis, we will investigate the function of ABC transporter proteins in Plasmodium species, 
to elucidate their contribution to decreased drug sensitivity and their physiological role in cellular 
processes. Increased knowledge of the specific mechanism of action of ABC transporters in 
antimalarial drug sensitivity may potentially aid in the rescue of known compounds and the design 
of new drugs. Insights into (essential) biological functions of these proteins could reveal novel drug 
targets, or contribute to the development of alternative antimalarial strategies. In Chapter 2 we will 
focus on the interaction of antimalarial compounds with human ABC transport proteins by using a 
vesicular inhibition assays. These experiments indicate that some antimalarial compounds inhibit 
ABC transport proteins at therapeutic concentrations, which can potentially lead to harmful drug-
drug interactions. In Chapter 3 we will aim at the identification of substrates of PfMRPs to elucidate 
their physiological function and assess the contribution of transport of specific substrates to drug 
sensitivity of the parasite. This is done through an untargeted metabolomics approach and LC/
MS-MS validation in parasites in which the mrp-encoding genes are stably deleted. These parasites 
are subsequently assessed in Chapter 4 for their antimalarial sensitivity. In order to evaluate 
essential functions of MRP transporter proteins, the effect of mrp deletion is studied in all stages 
of the parasite life cycle in both P. berghei and P. falciparum. Finally, we focus on MDR transport 
proteins in Chapter 5, where we target all encoded transporters for gene deletion in P. berghei 
and evaluated parasite viability throughout the life cycle, and also assess targetable transporters 
in P. falciparum. In Chapter 6, we evaluate the implications of our findings and including a future 
perspective on ABC transport protein research in Plasmodium parasites. Targeting the interaction 
of the parasite with its host environment through ABC transport proteins, either by extrusion of 
toxic waste products or protection against host metabolites, might be an important new weapon 
in the battle against malaria.
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ABSTRACT
Background Therapeutic blood plasma concentrations of anti-malarial drugs are essential 
for successful treatment. Pharmacokinetics of pharmaceutical compounds are dependent of 
adsorption, distribution, metabolism, and excretion. ATP binding cassette (ABC) transport proteins 
are particularly involved in drug deposition, as they are located at membranes of many uptake 
and excretory organs and at protective barriers, where they export endogenous and xenobiotic 
compounds, including pharmaceuticals. In this study, a panel of well-established anti-malarial 
drugs which may affect drug plasma concentrations was tested for interactions with human ABC 
transport proteins.
Methods The interaction of chloroquine, quinine, artemisinin, mefloquine, lumefantrine, 
atovaquone, dihydroartemisinin and proguanil, with transport activity of P-glycoprotein (P-gp), 
breast cancer resistance protein (BCRP), bile salt export pump (BSEP) and multidrug resistance-
associated proteins (MRP) 1–4 were analysed. The effect of the anti-malarials on the ATP-dependent 
uptake of radio-labelled substrates was measured in membrane vesicles isolated from HEK293 cells 
overexpressing the ABC transport proteins.
Results A strong and previously undescribed inhibition of BCRP-mediated transport by atovaquone 
with a 50% inhibitory concentration (IC50) of 0.23 μM (95% CI 0.17-0.29 μM) and inhibition of P-gp-
mediated transport by quinine with an IC50 of 6.8 μM (95% CI 5.9-7.8 μM) was observed. Furthermore, 
chloroquine and mefloquine were found to significantly inhibit P-gp-mediated transport. BCRP 
transport activity was significantly inhibited by all anti-malarials tested, whereas BSEP-mediated 
transport was not inhibited by any of the compounds. Both MRP1- and MRP3-mediated transport 
were significantly inhibited by mefloquine.
Conclusions Atovaquone and quinine significantly inhibit BCRP- and P-gp-mediated transport at 
concentrations within the clinically relevant prophylactic and therapeutic range. Co-administration 
of these established anti-malarials with drugs that are BCRP or P-gp substrates may potentially lead 
to drug-drug interactions.
INTRODUCTION
ATP binding cassette (ABC) transporters are membrane-bound proteins that allocate a wide variety 
of compounds at the expense of ATP, even against steep concentration gradients87. P-glycoprotein 
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(P-gp/ABCB1), bile salt export pump (BSEP/ABCB11), multidrug resistance-associated proteins 
(MRP1-4/ABCC1-4), and breast cancer resistance protein (BCRP/ABCG2) are among the most 
important drug transporters of the ABC protein family. ABC transport proteins are known for their 
capacity to protect the organism from potentially toxic xenobiotics through excretion, thereby 
decreasing intracellular concentrations. Indeed, typical localization of these export transporters 
are at the blood-brain barrier, placenta, gut, and at the apical side of liver and kidney cells. Two 
compounds may interact with the same transport protein through induction of expression, 
inhibition of protein function or competition of substrates. Pharmacokinetics of co-administered 
drugs can be critically altered when drug-drug interactions occur at the level of the ABC transport 
proteins, as distribution and selective excretion of these compounds may depend heavily on 
ABC protein-mediated transport. This can be reflected either in unexpected high blood plasma 
concentrations potentially causing toxic effects, or subtherapeutic concentrations at the site of 
action, diminishing therapeutic effects. 
It is essential to assure effective blood plasma concentrations upon treatment with anti-malarial 
compounds in order to cure severely ill patients and prevent resistance acquisition through 
exposure of the parasite to sublethal blood plasma concentrations. The first-line treatment as 
recommended by the World Health Organization (WHO) currently consists of artemisinin-based 
combination therapy88. However, resistance against these regimens has been detected and the 
number of anti-malarials that can be subsequently applied are limited8. Toxic effects by unintended 
elevated blood plasma concentrations, however, should also be avoided.
Direct interaction with ABC transporter capacity of anti-malarial compounds has not been explored in detail. 
In vitro assays have indicated a possible effect on P-gp mediated transport or expression after exposure to 
chloroquine, quinine, mefloquine, primaquine, amodiaquine, piperaquine, artemisinin and dihydroartemisinin, 
however, contradictory conclusions concerning the interaction of anti-malarial compounds with ABC transport 
proteins could be drawn from different experimental set-ups89-94. A possible interaction of antimalarial compounds 
with MRP-type transporters and BCRP has also been described95-98. Co-administration of anti-malarial compounds 
with other drug-types is highly anticipated. For instance, human immunodeficiency virus (HIV) and malaria co-
infections are likely to occur, as there is a high overlap in geographical dissemination99. Therefore, the effect of 
antimalarial compounds on ABC-mediated transport capacity should be explored in more detail in order to secure 
the most effective treatment strategies for patients receiving multiple drug regimens. 
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In this study the direct interaction of a panel of eight well-known anti-malarial compounds (chloroquine, 
quinine, artemisinin, mefloquine, lumefantrine, atovaquone, dihydroartemisinin and proguanil) with 
transport activity of P-gp, MRP1-4, BCRP and BSEP in a vesicular overexpression transport assay have 
been analysed. Anti-malarials (100 µM) that caused a decrease in substrate transport larger than 66.7% 
were further characterized to determine their 50% inhibitory concentrations (IC50). Potent and previously 
undescribed inhibition of BCRP-mediated transport by atovaquone and P-gp-mediated transport by 
quinine was observed at concentrations within their therapeutic range.
METHODS
Materials
[6,7-3H(N)]Estrone-sulphate ammonium salt ([3H]-E1S, specific activity 45.6 Ci/mmol), Tauro[carbonyl-
3H]Cholic Acid sodium salt ([3H]TCA) (5 Ci/mmol) and [6,7-3H(N)]Estradiol 17-β-D-glucuronide ([3H]-
E217βG) (34.3 Ci/mmol) were purchased from PerkinElmer Life and Analytical Sciences (Groningen, 
Netherlands).  [3H(N)]-methyl quinidine ([3H]-NMQ) (80 Ci/mmol) and unlabelled NMQ [N-methyl-
quinidine] were purchased from Solvo Biotechnology (Szeged, Hungary). Bac-to-Bac and Gateway 
systems, Dulbecco’s modified Eagle’s medium, GlutaMAX-I culture medium, and  foetal calf serum 
were purchased from Life Technologies (Bleiswijk, Netherlands). Primers were purchased from 
Biolegio (Nijmegen, Netherlands), and a plasmid purification midiprep kit was from Genomed 
(Löhn, Germany). Triple flasks (500 cm2) were purchased from Sanbio BV Biological Products (Uden, 
Netherlands). Estradiol 17-β-D-glucuronide (E217βG), estrone-sulphate (E1S), taurocholic acid 
(TCA) adenosine 5’-triphosphate magnesium salt (bacterial source), goat-anti-mouse IgG antibody 
IRDye 800 and goat-anti-rabbit Alexa 680 secondary antibodies, chloroquine (CQ), quinine (Q), 
artemisinin (ART), mefloquine (MQ), lumefantrine (L), atovaquone (ATO), dihydroartemisinin 
(DHA) and proguanil (PG) were purchased from Sigma-Aldrich (Zwijndrecht, Netherlands). Protein 
concentrations were determined with a Bio-Rad protein assay kit from Bio-Rad Laboratories 
(Veenendaal, Netherlands), and 96-well filter plates were purchased from Millipore (Etten-leur, 
Netherlands).
Baculovirus generation
Human P-gp, BCRP, BSEP and MRP1-4 had previously been cloned into the Gateway pDONR221 
vector. Sequences matched accession numbers NM_000927, NM_004827, NM_003742, 
Manuscript_SR_DEF.indd   24 21-04-16   07:57
25
Atovaquone and quinine antimalarials inhibit ATP Binding Cassette transporter activity
NM_004996, NM_000392, NM_00378, and NM_005845 respectively100-104. Some sequences did 
hold silent mutations of described polymorphisms. Gateway cloning was used to transfer the genes 
into a VSV-G improved pFastBacDual vector for mammalian cell transduction. The production of 
baculovirus was executed according to the Invitrogen Bac-to-Bac manual. 
Cell culture and transduction
HEK293 cells were grown to 40% confluency in Dulbecco’s modified Eagle’s medium-GlutaMAX-I 
containing 10% foetal calf serum at 5% CO2 in 500 cm2 triple flasks. Culture medium was removed 
and 25 mL of medium combined with 10 mL virus was added and incubated at RT for 20 min, 
followed by the addition of another 40 mL of complete medium including 5 mM sodium butyrate 
to enhance protein expression. 
Membrane vesicle isolation and protein analysis
Cells were harvested three days post transduction by a 5 min centrifugation step at 3,000 g. Cells 
were resuspended in ice-cold hypotonic buffer (0.5 mM sodium phosphate, 0.1 mM EDTA, pH 7.0) 
containing protease inhibitors (100 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, 5 mg/
ml leupeptin, 1 mg/ml pepstatin and 1 mg/ml E-64) and shaken at 4°C for 30 min. This lysate was 
centrifuged 100,000 xg for 30 min at 4°C, after which the pellet was homogenized in ice-cold TS 
buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) supplemented with protease inhibitors 
described before using a tight-fitting Dounce homogenizer for 25 strokes. Two subsequent 
centrifugation steps at 4°C of firstly 20 min at 4000 g followed by supernatant centrifugation for 
60 min at 100,000 g ensured harvesting of the membrane fraction. The pellet was resuspended 
in ice-cold protease free TS buffer and passed 25 times through a 27-gauge needle to enhance 
membrane vesicle formation. Protein concentration in these vesicles was determined using the 
Bio-Rad protein assay, vesicles were flash-frozen in N2 and stored at -80 °C.
Vesicular transport assays
A rapid filtration technique that has been described earlier was applied to evaluate uptake of 
transporter specific substrates into the vesicles; NMQ for P-gp, E1S for BCRP, E217βG for MRP1-4 
and TCA for BSEP105. Briefly, 0.015-0.15 µCi of labelled substrate was combined with unlabelled 
substrates to a concentration of 0.1-1 µM in a 30 µL reaction mixture with 4 mM ATP, 10 mM MgCl2 
and 7.5 µg total protein membrane vesicles in TS buffer. Transport was allowed by transfer of the 
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plates to 37 °C during 1-5 min, a time-point within the linear phase of time-dependent transport, 
as previously determined100-104. Hereafter, the reaction was rapidly stopped by placing the plates 
back on ice and the addition of 150 µL ice-cold TS buffer. Samples were subsequently transferred 
to a 96-well filter plate that had been pre-incubated with TS buffer, and filtered using a multiscreen 
HTS-vacuum manifold filtration device (Millipore). Filters were washed and extracted, after which 
2 mL scintillation fluid was added to each filter. Radioactive signal on the filters was determined by 
liquid scintillation counting. Negative controls included eYFP-transduced vesicles and AMP instead 
of ATP in the reaction mixture. 
In the first screen, all anti-malarial compounds were added to the reaction mixture to evaluate 
transport inhibition at a concentration of 100 µM. Solvents were used as negative controls, as CQ 
was dissolved in milliQ, Q and ART in methanol, MQ, L, ATO and DHA in DMSO and PG in 50% ethanol. 
When ATP-dependent uptake was reduced more than 66.7%, the compound was considered a 
potential inhibitor, and multiple concentrations were tested in the reaction mixture to determine 
the IC50 value. All concentrations were tested in duplicates or triplicates in two individual biological 
replicates containing vesicles of independent transductions. Results were depicted and statistically 
analysed using Graphpad Prism, version 5.03. IC50 values were determined by nonlinear regression 
analysis of (log) inhibitor-response curves with variable slope. Maximal transport was restricted to 
100%, and the minimum was set to be equal or greater than 0%. Statistical analysis was performed 
using IBM SPSS Statistics 20, applying one-way ANOVA (Analyis of variance).
RESULTS
Inhibitory profile of anti-malarials against ABC transporter activity
The inhibitory characteristics against the ABC transporters of eight well-known antimalarials; CQ, Q, 
ART, MQ, L, ATO, DHA and PG, was investigated at at a 100 µM concentration. For each transporter 
protein, specific radio-labelled substrates were applied to measure ATP-dependent transport into 
the vesicular overexpression system; N-methyl quinidine (7nM radio-labelled diluted with 90 nM 
non-radio-labelled) for P-gp, estrone sulphate (74 nM) for BCRP, estradiol 17-β-D glucuronide (150 
nM) for MRP1-4 and taurocholic acid (1 µM) for BSEP101-104. 
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A significant inhibitory effect of 100 μM CQ, Q, MQ and PG on P-gp-mediated NMQ transport was 
observed. CQ reduced NMQ transport to 50% (p < 0.001) and PG to 76% (p < 0.001), whereas Q and 
MQ gave more pronounced inhibitory effects to 15% (p < 0.001) and 30% (p < 0.001) P-gp-mediated 
NMQ transport, respectively. ART and DHA slightly induced transport activity to 131% (p < 0.001) 
and 112% (p = 0.033), respectively (Figure 1A). All anti-malarials inhibited BCRP-mediated estrone 
sulphate transport activity at 100 μM concentrations. Most potent inhibitors were MQ, ATO and 
PG, which reduced estrone sulphate transport to 8.5%, 22% and 36% with p < 0.001, respectively 
(Figure 1B). CQ reduced transport to 69%, Q to 45%, ART to 62%, L to 44%, and DHA to 70% of 
solvent-exposed BCRP-mediated transport capacity (p < 0.001). Significant inhibition of taurocholic 
acid transport by BSEP was observed for ATO, which reduced uptake to 54% (p < 0.001) and MQ, 
which reduced uptake to 72% (p = 0.037). Furthermore, induction of BSEP transport activity was 
found for CQ (117%, p < 0.001), ART (117%, p < 0.001) and DHA (114%, p < 0.001) (Figure 1C). MQ was 
found to have a modest but significant inhibitory effect on estradiol 17-β-D glucuronide transport 
by MRP1 as this was reduced to 50% (p < 0.001), whereas ATO was observed to induce this process 
to 141% (p < 0.001) (Figure 1D). Induction was also observed for ART and ATO on MRP2-mediated 
estradiol 17-β-D glucuronide transport to 151% (p = 0.015) and 162% (p = 0.020), respectively. 
However, no significant inhibition was measured for any of the anti-malarials tested (Figure 1E). 
MRP3-mediated translocation of estradiol 17-β-D glucuronide was significantly inhibited by MQ at 
a 100 μM concentration to 70% (p = 0.001), whereas ART and DHA induced this process to 122% (p 
= 0.016) and 121% (p = 0.020), respectively (Figure 1F). No significant estradiol 17-β-D glucuronide 
transport inhibition of MRP4 could be detected (Figure 1F). As the 100 μM concentration is not 
within the physiological range of compound exposure, the most potent inhibitors were selected 
for further investigation. Inhibition of Q and MQ on P-gp-mediated transport, as well as BCRP 
inhibition by MQ, ATO and PG, were studied in more detail to determine their potencies.
Determination of inhibitory potency of strong inhibitors
Subsequently, transport inhibition assays were performed for a larger concentration range of 
Q, MQ, ATO and PGP to evaluate P-gp or BCRP activity. Inhibition of transport was measured in 
a similar fashion applying the same specific radio-labelled substrates. Drug concentrations were 
logarithmically depicted, and a sigmoidal, inhibitor-response, variable slope equation was fitted 
to the data to determine the inhibition curve. Maximal inhibition to 0% transport was not always 
reached, which might be due to endogenous transport present in the vesicular membranes.
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Figure 1. Inhibitory effect of anti-malarial drugs on ABC transport activity. 
The inhibitory effect of 100 μM of CQ, Q, ART, MQ, L, ATO, DHA and PG on ABC transporter activity was 
assessed. Transport was measured in pmol/mg protein/min and expressed as percentage of solvent controls, 
which represent 100% transport. Bars with * are significantly different from solvent controls, p < 0.05. A P-gp-
mediated transport of NMQ was significantly inhibited by CQ, Q, MQ and PG, and increased by ART and DHA. 
B BCRP-mediated transport of E1S was significantly inhibited by all compounds, most pronounced inhibitors 
were MQ and ATO. C BSEP-mediated transport of TCA was significantly inhibited by ATO, but not by the other 
anti-malarials. Induction of transport was observed for CQ, ART and DHA. D-G MRP1-4-mediated E217βG 
transport. MQ significantly inhibited MRP1 and MRP3 transport activity. Furthermore, induction of MRP1 
mediated transport was found for ATO, which, together with ART, also stimulated MRP2 transport activity. 
MRP3 mediated transport was stimulated by both ART and DHA. Inhibition larger than 66.7% was found for Q 
and MQ on P-gp transport, as well as MQ, ATO and PG on BCRP transport activity (highlighted bars).
The strongest inhibitory effect for ATO on BCRP-mediated transport was found at median nanomolar 
range. Transport of estrone sulphate was inhibited with 50% by this compound at 0.23 μM (95% CI 
0.17-0.29 μM) (Figure 2A), whereas MQ and PG required the addition of 18 μM (95% CI 17–20 μM) 
(Figure 2B) and 118 μM (95% CI 93–148 μM) (Figure 2C) to achieve a similar effect on BCRP activity, 
respectively. Also for the other compound-transporter combinations, IC50 values were found in the 
low to median micromolar range. The effect of Q on P-gp-mediated NMQ transport inhibition was 
the strongest, and the IC50 was defined at 6.8 μM (95% CI 5.9-7.8 μM) (Figure 2D). MQ was a less 
potent inhibitor with an IC50 of 72 μM (95% CI 49–104 μM) (Figure 2E). The inhibitory concentration 
of ATO and Q transport were within the therapeutic range of blood plasma concentrations after 
both prophylactic and curative anti-malarial dosing.
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Figure 2. Concentration-dependent inhibition of potent anti-malarial inhibitors of P-gp and BCRP. 
The inhibition of NMQ transport by P-gp was determined for A MQ and B Q. BCRP activity was inhibited 
according to the dose–response curves for C MQ D ATO and E PG.
DISCUSSION
 
In this study, the interaction of anti-malarial compounds CQ, Q, ART, MQ, L, ATO, DHA and PG 
with the activity of P-gp, BCRP, MRP1-4 and BSEP ABC transport proteins were investigated. ATO 
was found to be a strong inhibitor of BCRP-mediated transport, which has not been described 
previously. Also Q was identified as a potent inhibitor of P-gp-mediated transport. In addition, 
subtle alterations on transporter activity have also been identified for other compound-transporter 
combinations, both inhibitory and stimulating. These interactions can be either competitive or 
non-competitive. Allosteric interactions that stimulate transport have been observed for several 
ABC transporters and are substrate dependent, due to which translation of these results to other 
transporter-substrate combinations is difficult.
A 50% inhibition of BCRP-mediated transport activity could be achieved with 0.23 µM ATO. This 
concentration is easily reached in blood plasma during both prophylactic and therapeutic use 
of ATO, as maximal ATO blood plasma concentrations are around 14 µM (range 8-26 µM) after a 
daily prophylactic dose of 250 mg106. Although the free concentration of ATO is reduced due to its 
high plasma protein binding, intracellular concentrations at the target site may be higher. ATO is 
used in a fixed combination with PG in Malarone®, which is prophylactively prescribed to travellers, 
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and at higher dosages to treat falciparum malaria especially in regions of ACT failure88,107.  BCRP is 
located primarily on the apical side of excretory organs, and it is highly involved in excretion of 
xenobiotics from the body108,109. As ATO is excreted into bile against steep concentration gradients, 
involvement of ABC transport proteins such as BCRP is likely110 and interactions with ATO can occur 
when elimination of co-administered therapeutics is inhibited. 
Indeed, cases of interactions with ATO have been reported. The azithromycin AUC (area under the 
curve) and maximal concentrations were lower in all patients when taken in combination with ATO 
by HIV-1 positive children111. Although direct interaction of azithromycin with BCRP has not been 
investigated, interaction at this level cannot be excluded. Moreover, a clear increase in plasma 
concentration of etravirine, a reverse transcriptase inhibitor, and saquinavir, a protease inhibitor, 
was observed in a Caucasian female who started malaria prophylaxis with ATO/PG (250/100 mg) 
fixed dose combination112. Etravirine and saquinavir were prescribed to treat HIV1 subtype B in an 
antiretroviral combination therapy, supplemented with raltegravir and maraviroc. AUCs during 
a 12-hour measurement interval were increased 55% for etravirine and 274% for saquinavir, and 
peak concentrations after administration of the antiretrovirals was markedly increased. Saquinavir 
and etravirine have previously been described as potent BCRP inhibitors, but not substrates, with 
IC50 concentrations of 19.5 and 1.0 µM113,114. Both raltegravir and maraviroc do not inhibit BCRP, 
indicating that interaction with BCRP is specific for saquinavir and etravirine115. An alternative or 
complementary explanation could be interaction at the level of Cytochrome P450 (CYP) enzymes, 
as PG is mainly metabolized by CYP2C19 but also partly by CYP3A4, saquinavir by CYP3A4 and 
etravirine mainly by CYP3A4 and to a minor extent by CYP2C9 and CYP2C19116-118. Raltegravir is not 
metabolized by members of the CYP family, however, maraviroc is a substrate of CYP3A4119,120. A 
strong correlation at this level of drug interaction could therefore not be observed, stressing the 
plausible role of transporter-mediated drug interactions. 
Another study demonstrated a significant decrease in ATO plasma concentration when taken in 
combination with efavirenz, lopinavir/ritonavir or atazanavir/ritonavir therapy121. Interaction at 
the level of metabolism through glucuronidation was proposed. However, as atovaquone is only 
marginally glucuronidated but mostly excreted unchanged into the bile, interaction at the level of 
ABC transport proteins and more specifically BCRP could play an important role110. Indeed, efavirenz, 
lopinavir and atazinavir have been described as inhibitors of BCRP-mediated transport122. Lopinavir 
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and efavirenz were found to be stronger inhibitors, and correspondingly, ATO concentration was 
decreased more drastically in these two combinations compared to atazinavir co-administration.
Other pharmaceuticals that interact with BCRP-mediated transport are fluoroquinolone antibiotics, 
kinase inhibitors, cytostatics, antifolates and statins123-129. Interactions with ATO therapy might be 
anticipated when co-administered. These drugs are not widely used in malaria-endemic areas, 
however, interactions with prophylactic doses of ATO used by travellers can be anticipated. 
A 50% inhibition of P-gp-mediated transport by Q was found at a concentration of 6.8 µM. Indeed, in 
other in vitro cellular uptake experiments Q has been described to be both an inhibitor and a substrate 
of P-gp89,93,94,130-133. The concentration at which Q was effective was lower in the current study than 
previously described. Most likely this can be attributed to the difference in substrates used. Maximal 
plasma concentrations reach 30 µM during a seven day regimen of 10 mg/kg oral dose three times 
daily of quinine sulphate, and although Q is bound to plasma-proteins to some extent, clinically relevant 
interactions at the level of P-gp-mediated transport during quinine treatmen may be expected134.
Interactions with Q have been described for ritonavir/lopinavir combination therapy as well 
as ritonavir monotherapy, and for nevirapine, rifampicin, cyclosporine and digoxin. Q co-
administration with digoxin decreased billary excretion of the latter, indicating specific involvement 
of transport processes135. When co-administered with ritonavir, Q blood plasma concentrations 
were increased136. Ritonavir indeed is both a substrate and inhibitor of P-gp, therefore interaction at 
this level may explain the increase in Q concentration137,138. After rifampicin, nevirapine and lopinavir 
co-administration, Q blood plasma concentrations were decreased134,139-141. Rifampicin interacts 
with P-gp as substrate, inhibitor and inducer, and lopinavir has been found to inhibit P-gp142-144. 
However, this has not been shown for nevirapine. Q is one of the oldest anti-malarial drugs still in 
use, and although it is not used any more in first line treatment strategy, its use has increased as it 
is often applied as an alternative treatment after ACT stock-outs145. Furthermore, for treatment of 
malaria infections in pregnant women it is one of the few compounds that can be applied safely146. 
Adherence to this compound is known to be low due to the large range of common and often 
plasma concentration-dependent side effects147. For these reasons, establishing effective but non-
toxic blood plasma concentrations is essential in the treatment of malaria, and interaction with 
co-administered compounds that mediate P-gp transport should be tightly monitored.
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Especially, the interaction of both ATO and Q with antiretroviral medication could have severe 
implications on treatment strategies for both infections, as HIV is another major contributing factor 
to morbidity, especially in sub-Saharan regions of Africa99. Many different antiretroviral compounds 
are being prescribed, depending on personal characteristics and resistance status, and for many of 
these compounds interactions with BCRP have been described. 
CONCLUSIONS
Anti-malarial compounds can reduce ABC transporter activity. ATO appeared to be a potent inhibitor 
of BCRP and Q of P-gp in vitro. Both compounds inhibited ABC transporter activity at concentrations 
equalling prophylactic and effective blood plasma concentrations. Potential involvement in interactions 
with antiretroviral and antibiotic compounds have been described for ATO and Q, which can be 
explained by the observed inhibitory effects on BCRP and P-gp transport activity.
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ABSTRACT 
Multidrug Resistance-associated Proteins (MRP) of Plasmodium falciparum have been associated 
with altered drug sensitivity. Knowledge on MRP substrate specificity is indispensible for the 
characterization of resistance mechanisms and identifying its physiological roles. An untargeted 
metabolomics approach detected decreased folate concentrations in red blood cells infected with 
schizont stage parasites lacking expression of MRP1. Furthermore, a tenfold decrease in sensitivity 
towards the folate analogue methotrexate was detected for parasites lacking MRP1. PfMRP1 is 
involved in the export of folate from parasites into red blood cells and is therefore a relevant factor 
for efficient malaria treatment through the folate pathway. 
INTRODUCTION
ATP Binding Cassette (ABC) proteins are membrane bound transporters known for their capacity 
to translocate a wide variety of compounds at the expense of ATP87,148. ABC export proteins 
have important physiological roles in homeostasis and signaling processes, but also contribute 
to resistance acquisition by lowering intracellular concentrations of curative drugs. Indeed, 
in Plasmodium falciparum (P. falciparum), single nucleotide polymorphisms and copy number 
variations of especially Pfmdr1 (PF3D7_0523000) and Pfmrp1 (PF3D7_0112200) have been 
associated with anti-malarial resistance. The multidrug resistance-associated proteins (MRPs) 
are members of the ABC subfamily C, and are typically involved in transport of organic anions 
including glutathione-, glucuronide- or sulfate-conjugated compounds from endogenous and 
exogenous origin. MRP1 has been localized at the plasma membrane of P. falciparum parasites 
during intra-erythrocytic development17. Increased expression of this gene has been associated 
with mefloquine and chloroquine resistance, and single nucleotide polymorphisms in Pfmrp1 with 
in vivo selection after sulfadoxine/pyrimethamine and artemether/lumefantrine treatment55,57,58. 
Furthermore, transient deletion of this gene in a chloroquine resistant parasite strain resulted in 
increased sensitivity towards chloroquine, quinine, artemisinin, piperaquine and primaquine. 
Besides unraveling the contribution of ABC transporters to anti-malarial resistance, the identification 
of MRP substrates can shed light on essential functions in biological processes of the parasite. The 
resistance portfolio of P. falciparum against anti-malarials now includes first-line artemisinin derivatives, 
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and as alternative treatments are scarce, evidently new compounds targeting parasite-specific processes 
are urgently required8,9,88. ABC transport proteins are attractive drug targets, as they are often expressed 
on the easily accessible plasma membrane, play key roles in biological processes and are involved in 
transportation of drugs to or from their targets site149.
Heterologous expression of ABC transport proteins has been proven successful at identifying 
substrates for many different organisms. Pfmdr1 has been expressed in Pichia pastoris and in 
Xenopus laevis oocytes after codon optimization41,43. Point mutations in this gene altered substrate 
specificity, resulting in decreased transport of a number of anti-malarial compounds. Despite the 
use of codon-optimized or codon-harmonized sequences, correct and functional orthologous 
expression of PfMRP1 could not be achieved by us after multiple attempts. Therefore, we have 
been unable to determine the substrate specificity of PfMRP1 in direct transport assays. 
Applying metabolomics to tissues and body fluids of wild type and knockout mice has proven to be 
a powerful approach to identify new substrates of (orphan) ABC transporters150. Compounds that are 
differentially distributed are identified using a metabolite database. In this manner, composition of 
urine, plasma and bile derived from wild type mice could be compared with that of knockout mice and 
specific ABC substrates were found. 
In this study, we aimed to identify new endogenous MRP1 substrates by applying untargeted 
metabolomics on erythrocytes infected with wild type and Δmrp1 P. falciparum parasites. 
MATERIALS AND METHODS
Parasite culture, gene deletion and selection of iRBC
Stable deletion of mrp1 was exerted via the double crossover recombination method previously 
described151. From these gene removal procedures, two gene-deleted lines from independent 
transfections were obtained: PfΔmrp1 and PfΔmrp1+hdhfr. In the PfΔmrp1 lines, the positive 
selectable marker that was used during the deletion procedure was removed through a FLPe 
recombinase procedure, which has not been performed in the PfΔmrp1+hdhfr gene deleted 
line152. This selectable marker consists of the human dihydrofolate reductase (hdhfr) gene, which 
confers resistance to and enables selection with the antifolate compound WR99210 for parasites 
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in which the gene targeting construct has been integrated. Parasites were cultured in a semi-
automated culture system using standard in vitro culture conditions for P. falciparum as previously 
described9,16,153. In short, human serum supplemented RPMI medium was changed twice daily and 
0,5% hematocrit shaken cultures were maintained at parasitaemias below 20%. Schizont stage 
parasites were selected through synchronization of the parasite cultures using a 63% percoll 
centrifugation at 2.000xg, and approximately 40 hrs after initial synchronization, a second percoll 
treatment was performed to select late stage schizonts only154. The RBCs with the selected parasite 
stages were washed with medium and counted in a Burker-Türk counting chamber, after which 
they were centrifuged, washed with PBS, and finally lysed in hypotonic buffer (5mM KH2PO4, pH 
7,4). Parasites and RBC membranes were removed with a second centrifugation step at 4.000xg for 
5 minutes, after which the supernatant was used for further analysis.
Identification of MRP substrates by untargeted metabolomics
Untargeted metabolomics was performed on RBC lysate as described previously155. In short, 250 µL 
of the RBC lysate was selected, and 750 µL methanol was added for deproteinization. Samples were 
vortexed, centrifuged and the supernatant evaporated in a speed-vac. Extracts were reconstituted 
in 50 µL 50% methanol, and HPLC was performed on a Dionex Ulti-Mate 3000 RSLCnano system 
(Thermo Fisher Scientific) using a ReprosilPur Basic C18 HPCL column protected by a KrudKatcher 
Ultra in-line filter (Phenomenex). Mass spectrometry was performed using an LTQ-Orbitrap 
Discovery mass spectrometer (Thermo Fisher Scientific), operated in negative ionization mode. 
Data acquisition was performed using Xcalibur software (Thermo Fisher Scientific). Data were 
analyzed using XCMS Online (xcmsonline.scripps.edu)156,157 after conversion of chromatograms 
to mzXML format using Proteowizard156,158. XCMSonline settings for feature detection: Polarity, 
negative; method, centWave;  ppm, 2.5; snthr, 20; peakwidth, 15-90; mzdiff, 0.01; prefilter peaks, 
3; prefilter intensity, 100; noise, 0;  On average we detected 2203 features per sample (range: 
1738-2801). XCMS online retention time correction settings: method, obiwarp; profStep, 0.1. XCMS 
online alignment settings: method, density; bw, 5; mzwid, 0.015; minfrac, 0.5; minsamp, 1. Accurate 
masses of differentially present compounds were used to search in the online databases HMDB 
and METLIN and their identity confirmed by making MS-MS fragmentation spectra. Relative 
metabolite concentrations were determined from ion chromatograms through manual peak 
integration after correction for parasite density159,160. Each parasite line was tested in triplicate, and 
two measurements were performed for every sample.
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Detection of folate by LC/MS-MS
Folate concentrations in the red blood cell department of parasitized cells were measured using a 
LC-MS/MS system consisting of a HPLC (Accela®, Thermo Scientific, San Jose, CA, USA), a quaternary 
ultra high pressure pump, a vacuum degasser and an autosampler, coupled to a (TSQ Vantage®, 
Thermo Scientific, San Jose, CA, USA) triple quadrupole mass spectrometer. Liquid Chromatographic 
(LC) separation was performed using a HSS T3 analytical column 
Figure 1. Pfmrp1 knockout confirmation
A Long range PCR was performed using primers P1 and P2, spanning the 5’ and 3’ TR, amplifying the targeted 
domain of mixed blood stage parasites. A PCR product for wild type mrp1 of 7937 bp was obtained, band sizes 
of 5353 and 2257bp were obtained for the PfΔmrp1+hdhfr and PfΔmrp1 lines, respectively. Stable deletion of the 
B mrp1 genes in P. falciparum was accomplished through double crossover recombination. Target regions (TR) 
at the 5’ and 3’ end of the gene allowed insertion of the disruptive vector and excision of the ORF upon positive 
selection of transfected parasites containing the hdhfr selection cassette, followed by negative selection of 
single crossover events using the fcu marker. Upon consecutive transfection with the FLPe encoding construct, 
selectable marker sequences between the FRT sites were excised, resulting in a gene deleted parasite with 
only a 34 base pair FRT site scar. 
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(1.8 μm; 100 × 2.1 mm,  Acquity UPLC®, Waters, Ireland) coupled to a VanGuard® HSS T3 pre-column 
(1.8 µm; 5 × 2.1 mm, Acquity UPLC®, Waters, Ireland). The elution gradient used consisted of 30 
seconds 100% A, 3 minutes 15% B, followed by 7 minutes 100% A. Solvent A of the mobile phase 
contained 0.1% (v/v) formic acid (HCOOH) in water and solvent B 0.1% (v/v) formic acid (HCOOH) in 
acetonitrile. The column temperature was set at 30°C, sample injection volume was 10 µL and total 
analysis run time 10 minutes. The effluent from the HPLC was passed directly into the electrospray 
ion source, where capillary temperature was set at 207°C and vaporizer temperature at 382°C. 
Heated electrospray ionization (HESI) in the positive mode was achieved at a spray voltage of +3.5kV, 
with nitrogen as sheath and auxiliary gas with a gas pressure of 20 and 15 AU (Arbitrary Units) 
respectively. Argon was used as collision gas at a pressure of 1.5 mTorr. During the LC–HESI–MS/MS 
analysis, a time-segment program was developed to switch the divert valve of the mobile phase 
to waste or detection mode to prevent ion suppression and contamination of the ion source. The 
positive ion mode was used with selected reaction monitoring (SRM) for the quantitative analysis 
of folic acid. The most abundant product ion was used for quantification, which was performed 
using peak areas. A second and third product ion were used for qualification purposes. The optimal 
SRM transitions and collision energies (CE) were determined according to Table 1.
Table 1. SRM Transition and Collision Energies
Compound Precursor Ion (m/z)  Product Ion (m/z) CE (eV)
Folic acid 442.1 295.0 17
Folic acid 
qualifier 1
442.1 119.9 35
Folic acid 
qualifier 2
442.1 176.0 37
Antifolate sensitivity assays
Blood stage parasites were routinely cultured non-synchronously. Drug sensitivity assays were 
performed in 100 µL sample formats in black low binding, clear-bottom 96-well culture plates. 
Cultures were started at 1% parasitaemia, 2,5% haematocrite in RPMI medium supplemented 
with 10% human serum. Antifolate compounds that were tested were pyrimethamine, proguanil, 
methotrexate, WR99210 and trimethoprim. Pyrimethamine, methotrexate and WR99210 were 
purchased from Sigma; proguanil and trimethoprim were obtained from the Medicines for 
Malaria Venture organization (www.mmv.org/malariabox). Samples were incubated for 72 hours 
in candle jars, after which samples were frozen in order to lyse cells and parasites. Each compound 
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concentration was tested in triplicate, with three replicates for compounds that differentially 
affected the gene deleted lines, and two for compounds that did not shift IC50 values for mutant 
parasites. Parasite growth and viability was measured through determining parasitic lactate 
dehydrogenase (pLDH) concentration, as described previously154,161. To each well, 70 µL reaction 
mixture containing 286 mM sodium lactate, 286 µM APAD, 357,5 µM resazurin and 5,66 U/mL 
diaphorase was added, starting a reaction in which pLDH hydrolyses APAD+ into APADH, at the 
expense of lactate which is converted into pyruvate. APADH on its turn is reduced to obtain the 
fluorescent compound resorufin after resazurin transformation. The reaction was incubated on 
room temperature for 60 minutes, after which resorufin concentration was measured on a Synergy 
2 (Bio-Tek, USA) fluorescent plate reader at 530 nm excitation and 590 nm emission settings. 
Solvent or lowest drug concentrations exposed parasite samples were set at 100% growth, and 
samples with maximal inhibition concentrations were equalized to 0% growth. The inhibition curve 
fitting and statistical analysis of IC50 concentrations were performed in GraphPad Prism, version 
5.03. Curves were fitted using an inhibitor response (variable slope) calculation, and slopes were 
adjusted to NF54 steepness. Maximal inhibition was fitted to greater than 0%.
RESULTS 
The PfΔmrp1 and PfΔmrp1+hdhfr lines were evaluated on correct gene deletion. Diagnostic long 
range PCR spanning the integration site was performed and mrp1 amplification resulted in the 
expected band sizes of 5353 bp in the PfΔmrp1+hdhfr mutant line, and 2257 bp for the PfΔmrp1 
mutant line in which the hdhfr selectable marker was removed (Figure 1A). PCR amplification of 
this gene of NF54 wild type genomic DNA resulted in a band size of 7937 bp. A schematic overview 
of the production of these mutant lines is depicted in Figure 1B.
Untargeted metabolomics was applied on parasites lacking MRP1 expression, to identify new 
endogenous substrates. We found that a compound with an m/z ratio of 440.1326 and a retention 
time of 19 minutes was less abundant in lysates of erythrocytes infected with schizonts lacking 
MRP1 expression than in erythrocytes infected with wild type schizonts (Figure 2A-C). Database 
searches putatively identified this compound as folate, which was subsequently confirmed by 
comparing its fragmentation spectra with that of folate present in DMEM culture medium. No 
additional differentially distributed compounds could be detected using this approach, and also 
Manuscript_SR_DEF.indd   41 21-04-16   07:57
42
CHAPTER 3
 
Figure 3. Sensitivity of Pfmrp1 deleted parasites towards anti-folate compounds
A Molecular structures of antifolate compounds that were used in drug sensitivity assays; B methotrexate, C 
pyrimethamine, D trimethoprim and E WR99210. For methotrexate, a tenfold decrease in sensitivity for the 
PfΔmrp1 parasites could be observed. No significant decrease in IC50 could be detected for PfΔmrp1 gene 
deleted parasites compared to NF54 wild types for the other anti-folate compounds that were tested. A small 
increase in sensitivity was observed for pyrimethamine in the PfΔmrp1 parasites. F Methotrexate sensitivity 
was tested in culture medium with a tenfold increase in folic acid concentration, to 23 µM. Sensitivity of NF54 
wild type parasites towards this antifolate was significantly decreased.
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folate concentrations were not decreased in erythrocytes infected with ring and trophozoite stage 
parasites lacking MRP1 expression.
For confirmation the of the results obtained with the untargeted metabolomics approach, we used 
a LC/MS-MS method to specifically detect folate in the erythrocyte lysates. Also with this targeted 
approach a significant decrease in folate concentrations of PfΔmrp1 infected red blood cells was 
detected (Figure 2D). Mean folate concentrations in NF54 infected red blood cells were detected 
at 3.4 µM (95% CI 2.1-4.8), whereas measurements in PfΔmrp1 infected cells resulted in a mean 
concentration of 1.2 µM (95% CI 0.5-2.1), which is lies within the reference range for uninfected red 
blood cells (0.32-1.4 uM).
Figure 2. Decreased folate concentrations in red blood cells infected with Δmrp1 schizonts
A Area under the curve measurement revealed a decreased abundance in red blood cells infected with Δmrp1 
schizonts for a compound with a /z ratio of 440.1326 and a retention time of 19 minutes B The fragmentation 
spectrum of the compound showed clear similarity of that of folate (C) D Folic acid concentrations were 
measured using LC/MS-MS in the red blood cell compartment of cells infected with NF54 wild type parasites 
or the PfΔmrp1 strain. Erythrocytes infected with NF54 wild type parasites were found to contain 3.43 µM (95% 
CI 2.11-4.75) folic acid, whereas measurements in PfΔmrp1 infected cells resulted in a significantly decreased 
concentration of 1.25 µM (95% CI 0,453-2.05).
We hypothesized that MRP1 acts as a direct or indirect folate efflux mediator, and cytosolic folate 
concentrations of the parasite are most likely influenced by the deletion of the gene encoding 
mrp1. Cytosolic folate concentrations can potentially alter the effect of anti-folates, which are 
commonly used in anti-malarial treatment. Therefore, we tested the sensitivity of the mrp1 deleted 
lines towards a panel of well-known antifolates; methotrexate, pyrimethamine, trimethoprim, 
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and WR99210 (Figure 3A). PfΔmrp1 parasite sensitivity towards methotrexate was decreased 
significantly with a tenfold shift (Figure 3B, Table 2). For the other anti-folate compounds that 
were tested, no significant decrease in IC50 was detected for PfΔmrp1 parasites compared to NF54 
wild type (Figure 3C-F, Table 2). Only for pyrimethamine, a small but significant increase in 
sensitivity was observed. In all cases the sensitivity of the PfΔmrp1+hdhfr line towards this class of 
compounds was measured as control. Consequently to retaining the hdhfr resistance marker, these 
parasites were resistant towards treatment with anti-folates. 
Folate concentrations measured in the red blood cell compartment were slightly higher (3.4 
µM) than in the culture medium (2.3 µM). In order to assess the contribution of an increased 
folate concentration to the decrease in anti-folate sensitivity, the methotrexate drug sensitivity 
assays were repeated with a tenfold higher folic acid concentration in culture medium (23 µM). 
Methotrexate sensitivity significantly decreased for NF54 wild type parasites (Figure 3F, Table 2). 
For the PfΔmrp1 line a smaller and insignificant decrease in sensitivity was observed. 
Compound NF54 (95% CI) PfΔmrp1 (95% CI)
Methotrexate 190 (160-230) 1800 (1200-2500)
Methotrexate - high folate 310 (230-420) 2700 (2100-3400)
Pyrimethamine 12 (11-13) 8.1 (7.0-9.4)
Trimethoprim 1200 (1100-1300) 840 (680-1000)
WR99210 0.039 (0.029-0.053) 0.048 (0.000-1800)
Table 2 
Drug sensitivity assays (IC50 in nM). 
DISCUSSION
Mutation and upregulation of ABC transporters have been associated with P. falciparum drug 
resistance. However, direct identification of substrates has been hampered by difficulties in cloning 
and heterologous expression37,162. In this study, we have applied untargeted metabolomics to 
identify MRP1 substrates using wild type and gene-deleted parasites. 
The metabolite profile of infected red blood cells was analyzed, and significantly decreased 
concentrations of folate were detected in infected cells when the Plasmodium mrp1 was deleted. 
These results were further confirmed by a targeted approach, that also showed a decrease in 
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Figure 4. Folate biosynthesis pathway in Plasmodium parasites
Plasmodium parasites can synthesize folate de novo through the Shikimate pathway or through salvage of host 
pABA or CH3-THF. Folate antagonists act either during de novo synthesis, where the pABA and hydroxymethyl 
dihydropteridine pyrophosphate are used to form dihydrofolate or during conversion of dihydrofolate to 
tetrahydrofolate (DHFR) enzyme. Adapted from 189,190.
folate concentration in PfΔmrp1 infected red blood cells. This indicates that MRP1 is involved in 
folate export, and we hypothesized that anti-folate sensitivity might be altered for mrp1-deleted 
parasites, as intraparasitic folate concentrations might be affected. Indeed, decreased sensitivity of 
the PfΔmrp1 parasites towards methotrexate was detected, however, the effectivity of other anti-
folate compounds including pyrimethamine, WR99210 and trimethoprim was not different in mrp1-
gene deleted parasites compared to NF54 wild type parasites. Although PfΔmrp1 parasites were 
initially selected by applying the antifolate WR99210, the selection marker (human dhfr) had been 
removed and parasite culture had been prolonged without the addition of selective drugs prior to 
these experiments. In addition, another ABC transporter knockout parasite that was selected using 
the same method did not show an indication of decreased folate levels (data not shown).
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Folate is a known substrate of MRP transport proteins in many organisms, including humans163-166. 
Also in P. falciparum, MRP1 has previously been suggested to be a folate exporter, which was based 
on the identification of specific point mutations in the encoding gene after prolonged antifolate 
(sulfadoxine/ pyrimethamine) pressure in the population57. Plasmodium parasites can synthesize folate 
de novo through the Shikimate pathway or through salvage of host para-aminobenzic acid (pABA) or 
5-methyltetrahydrofolate (CH3-THF) imported from extracellular compartments (Figure 4)167,168. The 
conservation of de novo synthesis enzymes underlines the high demand for folate during specific 
life cycle stages in which proliferation of the parasite is unparalleled169. Although folate is involved in 
multiple processes, its function as one-carbon donor in purine synthesis is most fundamental and 
explains its high consumption during cellular replication170,171. Folate antagonists act upon schizont 
stage parasites in which DNA replication peaks, and inhibit folate synthesis at two levels; either 
during de novo synthesis, where the pABA and hydroxymethyl dihydropteridine pyrophosphate 
components are joined into dihydrofolate by the hydroxymethyl dihydropteridine pyrophosphokinase 
– dihydropteroate synthase enzyme complex, or during conversion of dihydrofolate to tetrahydrofolate 
by the dihydrofolate reductase (DHFR) enzyme. Sulfadoxine, sulfalene, sulfamethoxazole and dapsone 
are structural analogues of pABA. The sulfa-adducts that are incorporated with these compounds lead 
to enzyme activity inhibition in downstream folate metabolism. DHFR is the target of a second set of 
anti-malarial antifolates; pyrimethamine, proguanil, methotrexate, trimethoprim and WR99210. These 
compounds in general bind to DHFR with high affinity, thereby inhibiting its function. Methotrexate is 
the only structural analogue of folate. 
We have evaluated the efficacy of multiple antifolate compounds on mrp1-deleted P. falciparum 
parasites. The IC50 concentrations that were obtained in this study are within the range of 
previously detected in vitro sensitivity profiles. For pyrimethamine, the IC50 value of 12 nM lies 
within the range of reported inhibitory concentrations (<10 to 480 nM) in different assay types172-177. 
Also for WR99210, the IC50 of 0.039 nM was very near to those previously reported for different 
parasite lines (0.075-0.21 nM)178-180. Trimethoprim IC50 concentrations that have been reported to 
range from 130 nM to 30 µM in different assay types of chloroquine sensitive and resistant strains 
in medium depleted of folic acid and pABA are in harmony with our observation (1,2 µM)180-182. For 
methotrexate, sensitivity reports range between 0.32 nM and 600 nM in in vitro assays, which is in 
agreement with our NF54 IC50 measurement of 190 nM
183-185. 
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Only for methotrexate we found a MRP1 specific effect on parasite sensitivity as the IC50 was increased 
by tenfold after deletion of mrp1. As folate concentrations are presumably increased in mrp1-deleted 
parasites resulting from reduced folate export, the affinity of methotrexate for DHFR may be antagonized 
by the increased intraparasitic folate concentrations. The intraparasitic folate concentrations could, 
however, not be determined due to the very small sample volume. The beneficial effect of increased 
folate concentrations on survival of antifolate treatment has been observed previously184,186. This 
mechanism was confirmed by methotrexate sensitivity assays in high folate medium, where a small but 
significant increase in the IC50 concentration for NF54 wild type parasites was observed. This shift was not 
seen in PfΔmrp1 parasites, most likely because a maximal beneficial intraparasitic folate concentration 
was already reached. The fact that the increase in IC50 concentration for the mrp1-deleted line is much 
larger than for the folate supplemented parasites might be explained by the assumption that folate only 
partly reaches its intraparasitic target when added to the culture medium. A mechanism of resistance 
related to the folate concentration has been previously proposed in a study on Pfmrp1 single nucleotide 
polymorphism selection in regions of prolonged sulfadoxine-pyrimethamine treatment57. Surprisingly, 
we did not observe decreased sensitivity towards the other anti-folate compounds. We speculate that 
the folate analogue, methotrexate, might have a different inhibitory mechanism than the other anti-
folates.
Methotrexate does not only mimic folic acid in its DHFR binding capacity, it is also a competent 
substrate of human MRP transport proteins, including the folate exporters163,164,187,188. The differential 
transport of folate in PfΔmrp1 parasites implies that also methotrexate is a likely substrate candidate 
for this export pump. This does not, however, explain the methotrexate-specific sensitivity shift in 
PfΔmrp1 parasites, as deletion of the gene results in decreased export. In case methotrexate would 
indeed be a PfMRP1 substrate, export from the cytosolic compartment of the parasite is abolished 
in PfΔmrp1 parasites, which would increase intracellular methotrexate concentrations and could 
counteract folate containment effects. 
In this study, we have identified folate as a likely PfMRP1 substrate through untargeted 
metabolomics, and confirmed differential transport in PfΔmrp1 parasites to the red blood cell 
compartment through LC/MS-MS. Drug sensitivity assays showed decreased sensitivity of PfΔmrp1 
parasites towards methotrexate. The involvement of PfMRP1 in the efficiency of anti-folate malaria 
treatment is therefore anticipated.
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ABSTRACT 
Multidrug resistance-associated proteins (MRP) belong to the C-family of ATP-binding cassette 
(ABC) transport proteins, and are known to transport a variety of physiologically important 
compounds and to be involved in the extrusion of pharmaceuticals. Rodent malaria parasites 
encode a single ABCC protein, whereas human parasites encode two: MRP1 and MRP2. Although 
associated with drug resistance, their biological function and substrates remain unknown. To 
elucidate the role of MRP throughout the parasite life cycle, P. berghei and P. falciparum mutants 
lacking MRP expression were generated. P. berghei mutants lacking expression of the single MRP as 
well as P. falciparum mutants lacking MRP1, MRP2 or both proteins have similar blood stage growth 
kinetics and drug-sensitivity profiles as wild type parasites. We show that MRP1-deficient parasites 
readily invade primary human hepatocytes and develop into mature liver stages. In contrast, both 
P. falciparum MRP2-deficient parasites and P. berghei mutants lacking MRP protein expression abort 
in mid- to late liver stage development, failing to produce mature liver stages. The combined P. 
berghei and P. falciparum data are the first demonstration of a critical role of an ABC transporter 
during Plasmodium liver stage development.
 
Manuscript_SR_DEF.indd   52 21-04-16   07:57
53
Multidrug ABC transporters are essential for hepatic development of Plasmodium sporozoites
INTRODUCTION 
ATP binding cassette (ABC) transport proteins are evolutionary well conserved membrane 
transporters that translocate structurally and functionally diverse compounds at the expense of 
ATP, even against steep concentration gradients87. The structure of a typical ABC transporter is 
composed of two transmembrane domains (TMDs), each consisting of six transmembrane helices 
(TM) and two cytosolic nucleotide binding domains (NBDs) (Figure 1A)20. Most of the ABC family 
members act as efflux systems and are therefore predominantly located on plasma membranes87. 
These transport proteins are well known for their role in multidrug resistance, as many classes of 
drugs are among their substrates. Mutations or upregulation of genes encoding ABC transporters 
may enhance efflux and decrease intracellular drug accumulation, ultimately resulting in 
resistance14,191. ABC proteins are classified into seven subfamilies (A-G), which can be distinguished 
upon phylogenetic analysis of the conserved NBDs and have differential compound specificities148.
Proteins of the ABC transporter subfamily C (ABCC) are often referred to as the MRPs (multidrug 
resistance-associated proteins)192. The human MRP family consists of 13 members. These 
transporters predominantly translocate organic anions across the plasma membrane, including 
glutathione-, glucuronate- or sulfate- conjugates from endogenous and exogenous sources as 
well as cyclic nucleotides, leukotriens and prostaglandins that are involved in cellular signaling 
processes193-195. Several MRP proteins are known to transport drugs and are involved in resistance 
acquisition196.
The genome of the human malaria parasite Plasmodium falciparum encodes sixteen ABC 
family members148. Three of these transporters, including the multidrug resistance protein 1 
(Pfmdr1) which has been most extensively characterized148, have indeed been associated with 
resistance to antimalarial drugs. The sequenced Plasmodium genomes contain either one or 
two genes encoding C-family ABC transport proteins. Human and non-human primate malaria 
parasites possess two genes, whereas rodent parasites have one gene (www.plasmodb.org)148. 
In P. falciparum, PF3D7_0112200 and PF3D7_1229100, encode the multidrug resistance protein 1 
(PfMRP1) and 2 (PfMRP2), respectively. These proteins have 41% sequence identity at the amino 
acid level. Characterization by phylogenetic analysis of the highly conserved nucleotide binding 
domain (NBD), which consists of the Walker A, ABC signature and Walker B regions, showed 
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47.2% and 57.0% identity of the first and second NBD regions, respectively17 (see Figure 1A for 
a schematic representation of the typical structure of ABCC proteins). The single P. berghei mrp 
gene (PBANKA_144380) has a syntenic genome location with Pfmrp2 (www.plasmodb.org). 
DNA sequence alignment of PBANKA_144380 with Pfmrp1 and Pfmrp2 shows 36.7% and 42.0% 
identity, respectively. The higher sequence similarity of PBANKA_144380 in combination with its 
syntenic location with Pfmrp2 suggests that it is the functional ortholog of Pfmrp2, as reported 
previously148,197, and is therefore referred to as Pbmrp2 in this work. 
Mutations in the gene encoding for P. falciparum MRP1 have been associated with increased 
resistance to antimalarials sulfadoxine-pyrimethamine, chloroquine and quinine, although its 
definitive role in drug responses remains controversial11,57,198. In addition, evidence has been 
presented that increased MRP2 expression confers tolerance to quinolone drugs199 and the high 
genetic variability in Pfmrp2 has been associated with reduced quinoline sensitivity66. We have 
previously shown that both MRP1 and MRP2 of P. falciparum are located on the plasma membrane 
of blood stage parasites17, indicating that MRP-mediated transport may play a role in parasite 
growth within the erythrocyte. Previous analysis of a P. falciparum mrp1 null-mutant, generated 
through targeted gene-deletion, provided evidence that blood stage MRP1-deficient parasites 
exhibited reduced growth; however, the ability to generate mrp1-null mutants demonstrates 
that MRP1 is dispensable for development within erythrocytes64. This may be the result of MRP2-
mediated compensation of MRP1 function. In other organisms, MRP proteins are known to share 
many substrates and redundancy in transport function of different ABCC subfamily members 
has been reported192. Furthermore, a role of MRP1 in glutathione efflux and transport of different 
antimalarial drugs was demonstrated in this mrp1-null mutant64. Another study showed that the 
deletion of 4.1 kb in the P. falciparum mrp2 upstream region resulted in altered transcription and 
increased expression, as well as increased tolerance to quinoline drugs200.
The role of MRP transporters in alternative parasite life cycle stages has not been investigated. In 
particular their role in how the parasite establishes an infection in hepatocytes after an infectious 
mosquito bite. Sporozoites injected by a mosquito penetrate the microvasculature and traverse 
multiple hepatocytes before establishing a stable infection in the liver. The pre-erythrocytic 
phase is clinically silent, but represents a phase of high expansion, as a single sporozoite can 
give rise to thousands of merozoites. There is a large variation in the duration of the liver stage 
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between various Plasmodium species, as for P. berghei this is approximately 52 hours, whereas 
P. falciparum parasites require 6-7 days to reach full maturation. It is known that during the liver 
stage development the parasite regulates the host cell response and metabolism (e.g. inhibition 
of apoptosis, autophagy etc.) and this is known to play an important role in parasite survival inside 
the nucleated hepatocyte201-203. MRP proteins may play a role both in cellular signaling mechanisms 
and/or metabolism supporting development within the hepatocyte. 
To further investigate the function and possible redundancy of MRP1 and MRP2 during all life cycle 
stages, and to determine their role in drug-sensitivity, we have genetically targeted the single mrp 
gene in the rodent parasite P. berghei and both P. falciparum mrp genes for gene-deletion. Analysis of 
the blood stages of the null-mutants of both species, including a P. falciparum mutant lacking both 
mrp1 and mrp2, showed asexual blood stage development and drug-sensitivity profiles to a number 
of known antimalarial drugs similar to wild-type parasites. In contrast, liver stage analysis showed 
that MRP transport is essential for Plasmodium development in hepatocytes. We demonstrate that 
expression of P. falciparum MRP2 and its P. berghei ortholog at the plasma membrane of hepatocytic 
stages is critical for producing liver stage merozoites that can subsequently infect erythrocytes. 
Our study is the first to demonstrate a critical and specific role of a Plasmodium ABC transporter 
during liver stage development.
MATERIALS AND METHODS
Experimental animals and parasites
Female C57BL/6 and Swiss OF1 mice (6–8 weeks), Swiss albino CD-1 mice and BALB/c (4-6 weeks 
old) from Charles River were used. Four different reference parasite lines P. berghei ANKA were 
used. The wild type (WT) reference line cl15cy1204 and three reference reporter lines that express 
fluorescent markers but are drug-selectable marker free: i) line 507cl1 (mutant RMgm-7, www.
pberghei.eu) expressing GFP under the control of the eef1aa promoter ii) line 820cl1m1cl1 (WT 
Fluo-frmg; RMgm-164) expressing RFP under the control of the female gametocyte specific 
promoter lap4(ccp2) (PBANKA_131950) and GFP under the control of the male gametocyte specific 
promoter of PBANKA_041610 and iii) line 676m1cl1 (mutant RMgm-29; www.pberghei.eu) which 
expresses the fusion protein GFP-Luciferase under control of the eef1α promoter. NF54 was used as 
WT reference line for P. falciparum205,206.
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Generation and genotyping of gene-deletion mutants
The abcc (mrp2) gene (PBANKA_144380) was deleted in P. berghei using standard methods of 
transfection (Fig 1A; Figure S1)207. In short, a double cross-over strategy was applied using 5’ and 
3’ target regions (TR) that were amplified from WT genomic DNA using primer pairs 2996/2993 
and 2981/2982 (Table S1). These products were cloned into the pL0001 plasmid (www.mr4.com), 
flanking the pyrimethamine resistant Toxoplasma gondii (Tg) dihydrofolate reductase-thymidylate 
synthase (dhfr/ts) selectable marker under the control of P. berghei dhfr/ts promoter. The resulting 
gene-deletion construct, pL1266, was linearized using the appropriate enzymes (Table S1). 
Transfection and selection of transformed parasites with pyrimethamine was performed as 
described previously204 using parasites of reference line 507cl1 and 820cl1 to obtain gene-deletion 
mutant lines 1025 and 1512, respectively. Clonal lines of the Pb∆mrp2 gene-deletion mutants 
(1025cl2, 1512cl1) were obtained by limiting dilution of the parasites in mice. Correct integration of 
the DNA construct was determined by Southern analysis of digested genomic DNA or chromosomes 
separated by pulse-field gel (PFG) electrophoresis. Southern blots were hybridized with P. berghei 
specific probes: 3’UTR dhfr/ts and 3’-region of mrp2. The last probe was PCR amplified from genomic 
WT DNA using primer pair 5094/5095 (Table S1). Transcription of mrp2 was determined by Northern 
analysis of RNA obtained from WT and gene-deletion mutant blood stages of asynchronous in vivo 
infections or from synchronous blood infections of WT parasites208. Northern blots were hybridized 
with a 5’-UTR fragment of mrp, PCR amplified from genomic WT DNA using primer pair 5092/5093 
and with the a/b-large subunit rrna probe as control (primer 644)209. Reverse transcriptase PCR 
reactions were carried out following manufacturer’s recommendations (Invitrogen) with primer 
pair 136 and 138 which amplify a 1.3 kb fragment of the internal part of the open reading frame of 
mrp2 (Table S1). As a control for gDNA contamination, PCRs were carried out on cDNAs synthesized 
in the presence (+) or absence (-) of reverse transcriptase. No cDNA (-D) and P. berghei WT gDNA (G) 
were used as negative and positive controls, respectively. 
For the generation of gene-deletion P. falciparum mutants, NF54 wild type parasites were cultured 
in a semi-automated culture system using standard in vitro culture conditions for P. falciparum 
and induction of gametocyte production was performed as previously described153,205,210. In short, 
human serum supplemented RPMI medium was changed twice daily and 0,5% hematocrit shaken 
cultures were maintained at parasitaemias below 20%. The Pfmrp1 (PF3D7_0112200) and Pfmrp2 
(PF3D7_1229100) genes were deleted using a modified construct based on plasmid pHHT-FRT-
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(GFP)-Pf52 for double crossover recombination through positive and negative selection (Figure 
1A; S2)151. 5’ and 3’ TR were PCR-amplified (LA Taq, Takara) from genomic P. falciparum DNA of the 
NF54 strain using primer pair SR001 /SR0002 (Pfmrp1 5’ TR), SR003/SR004 for the Pfmrp1 3’ TR, SR005/
SR006 for the Pfmrp2 5’ TR and SR007/SR008 for the Pfmrp2 3’ TR (Table S1). All PCR products were 
sequenced after TOPO TA (Invitrogen) sub-cloning, and consecutively cloned into pHHT-FRT-(GFP)-
Pf52 upon digestion with BssHII/BsiWI and XmaI/NheI for the 5’ and 3’ TR, respectively, resulting in 
plasmids pHHT-FRT-(GFP)-Pfmrp1 and pHHT-FRT-(GFP)-Pfmrp2. Transfection with these constructs 
and selection of mutant parasites was performed as described211. These lines were subsequently 
transfected with pMV-FLPe to remove the FRT flanked drug-selectable marker cassette as 
described152, resulting in Pf∆mrp1*FLPe (PfΔmrp1) and Pf∆mrp2*FLPe (PfΔmrp2) mutant lines (Figure 
S2). A consecutive gene deletion was made in the PfΔmrp2 gene deletion mutant, targeting mrp1 
using plasmids pHHT-FRT-(GFP)-Pfmrp1 as described above, thereby creating the double gene-
deletion parasite PfΔmrp1Δmrp2. Clonal lines for the PfΔmrp1, PfΔmrp2 and PfΔmrp1Δmrp2 parasites 
were selected by limiting dilution in 96-well plates as described212. Genotype analysis of all gene 
deletion mutants was performed by an internal gene specific PCR using primer pair SR009/SR010 
for mrp1 and SR013/SR014 for mrp2 (Table S1), combined with an Expand Long range dNTPack 
(Roche) diagnostic long-range PCR (LR-PCR, using primer pairs SR011/SR012 for mrp1 and SR015/
SR016 for mrp2, restricted with the appropriate enzyme) (Figure S2C). Northern analysis of RNA 
was performed as described above; blots were hybridized with the respective 5’ TR.
Generation and genotyping of transgenic P. berghei parasites expressing cmyc-tagged Pbmrp2
The pL1419 construct was used to generate transgenic P. berghei parasites expressing a C-terminally 
cmyc-tagged MRP2213. The smac targeting region was replaced by a PCR-amplified targeting region 
of mrp2 using primer pair 5090/5091 (Table S1). Subsequently, the mCherry reporter cassette was 
replaced in this construct with a DNA-fragment containing the triple cmyc cassette which was 
PCR-amplified from plasmid pL1435 using primer pair 4816/4817 (Table S1) resulting in the final 
construct pL1672. After linearization with restriction enzyme NdeI, this construct was used to 
transfect parasites of line 676cl1 as described above. Transgenic parasites were selected and cloned 
as described above (mrp::cmyc, 1732cl3). Correct integration of the DNA construct was determined 
by Southern analysis of chromosomes separated by PFG electrophoresis hybridized with the P. 
berghei specific probe 3’UTR dhfr/ts.
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Phenotypic analysis of P. berghei gene-deletion mutants
The in vivo multiplication rate of asexual blood stages was determined during the cloning 
procedure as described214. Parasitaemias (in percentage) in Swiss OF1 mice injected with a single 
parasite were determined at day 8 to 11 on Giemsa stained blood films. Per mouse, an estimated 
number of 1.2 x 1010 erythrocytes (2 mL of blood) was used to calculate the multiplication rate 
per 24 hours. The percentage of infected erythrocytes in mice infected with reference lines of the 
P. berghei ANKA strain consistently ranged between 0.5-2% at day 8 after infection, resulting in a 
mean multiplication rate of 10 per 24h204. In addition, parasite growth was analyzed in Swiss mice 
(5 mice per group) infected intraveneously (i.v.) with 200 parasites of two reference lines (WT and 
507cl1) and two mrp2 gene-deletion mutants (PbΔmrp2-a, 1025cl2 and PbΔmrp2-b, 1512cl1). In these 
mice, parasitemia was determined in Giemsa-stained blood smears on days 1–7 after infection.
 
Feeding of A. stephensi mosquitoes with P. berghei infected mice and sporozoite collection from 
salivary glands as well as P. berghei gliding motility were performed as described215. Infectivity of P. 
berghei sporozoites and development was determined in cultures of Huh7 cells215. For analysis of 
liver stage development by immunofluorescence, parasites were stained with the following primary 
antibodies: anti-PbEXP1 (PBANKA_092670) raised in chicken216, anti-PbHSP70 (PBANKA_081890) 
raised in mouse217 and anti-MSP1 (PBANKA_083100) antibody obtained through MR4 (MRA-78, 
www.mr4.org)218. 
C57BL/6 and Swiss mice were i.v. inoculated with 5x104 and 3x105 sporozoites. Blood stage 
infections were monitored by Giemsa-stained thin smears collected on day 4–14 post-inoculation. 
The prepatent period (measured in days) was defined as the first day with a parasitemia of 0.5–2%.
Phenotypic analysis of P. falciparum gene-deletion mutants
P. falciparum blood stage multiplication was evaluated upon subculturing at 0,1% parasitaemia in a 2,5% 
hematocrit candle-jar culture with daily change of medium. Parasitaemias were determined on Giemsa-
stained blood films of day 0, 3, 5, 6 and 7. Mature stage V gametocytes were produced in cultures 
optimized for gametocytogenesis as described previously206. Gametocytaemia and gametocyte 
morphology were evaluated after 14 days. 
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Drug sensitivity assays for P. falciparum parasites were performed using an adapted Plasmodium 
lactate dehydrogenase (pLDH) activity assay employing resazurin conversion as a read-
out154. Cultures were started in 100 µL sample format at 1% parasitaemia and 2,5% hematocrit 
and incubated for 72 hours. Antimalarial sensitivity was tested for chloroquine, artemisinin, 
dihydroartemisinin, atovaquone, lumefantrine, quinine and mefloquine, all purchased from Sigma-
Aldrich. Each compound concentration was tested in triplicate and in three independent assays. 
Resorufin concentration was measured with a Synergy 2 (Bio-Tek, USA) fluorescent plate reader 
at 530 nm excitation and 590 nm emission. Solvent exposed parasite samples represented 100% 
growth, and samples with maximal inhibitory concentrations were equalized to 0% growth. The 
inhibition curve fitting and statistical analysis of IC50 concentrations were performed in GraphPad 
Prism, version 5.03. An inhibitor response (variable slope) fit was used to determine inhibitory 
curves and hill slopes were adjusted to NF54 steepness. Statistical analysis was performed in 
GraphPad where comparisons for significant differences between the obtained log IC50-values of 
wild type and mutant groups were carried out by a one-way-Anova.
Male exflagellation capacity was evaluated after stimulation with fetal calf serum at pH 8.0152. 
In the standard membrane feeding assays, oocyst development was monitored at day 7 and 
selection of sporozoites from mosquito salivary glands was performed around day 14153,219. 
Sporozoite gliding motility on glass plates was evaluated by visualizing gliding trails using anti-CSP 
(PF3D7_0304600; 3SP2) antibody and hepatocyte traversal capacity was analyzed through FACS 
analysis of rhodamine-labelled dextran positive cells, as previously described220,221. The infection 
and development monitoring of P. falciparum parasites in primary human hepatocytes that were 
freshly isolated from human remnant material after tumor removal surgery were performed 
during maximal ten days as described previously222,223. Immunocytochemistry was performed 
after fixing the cultures with 4% para-formaldehyde (PFA), quenching with 0.1 M glycine, blocking 
with 10% FCS and permeabilization with 1% Triton-X-100. Localization of was performed using 
specific antibodies against HSP70 (PF3D7_0930300) raised in rabbit224; CSP raised in mouse225; EXP1 
(PF3D7_1121600) raised in mouse226, MSP1 (PF3D7_0930300) raised in mouse227, MRP1 and MRP2, 
both raised in rabbit17. Epitopes were then identified using anti-rabbit-ALEXA488  and anti-mouse-
ALEXA594 (Molecular probes) and nuclei were stained with 1 µg/ml DAPI. Analysis was performed 
using a Olympus FV1000 and a Zeiss LSM510 meta microscope.
Manuscript_SR_DEF.indd   59 21-04-16   07:57
60
CHAPTER 4
Figure 2. Liver stage development of P. berghei Pbmrp::cmyc and PbΔmrp2 parasites
A Development of Pbmrp::cmyc liver stages in cultured hepatocytes visualized by staining with antibodies 
recognizing cmyc (green) and the parasite cytoplasm (anti-HSP70; red). Nuclei are stained with Hoechst-33342. 
Scale bar 10μm. B Standard (top row) and confocal (bottom row) fluorescence microscopy images of 
Pbmrp::cmyc liver stages in cultured hepatocytes.  Pbmrp::cmyc liver stages were stained with antibodies 
recognizing cmyc (red) and the parasite vacuole membrane protein EXP1 (green). Nuclei are stained with 
Hoechst-33342. Images were acquired with a DM RA Leica fluorescence microscope and confocal microscope 
Leica TCS SP8 X with white light laser (WLL). Scale bar 10μm. C WT and Pb∆mrp2 liver stages in cultured 
hepatocytes visualized by staining with antibodies recognizing the PVM (anti-EXP1; green) and the formation 
of merozoites (anti-PbMSP1, red). Hoechst-33342: nuclear staining (blue). Scale bar 10 μm. D Development of 
liver stages in cultured hepatocytes at different hours post infection (hpi) of wild type (WT) parasite (left panel) 
and mrp2 gene-deletion mutant (PbΔmrp2). Both WT and PbΔmrp2 express the GFP reporter protein under 
control of the constitutive eef1a promoter. Fluorescence images are from live parasites. Nuclei are stained with 
Hoechst-33342 (blue). Scale bar 10μm. Parasites appear to invade and develop like WT parasites until 30 hpi; 
they become  significantly smaller from 40 hpi (see B) and contain much fewer nuclei than WT parasites at 52 
hpi. E Sizes (area of fluorescence) of WT and PbΔmrp2  liver stages in cultured hepatocytes at 24, 30, 40, 48 
and 52 hpi. F Invasion of hepatocytes by sporozoites and development of liver stages (LS) WT and PbΔmrp2 
parasites. LS development is determined by counting liver stages at 24 and 52 hours post invasion (hpi), the 
size of LS at 52 hpi and the percentage of LS that stain with anti MSP1-antibodies at 52 hpi. 
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Immunisation of mice with mutant (Pb∆mrp2) P. berghei sporozoites
P. berghei sporozoites were collected at day 21-27 after mosquito infection by dissection of salivary 
glands. 5 BALB/c mice per group were immunized by intravenous injection with either saline, 400, 800 
or 1200 Pb∆mrp2 sporozoites. Immunized mice were challenged after 21 days by intravenous injection 
of 1x104 sporozoites of the P. berghei ANKA reference line 676m1cl1 which expresses the GFP-Luciferase 
reporter protein. Liver stage development  in the challenged mice was monitored by real time in vivo 
imaging and parasite load was quantified by measuring luciferase activity using a Lumina luminescence 
detector (Caliper Life Sciences, USA)228. After challenge, mice were monitored for blood infections by 
analysis of Giemsa stained films of tail blood at day 4‐21. Pre‐patency (measured in days after sporozoite 
inoculation) was defined as the day when a parasitemia of 0.5-2% was observed.
Ethics Statement
All animal experiments performed at the LUMC were approved by the Animal Experiments Committee 
of the Leiden University Medical Center (DEC 07171; DEC 10099) and all animal experiments performed at 
the RUNMC were approved by the Animal Experiments Committee of the Radboud University Nijmegen 
Medical Center (DEC 2010-229). The Dutch Experiments on Animal Act is established under European 
guidelines (EU directive no. 86/609/EEC regarding the Protection of Animals used for Experimental 
and Other Scientific Purposes). All mice procedures conducted at the UPR-School of Medicine were 
approved by the IACUC of the Medical Sciences Campus, University of Puerto Rico, and all work was 
done in accordance with the “8th Guide for the Care and Use of Laboratory Animals” (National-Research-
Council, 2011) and regulations of the PHS Policy on Humane Care and Use of Laboratory Animals.
Primary human liver cells were freshly isolated from remnant material upon tumor removal surgery.  As samples 
were anonymized, no diagnostic techniques were applied and material was destroyed upon use, general approval 
for use of remnant material prior to surgery was sufficient according to Dutch ethical legislation as described in 
the Medical Research (Human Subjects) Act, and confirmed by the Committee on Research Involving Human 
Subjects region Arnhem-Nijmegen. 
RESULTS
The single P. berghei MRP protein, MRP2, is dispensable for asexual blood stages
We found evidence for expression of Pbmrp2 in blood stages by Northern analysis. In blood 
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Figure 3. Liver stage development of P. falciparum PfΔmrp parasites in human primary hepatocytes
A Localization of different proteins in WT liver stages (LS) visualized by staining antibodies recognizing MRP1, 
MRP2 (green), MSP1 (merozoite formation; red) and EXP1 (PVM; red). DAPI: nuclear staining (blue). Scale bar 
10 μm. B Development of WT and mutant LS at different days post infection, visualized by staining of the 
cytoplasm with anti-HSP70 antibodies (green). DAPI: nuclear staining (blue). Scale bar 10 μm. C Localization 
of circumsporozoite protein (CSP; red), EXP1 (PVM; red) and HSP70 (cytoplasm; green) in LS of WT and mutant 
parasites by staining with antibodies. DAPI: nuclear staining (blue). Scale bar 10 μm. D Localization of MSP1 
(merozoite formation; red) and HSP70 (cytoplasm; green) in LS of WT and mutant parasites by staining with 
antibodies. DAPI: nuclear staining (blue). Scale bar 10 μm. E Hepatocyte cell traversal of WT and mutant 
sporozoites as determined by FACS counting of dextran positive HCO4 cells. The mean percentage of traversed 
cells was for WT 14.6% (95% CI 13.4-15.8), for PfΔmrp1 26.7% (95% CI 19.6-33.7), for PfΔmrp2 17.9% (95% CI 10.8-
25.0) and for PfΔmrp1Δmrp2 22.7% (95% CI 18.8-26.6). Dextran control: hepatocytes in the presence of Dextran 
but without addition of sporozoites. F Size and numbers of WT and mutant LS in cultures of human primary 
hepatocytes. The size was determined at day 6 post infection (p.i.). Parasite numbers per well were counted at 
different days p.i.
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stages of wild type (WT) parasites, Northern analysis showed two different-sized transcripts of 
approximately 7.5 and 8 kb, indicating alternative processing of the untranslated regions as in the 
Pbmrp2 gene no introns are present (Figure 1B). The presence of Pbmrp2 transcripts have been 
reported previously in blood stage parasites;  however, the protein has not been detected in 
published proteome analyses of P. berghei blood stages (www.plasmodb.org). To analyze whether 
the MRP2 protein is expressed in blood stages we generated a transgenic line expressing a cmyc-
tagged version of PbMRP2 (mrp::cmyc) using a DNA construct that was integrated by single cross-
over into the endogenous Pbmrp2 locus, resulting in a C-terminally 3xcmyc-tagged MRP2 (Figure 
S1). The mrp::cmyc parasites showed in vivo asexual multiplication rates during the initial phase of 
infection similar to wild type (mean multiplication rate/24 hour (s.d.): WT 10 (0), n=12; mrp::cmyc 10 
(0), n=3). We were unable to detect Pbmrp::cmyc protein in blood stages by immunofluorescence 
using anti-cmyc antibodies, whereas the tagged protein was readily detected in liver stages (see 
below). The absence of Pbmrp::cmyc in blood stages indicates that either PbMRP is not expressed 
as a protein in blood stage parasites or that the expression level is too low for detection by 
immunofluorescence. To investigate if PbMRP2 was essential for growth within erythrocytes, 
PbMRP2 null-mutants were generated. The Pbmrp2 gene was targeted for deletion by double 
cross-over homologous integration of a DNA construct containing a dhfr/ts selection marker using 
standard methods of genetic modification204 (Figure 1A, S1). In two independent experiments, 
gene-deletion mutants (PbΔmrp2-a and PbΔmrp2-b) were selected indicating that PbMRP2 is not 
essential for asexual blood stage development. Correct deletion of Pbmrp2 was confirmed through 
Southern integration analysis and diagnostic PCR (Figure S1) as well as Northern and RT-PCR analysis 
(Figure 1B, S1). The PbΔmrp2 parasites showed wild type (WT) in vivo asexual multiplication rates 
through the course of an infection (Figure 1C) and during the initial phase of infection after mice 
had been infected with a single parasite (mean multiplication rate/24 hour (s.d.): WT 10 (0), n=18; 
PbΔmrp2-a 10 (0) n=7; PbΔmrp2-b 10 (0) n=5). 
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Figure 1. Generation and characterization of P. berghei and P. falciparum mutants lacking expression 
of MRP transporters
A Schematic representations of a typical MRP transporter (adapted from17, with permission) and DNA constructs 
to disrupt the mrp genes. Shown are the transmembrane domains (TMD) with 6 transmembrane segments 
and the nucleotide binding domains (NBD), the DNA constructs used to delete the complete mrp genes by 
double cross-over homologous recombination using the 5’ and 3’UTR regions replacing the gene with a drug-
selectable marker cassette (SM). See Figures S1 and S2 for details of the gene-deletion constructs and genotype 
analysis of the different P. berghei and P. falciparum mutants. B Northern analysis of mrp transcripts in wild type 
(WT) and mutant P. berghei and P. falciparum parasites confirms absence of transcription of the mrp genes in 
blood stages of the mutant parasites. P. berghei (left panel): transcripts detected in WT blood stages. P. berghei 
(right panel): absence of mrp transcripts in mutant parasites. Northern blots were hybridized with a probe 
specific for the 5’UTR of mrp2 and as a loading control with probe L644R recognizing large subunit ribosomal 
RNA (rRNA). P. falciparum (upper panel): Northern analysis of mrp1 and mrp2 transcripts in WT and mutant 
parasites. Blots were hybridized with probes specific for the 5’UTR of mrp1 and mrp2 and as a loading control 
with a probe recognizing hsp70 transcript (gene ID PF3D7_0818900 lower panel). C Asexual multiplication of 
WT and mutant parasites. Left: Parasitemia in mice infected with P. berghei WT (WT and WT-GFP) and PbΔmrp2 
parasites. Right: Parasitemia in candle jar cultures of P. falciparum WT and the different PfΔmrp mutants. 
Parasitaemia was determined in Giemsa-stained thin blood smears. 
MRP protein expression is dispensable for P. falciparum blood stage growth in vitro
In contrast to P. berghei, expression of the two MRP proteins in P. falciparum blood stages was pre-
viously demonstrated both by transcriptome and proteome analyses (www.plasmodb.org), as 
well as by immunofluorescence assays using MRP1- and MRP2-specific antibodies17. We generated 
three different gene-deletion mutants by standard reverse genetic approaches: one lacking Pfmrp1 
(PfΔmrp1), another lacking Pfmrp2 (PfΔmrp2) and a double gene-deletion mutant lacking both Pfm-
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rp1 and Pfmrp2 (PfΔmrp1Δmrp2). PfΔmrp1 and PfΔmrp2 were generated by gene-deletion through 
double cross-over homologous recombination where the genes were replaced with the hdhfr::g-
fp selectable marker cassette (Figure S2). After deletion of the mrp genes, the selectable marker 
was removed from the genome through FLPe-mediated excision of the sequence between the 
FRT sites integrated in the gene-targeting construct (Figure S2), resulting in the selectable-marker 
free mutants PfΔmrp1 and PfΔmrp2152. The double gene-deletion mutant PfΔmrp1Δmrp2 was subse-
quently generated by targeting Pfmrp1 in the selection-marker free PfΔmrp2 mutant using the DNA 
construct used for generation of PfΔmrp1 (Figure S2). Diagnostic PCR analysis in combination with 
Northern analysis of transcription confirmed correct deletion of the mrp genes in clonal lines of the 
three different mutants (Figure 1B and Figure S2). 
Analyses of asexual blood stage parasites in vitro showed that asexual blood stage multiplication 
in candle jar culture conditions for all three mutants were comparable to parent WT NF54 
parasites of the P. falciparum NF54 strain (Figure 1C). Also, during routine culturing in the semi-
automated culture system, growth rates comparable to WT were observed for all three mutant 
lines and parasitaemias of >20% were readily obtained in more than 5 independent cultures per 
mutant. In addition, gametocyte production of the three mutants was not significantly different 
from WT (Table 1). Morphology by light-microscopy was comparable to WT gametocytes and 
male gametocytes of mutants successfully produced exflagellation centers upon activation of 
gametogenesis (Table 1). Combined, these observations demonstrate that expression of MRP 
proteins is dispensable for P. falciparum development of asexual and sexual blood stages in vitro. 
Parasite Gametocytes 
(106 per mL; 
mean and 
range)
Exfl1 Oocyst 
production2
% Infected 
mosquitoes 
(mean and 95% 
CI)
Sporozoite number 
per oocyst (mean 
and range)
% of sporozoites 
with ≥1 gliding 
trail - (mean and 
range)
WT 1.9 (1.12-2.8) ++ 21.5 (13.1-29.9) 93.9 (89.9-97.8) 2850 (2388-3538) 30.2 (28.2-33.3)
Δmrp1 2.2 (0.8-3.2) ++ 13.2 (-7.9-34.3) 95.0 (79.1-111) 3982 (3569-4360) 53.6 (31.6-70.0)
Δmrp2 1.6 (0.6-2.8) ++ 35.0 (23.3-46.7) 90.0 (71.6-108) 3152 66.0 (57.1-70.8)
Δmrp1Δmrp2 0.9 (0.3-1.6) ++ 3.7 (0.75-6.57)* 46.9 (25.3-68.4)* 3517 (1614-5421) ND
Table 1: Gametocyte production and mosquito development of P. falciparum PfΔmrp parasites
1  Exflagellation (Exfl) of male gametocytes was determined in stimulated samples from day 14 gametocyte cultures 
in wet mounted preparations at 400x magnification using a light microscope; ++ score = >5 exflagellation centers 
per microscope field
2  Oocyst production is the median (95% CI) of the oocysts counted at day 7 after feeding of the mosquitoes, 
analyzed in 130, 40, 40 and 220 mosquitoes for the respective parasite strains.
* Significant different from WT (p<0. 05); One-way ANOVA
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The absence of MRP expression in blood stages does not affect sensitivity of P. falciparum to 
a number of known anti-malarial drugs
To determine if MRP contributes to drug sensitivity, in vitro sensitivity of PfΔmrp1, PfΔmrp2 and 
PfΔmrp1Δmrp2 to a number of known anti-malarial was assayed. The IC50 concentrations of 6 out of 
7 drugs tested (chloroquine, artemisinin, dihydroartemisinin, atovaquone, lumefantrine, quinine) 
were not significantly different from WT (Figure S3, Table S2) and were comparable to previously 
published data175,229-236. Only for mefloquine we detected a small but significant decrease in 
sensitivity for the three mutants, however all IC50 values are well above previously reported values. 
P. berghei MRP2 is essential for complete development within hepatocytes
Whereas no published evidence for expression of MRP transporters is available for the liver stages 
of P. berghei and P. falciparum, RNA sequencing analysis in P. yoelii reveals that it is transcribed 
at this stage of parasite development (www.plasmodb.org). Moreover, and in agreement with 
this, we can readily detect Pbmrp::cmyc protein expression during liver stage development by 
immunofluorescence analysis of infected hepatocytes in vitro at 24, 40, 48 and 52h (Figure 
2A, Figure S4A and B). Pbmrp::cmyc showed a circumferential pattern when compared to 
the cytoplasmic HSP70 (Figure 2A) protein and did not co-localize with EXP1, a protein on the 
parasitophorous vacuole membrane (PVM) (Figure 2B, Figure S4A and B). These staining patterns 
suggest that PbMRP2 is at the plasma lemma membrane of liver stage parasites. The transgenic 
parasite expressing MRP::cmyc showed a normal development of liver stages in vitro and in vivo 
(Figure S5). As the transgenic parasites exhibit a WT developmental phenotype (unlike the MRP 
deletion mutants) both in mice and mosquitoes we believe that tagging P. berghei MRP did not alter 
its function or its intracellular location.   
To assess if deletion of MRP affected parasite transmission, PbΔmrp2-infected mosquitoes were 
allowed to feed on naïve mice. None of the mice (nr=5) developed a blood stage infection (data not 
shown). Similarly, intravenous injection of 5x104-3x105 purified PbΔmrp2 salivary gland sporozoites 
(2 experiments; 14 C57Bl/6 mice) did not result in a blood stage infection. Gliding motility and in vitro 
hepatocyte invasion of PbΔmrp2 sporozoites were comparable to WT parasites (Figure 2). Gliding 
motility assays showed that 70.2% (+7.3) of the PbΔmrp2 sporozoites produced the characteristic 
circular trails compared to 73.5% (+4.2) of WT sporozoites. Infection of Huh7 cell cultures with 
PbΔmrp2 and WT sporozoites show that 49.1% (+3.5) and 53.1% (+5) of the sporozoites were able 
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A: DNA-constructs 
Gene Construct Basic 
construct
Primer Sequences Restriction 
sites
Description
Pfmrp1 PFC-MRP1 PHHT-FRT-
FCU 
SR001 GGGGCGCGCGAATCA 
AAAGGAGGTTCTTC
BsHII 5’- mrp1 targeting 
region F; probe
SR002 GGGCGTACGTTCATG 
TAATACGCATACC
BsiWI 5’- mrp1 targeting 
region R; probe
SR003 GGGCCCGGGCTTAC 
ACACACCCATGCATAC
XmaI 3’- mrp1 targeting 
region F
 SR004 GGGGCTAGCGTAAC 
TATTTCTGACCAATTC
NheI 3’- mrp1 targeting 
region R
Pfmrp2 PFC-MRP2 PHHT-FRT-
FCU 
SR005 GGGGCGCGCCTTCT 
TACATTTGTTTATCG
BsHII 5’- mrp2 targeting 
region F; probe
SR006 GGGCGTACGCGAAA 
TTGTAAACGCTTCTCCG
BsiWI 5’- mrp2 targeting 
region R; probe
SR007 GGGCCCGGGCCGA 
ATTAGCTAACTTGC
XmaI 3’- mrp2 targeting 
region F
  SR008 GGGGCTAGCGGTTC 
ATGCAAATGTTTATGC
NheI 3’- mrp2 targeting 
region R
Pbmrp2 pL1266 pL0001 2996 GGGGGTACCGATGAA 
CCGAAAAATGAAGAA 
AAATTATATAGATAAG
KpnI 5’- mrp2 targeting 
region F
2993 GGGAAGCTTGTTTTG 
CAGTTTTAGATTGTAAT 
AATGGAG
HindIII 5’- mrp2 targeting 
region R
2981 GGGGGGGGATCCTATT 
GAAGGAATTGAAACTT 
TTACACCATA
BamHI 3’- mrp2 targeting 
region F
2982 GGGGGGTCTAGAAAA 
TACTTCTGTGTGAATTGC 
CTTTGCTGA
XbaI 3’- mrp2 targeting 
region R
pL1672 pL1419 5090 GGGACTAGTCATTTT 
ATAGTCATAATATAGGG
SpeI 3’- mrp2 targeting 
region F
5091 GGGGGATCCATTTGCC 
TGGTCCTGTATAATATTAG
BamHI 3’- mrp2 targeting 
region R (without 
stop codon)
pL1435 4816 CGGGATCCGGTGGAGGTG 
GAAGATCCGAACAAAAAC 
TCATCTCAGA
BamHI 3xcmyc-3’UTR 
cam F
   4817 CGATATCGAATTCGAG 
CTCGGTACC
EcoRI 3xcmyc-3’UTR 
cam R
to invade hepatocytes, respectively. During the first 24-30 h the development of PbΔmrp2 liver 
stages with respect to number, size and number of nuclei per parasite was similar to WT liver stage 
development. In contrast, subsequent intra-hepatocytic development of PbΔmrp2 parasites was 
abnormal while parasites appear to invade and develop like WT parasites until 30 hpi they become 
significantly smaller from 40 hpi and contain fewer nuclei than WT parasites at 52 hpi (Figure 2C, 
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D and E). While expression of the PVM protein EXP1 was readily detected in PbΔmrp2 parasites, 
the liver stages remained MSP1-negative during the complete culture period. The combined 
observations demonstrate that PbΔmrp2 parasites can invade hepatocytes, establish a PVM and 
start nuclear division but are unable to form mature schizonts containing infectious merozoites.
P. falciparum MRP2 is essential for development of mature liver schizonts
Expression of both MRP proteins in P. falciparum parasites was analyzed in cultured primary human 
hepatocytes using specific antibodies against both proteins17. A circumferential staining pattern was 
observed for both PfMRP1 and PfMRP2, indicating they are likely present in the plasma lemma (Figure 
3A, Figure S4C), which is in agreement with previous observations of PfMRP1 and PfMRP2 localization 
in P. falciparum blood stages148. Also co-localization of the MRP proteins with plasma membrane protein 
MSP1237 (Figure 3A) on membranes separating individual merozoites at day 6 indicated a plasma lemma 
localization. However, staining of the PVM-resident protein EXP1 also shows a tight circumferential 
staining pattern in P. falciparum liver stages from cultured primary hepatocytes that makes it difficult to 
determine a conclusive MRP localization in P. falciparum infected hepatocytes. 
Parasites of all three mutants produced oocyst and sporozoites in A. stephensi mosquitoes. The 
two single gene-deletion mutants, PfΔmrp1 and PfΔmrp2, produced oocyst numbers in the same 
range as WT, whereas oocyst production by the PfΔmrp1Δmrp2 double gene-deletion mutant 
was strongly reduced (Table 1). Sporozoite production per oocyst in all three mutants was not 
significantly different from WT (Table 1). Sporozoites of the PfΔmrp1 and PfΔmrp2 clones showed 
effective gliding motility as well as hepatocyte traversal (Figure 3E). PfΔmrp1 and PfΔmrp1Δmrp2 
sporozoites showed even increased traversal rates compared to WT. These combined observations 
show that all mutants produce viable sporozoites that are able to glide and traverse hepatocytes. 
In primary human hepatocytes at day 2 p.i., a mean of 107 infected hepatocytes per well (95% CI 42-172) 
was observed for NF54 WT parasites, and for the 3 mutant lines, PfΔmrp1, PfΔmrp2, and PfΔmrp1Δmrp2, 
448 (95% CI 375 - 521), 348 (95% CI 249-417) and 343 (95% CI 195-492), respectively (Table S3). The 
development of liver stages of PfΔmrp1 was similar to that of WT parasites, both in total numbers, size 
and morphology (Figure 3B-F; Table S3). Both WT and PfΔmrp1 showed a gradual decrease in parasite 
numbers between day 2 and 6, as previously shown for WT parasites238. A strong increase in parasite 
diameter and nucleic content was observed in WT and PfΔmrp1 parasites (Figure 3B, F; Table S3). In 
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both WT and PfΔmrp1, multi-nucleated parasites were already observed on day 2 p.i.; the number of 
nuclei per parasite increased rapidly up to day 7 (Figure 3B). In strong contrast, liver stage development 
of both PfΔmrp2 and PfΔmrp1Δmrp2 parasites was aberrant compared to WT in terms of numbers, size, 
and morphology (Figure 3F; Table S3). After 7 days of intra-hepatocyte development, these parasites 
measured diameters comparable to WT day 2 p.i.. In addition, nuclear division was strongly inhibited in 
parasites of both lines. On day 2 p.i. all parasites showed only a single, DAPI-positive, nucleus; on day 7 
p.i. a maximum number of only 6 nuclei was observed. 
Analysis of liver stages using antibodies against CSP and EXP1 was used to determine if these 
proteins were expressed in all three mutants. CSP40 was observed in both WT and mutant parasites 
at day 2-5 p.i. (Figure 3C).EXP1 shows the typical circumferential staining pattern in all mutants, 
indicating that the lack of MRP1 and/or MRP2 expression does not affect PVM formation (Figure 
3C). In contrast, MSP1 expression could not be detected in PfΔmrp2 and PfΔmrp1Δmrp2, whereas 
expression was readily observed in both WT and PfΔmrp1 parasites (Figure 3D). The lack of MSP1 
expression indicated the absence of merozoite formation in PfΔmrp2 and PfΔmrp1Δmrp2 mutants239. 
The phenotype of arrested liver stage development of the P. falciparum mutants lacking PfMRP2 is 
similar to the phenotype of P. berghei mutants lacking PbMRP2, demonstrating that these proteins 
play an essential role in development of liver stages and formation of infectious merozoites. 
 
The abortion of liver stage development during mid-liver stages and the complete attenuation 
of PbΔmrp parasites are both features that can make such mutants attractive candidates for 
whole parasite vaccination strategies using attenuated sporozoites240. In preliminary experiments 
we evaluated protection induced by immunization of BALB/c mice with low doses of PbΔmrp2 
sporozoites. 5 mice per group were immunized with a single dose of 1200, 800 and 400 sporozoites. 
These immunized mice were challenged after 21 days by intravenous injection of sporozoites from 
the P. berghei ANKA reference line 676m1cl1, which expresses the GFP-Luciferase reporter protein. 
Liver stage development and parasite load were monitored in the challenged mice by real time in 
vivo imaging, which showed the absence of detectable liver loads in 80-100% of the immunized 
mice (Figure S6). All control mice showed high liver loads and developed blood stage parasitemia 
with a prepatent period of 5 days. In contrast, only one immunized mouse (dose of 800 sporozoites) 
had a liver load and two mice in this group developed blood stage parasitemia whereas all other 
immunized mice did not develop parasitemia (up to 21 days after challenge). These observations 
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demonstrate that single immunisation with doses as low as 400 sporozoites can induce sterile 
protective immune responses.
DISCUSSION
Parasites interacting with the host environment require cellular mechanisms for either molecular 
exchange with or defense against host cell metabolites. Energy-dependent transporters, 
such as ABC proteins, are responsible for maintaining this metabolic homeostasis. Identifying 
which transporters are essential for parasite development, transmission or metabolite efflux in 
Plasmodium spp. will provide critical information about their biological role. In this study, the role 
of MRP in the Plasmodium life cycle was investigated by the analysis of gene-deletion mutants 
that lack expression of these proteins. We demonstrate that in both Plasmodium species, MRP 
proteins are dispensable for growth within erythrocytes and for sporogonic development in the 
mosquito. In contrast, we observed an essential function of MRP2 for development in hepatocytes 
for both Plasmodium species. Whereas MRP2-deficient parasites readily invade hepatocytes at 
WT rates and establish a PV as shown by the expression and correct localization of EXP1, they are 
unable to mature into liver stage schizonts as shown by the reduced size, DNA replication and the 
absence of MSP1, a marker for merozoite formation239. The lack of MRP2 alone resulted in complete 
developmental arrest of liver stages, while the phenotype of the mrp1 gene deletion mutant was 
not altered in any of the P. falciparum life cycle stages. This indicates that MRP2 transports essential 
substrates during liver stage development, a function that cannot be compensated for by MRP1 or 
other (ABC)-transporters. 
Compared to many other organisms including humans, malaria parasites contain fewer genes 
belonging to the ABC transporters of subfamily C. Rodent Plasmodium species encode only a single 
MRP protein, whereas in human parasites two members have been identified. The single copy 
abcc gene of P. berghei is the syntenic ortholog of Pfmrp2 and shows a higher sequence similarity 
to Pfmrp2 compared to Pfmrp1, which is suggestive of functional orthology of the P. berghei 
MRP protein and PfMRP2. Indeed, upon the deletion of the P. berghei mrp gene, we observed a 
phenotype of aborted liver stage development comparable to Pfmrp2 deletion. The absence of 
blood infections after injecting high numbers of mutant P. berghei sporozoites in mice indicates 
complete abortion of liver stage development in the absence of P. berghei MRP2.
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The deletion of the single P. berghei mrp gene and the combined deletion of the two P. falciparum 
mrp genes did not result in a detectable effect on asexual blood stage multiplication, suggesting 
that MRP proteins do not play an essential role in asexual stages. In apparent contradiction, we 
have previously demonstrated that P. falciparum MRP1 and MRP2 are located on the plasma 
membrane of blood stage parasites17. However, we were unable to detect PbMRP using transgenic 
P. berghei parasites expressing cmyc-tagged PbMRP. Since we were able to detect Pbmrp::cmyc in 
hepatocytes, failure to detect it in blood stages suggests that PbMRP is either not expressed or that 
the protein expression level is too low for detection by immunofluorescence. MRP transporters do 
not have an essential function during blood stage multiplication, or alternatively other subfamily 
transporters are able to compensate for MRP function, sensitivity of the applied assays is too low 
or tested conditions deviate from natural infections. A previously reported P. falciparum mutant 
lacking MRP1 showed a reduced growth of blood stages at higher parasite densities64. Parasitaemias 
>5% could not be obtained in cultures of this mutant when medium was replaced once a day, 
which could be increased to a maximum of 7% in case culture medium was replaced twice a day. In 
contrast, we readily obtained parasitaemias between 10-20% in cultures of MRP1-deficient parasites 
using the semi-automated culture system where medium is changed twice daily206. These findings 
indicate that culture conditions may indeed act upon growth kinetics of MRP-deleted parasites. 
However, in the light of the wide range of MRP substrates in other eukaryotes, it is also possible 
that MRP2 transports molecules in the liver cell that it does not in the blood. For example, human 
MRPs are known to transport factors that are involved in intracellular signaling pathways, which 
may profoundly affect parasite development in the nucleated hepatocyte but not anucleate RBCs.
MRP1 has been associated to sensitivity of P. falciparum to anti-malarial drugs11,57,58. Single nucleotide 
polymorphisms (SNP) in MRP1 and upregulation of expression of MRP1 and MRP2 alter drug-
sensitivity profiles, possibly by increased substrate affinity and export of antimalarials. Using the 
chloroquine-resistant W2 strain, Raj et al. found an increase in sensitivity of MRP1-deficient mutants 
to chloroquine, quinine, artemisinin, piperaquine and primaquine, resulting in a decreased IC50 
concentration compared to parent WT parasites64. We did not detect changes in drug-sensitivity 
profiles of the three P. falciparum mutants lacking MRP proteins in the chloroquine-sensitive NF54 
background, except for a small decrease in mefloquine sensitivity. The differential use of Pf parasite 
background lines may be responsible for this discrepancy. Moreover, we removed the selectable 
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marker though FLPe mediated recombination, whereas the deletion of mrp1 by Raj et al. was 
exerted in a single crossover fashion, and heterologous DNA including the selectable marker was 
maintained.
Immunofluorescence analysis of liver stages of both P. falciparum and P. berghei indicate that MRP2 
is localized at the plasma lemma membrane of liver stage parasites, a site consistent with ABC 
transporters of other eukaryotic cells, and it is here that they are usually involved in the extrusion of 
various compounds. MRP transporters predominantly translocate organic anions. Substrates may 
include potentially toxic metabolites for which extrusion may be essential for parasite survival or 
glutathione that plays an important role in intracellular oxidative stress management 87. Moreover, 
MRP2 might also be involved in transport of substrates that are involved in host-cell or parasite 
signaling pathways, which include cyclic nucleotides, leukotrienes and prostaglandins193-195. An 
important role of cGMP signaling has been identified in liver stage development, as merozoite 
release was inhibited in the absence of cGMP-dependent protein kinase G (PKG), the main mediator 
of cGMP signaling241. 
As MRP2 is essential for parasite survival during liver stage, this protein may be an attractive drug-target to 
arrest liver stage development. MRP2 is located at an easily accessible site, and drug resistance mechanisms 
depending on transporter activity may be evaded149. Specific inhibitory compounds that have been 
identified for human MRP proteins such as MK571 can be used as prototypes for the development of 
specific and safe Plasmodium MRP2 inhibitors196.
In addition, MRP2-deficient P. falciparum parasites may be attractive genetically attenuated 
parasites (GAP) vaccine candidates. A number of rodent GAPs have previously been reported to 
arrest at early time points during development in the liver240,242. These include GAPs based on genes 
essential for the formation and maintenance of a parasitophorous vacuole (PV) (b9, p52, p36, uis3 
and uis4; 243-245), type II fatty acid synthesis (i.e. fabb/f, fabz, pdh e1α; 246,247), and regulation of gene 
expression (sap1/slarp248-250). Unfortunately, many of the above mentioned target genes show leaky 
phenotypes, resulting in blood stage infections after administration of high numbers of sporozoites. 
Incomplete liver stage arrest obviously disqualifies GAPs for further clinical development for safety 
reasons. The PbΔmrp2 gene deletion mutant, however, showed no breakthrough to blood stage 
infection upon injection with a high doses of sporozoites in C57bl/6 mice, the most sensitive mouse 
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strain. The only alternative GAP candidate that arrests completely during liver stage is lacking the 
sap1/slarp gene249-252. This GAP arrests early after hepatocyte invasion as these parasites do not 
construct a functional PV249,250, however, for rodent GAPs it has been shown that immunization 
with parasites arresting later during liver stage induces a superior immune response presumably 
through the prolonged presentation of a larger repertoire of antigenic stimuli253,254. Parasites lacking 
MRP2 develop to a much further extent and persist in hepatocytes as the PV is correctly formed and 
maintained. The prolonged presentation of a larger repertoire of antigens including PV-associated 
proteins renders mutant parasites lacking MRP2 attractive GAP candidates. 
In conclusion, whereas MRP proteins are redundant for blood stage and sporogonic development, 
parasites lacking MRP2 fail to produce mature liver stage parasites. The MRP2 protein is therefore 
an interesting target for development of drugs targeting Plasmodium liver stages. Furthermore, 
safety and immunogenicity of parasites lacking the mrp2 gene should be further investigated 
to explore the possibilities of applying these parasites as GAP candidates in a whole parasite 
vaccination strategy. 
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B: probes and other PCRs
Gene Construct Basic 
construct
Primer Sequences Restriction 
sites
Description
Pfmrp1 SR009 GACGACATATAAAGA 
AAATGTTGG
mrp1 F iPCR
SR010 CTTGCATCATTTGAA 
TTACAATGG
mrp1 R iPCR
SR011 CAAATGCATGAATATTGG mrp1 F LR PCR
  SR012 TCAAAATAATCAACTAGCC  mrp1 R LR PCR
Pfmrp2 SR013 CAGAATGATCAGAA 
TGAGCAAAGCG
mrp2 F iPCR
SR014 GCCTGTACACGTTA 
AACATGTCG
mrp2 R iPCR
SR015 CATGACAAGAATAA 
TAACGAC
mrp2 F LR PCR
   SR016 CTCAATAAGGAG 
GATTCATC
 mrp2 R LR PCR
Pbmrp  136 GGTATTATCCTTGA 
ATTTATTTATG
mrp2 orf F, RT-PCR
138 GGTCGCCACTATTA 
TTTCG
mrp2 orf R, RT-
PCR
644 GAACAAATTACTT 
CATTCATAGC
a/b-large subunit 
(lsu) rrna, probe
692 CTTATATATTTATAC 
CAATTG
3’UTR dhfr-ts, F 
probe
693 GTTTTTTTTTAATTT 
TTCAAC
3’UTR dhfr-ts, R 
probe
5092 GGGAATTATATAGA 
TAAGAATAATGAGGG
5’ UTR mrp2, F 
probe
5093 GCTTGTTTGAAAGTA 
TAAGTCAATGCCGC
5’ UTR mrp2,  R 
probe
5094 GCGGTCTGATAATGA 
AATTATTGATGCT
3’mrp2 orf, F 
probe
   5095 GGTGCCTGGTCCT 
GTATAATATTAGC
 3’mrp2 orf,  R 
probe
Table S1: Details of DNA constructs and primers used in this study 
F: Forward
R: Reverse
iPCR: internal PCR
ORF: Open Reading Frame
LR: Long Range
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P. falciparum in vitro WT PfΔmrp1 PfΔmrp2 PfΔmrp1Δmrp2
Chloroquine 12.9 (10.1 - 16.4) 10.7 (9.14 - 12.5) 9.25 (8.50 - 10.1) 13.6 (9.21 - 20.1)
Artemisinin 39.8 (26.3 - 60.3) 22.0 (17.5 - 27.7) 19.6 (17.3 - 22.1) 39.1 (23.3 - 65.6)
Dihydroartemisinin 42.9 (21.8 - 84.2) 30.9 (20.1 - 47.6) 36.2 (26.3 - 49.7) 134 (70.3 - 256)
Atovaquone 3.69 (2.23 - 6.11) 4.19 (3.06 - 5.74) 3.92 (3.32 - 4.63) 4.55 (3.55 - 5.84)
Lumefantrine 60.0 (35.0 - 103) 43.9 (37.6 - 51.3) 69.1 (52.7 - 90.5) 102 (69.1 - 151)
Quinine 25.4 (20.9 - 30.9) 36.2 (26.0- 50.4) 26.5 (20.5 - 34.2) 39.1 (26.9 - 56.9)
Mefloquine 121 (99.2 - 147) 241 (184 - 316)* 242 (148 - 390)* 272 (193 - 382)*
Table S2: Drug sensitivity (IC50 values and 95% CI) of P. falciparum mutants lacking expression of MRP 
proteins  
1  Drug sensitivity determined in culture. IC50 values are calculated from the dose response curves shown in 
Figure S3
*  Significant different from WT (p<0.05)        
        
Parasite count per well (mean and S.D.) 
Day p.i. WT PfΔmrp1 PfΔmrp2 PfΔmrp1Δmrp2 
2 106.5 (61.9) 448.3 (29.4) 347.7 (27.8) 343.7 (141.4)
3 118.5 (68.4) 375.0 (39.6) 64.3 (1.16) 443.0 (18.0)
4 71.8 (56.7) ND 35.3 (4.73) 37.7 (15.0)
5 60.5 (37.9) 173.7 (9.24) 24.7 (11.0) 11.5 (7.40)
6 44.7 (37.2) 166.3 (22.5) 17.0 (4.36) 2.00 (1.79)
7 28.7 (13.4) 77.0 (4.24) 3.67 (0.58) 0.83 (0.98)
10 0.33 (0.58)
    
Parasite diameter - µm (mean and S.D.)  
Day p.i. WT PfΔmrp1 PfΔmrp2 PfΔmrp1Δmrp2 
2 2.0 (0.2) 1.8 (0.1) 1.1 (0.1) 2.4 (0.2)
3 3.0 (0.4) 3.0 (0.6) 1.1 (0.2) ND
4 5.5 (0.8) ND 1.5 (0.1) 2.2 (0.4)
5 6.3 (0.6) 5.4 (0.6) 1.8 (0.2) 2.3 (0.5)
6 8.4 (1.1) 6.6 (0.2) 2.0 (0.1) 2.3 (0.5)
7 10.6 (2.2) 9.2 (1.3) 2.1 (0.4) 2.4 (0.2)
Table S3: Number and size of P. falciparum WT and mutant liver stages in cultures of primary human 
hepatocytes at different days after infection
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Figure S1. Generation and genotype analysis of P. berghei Pbmrp::cmyc and PbΔmrp2 parasites 
A Schematic representation of the DNA construct (pL1672) used to C-terminal tag the Pbmrp2 gene with cmyc 
by single cross-over homologous recombination (SM: selectable marker cassette). See Table S3 for primer 
sequences used to amplify the target region. Southern analysis of separated chromosomes of Pbmrp::cmyc 
(1732cl3) confirms correct integration of the tagging construct. Separated chromosomes were hybridized using 
an 3’UTR pbdhfr probe that recognizes the DNA-construct integrated into the mrp2 locus on chromosome 
14, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on 
chromosome 3. B Schematic representation of the DNA construct (pL1266) used to disrupt the Pbmrp2 gene. 
The construct is aimed at disruption of the target gene by double cross-over homologous recombination at 
the 5’- and 3’UTR regions (SM: selectable marker cassette). Two gene-deletion mutants were selected from 
two independent transfections, Pb∆mrp2-a (line 1025cl2) and Pb∆mrp2-b (line 1512cl1). See Table S3 for primer 
sequences used to amplify the target regions. The DNA-probe (red) and restriction sites used for Southern 
analysis (see C) are indicated: Nhe I (N) and Sca I (S). C Southern blot analysis of separated chromosomes 
and digested genomic DNA confirm correct deletion of the mrp2 gene (left). Separated chromosomes were 
hybridized using an 3’UTR pbdhfr probe that recognizes the DNA-construct integrated into the mrp2 locus 
on chromosome 14, the endogenous dhfr/ts on chromosome 7 and the GFP reporter cassette (Pb∆mrp2-a; 
1025cl2) or the GFP male- RFP female reporter cassette (Pb∆mrp2-b; 1512cl1) in the 230p locus on chromosome 
3. Nhe I (N) and Sca I (S) digested DNA was hybridized (right) with a 3’ mrp2 probe (see B for the location), 
recognizing the expected DNA fragments indicated in C (a 5 kb fragment in WT and a 2.8 kb fragment in 
the Pb∆mrp2 lines).  D RT-PCR analysis of mrp transcription in WT and Pb∆mrp2 parasites using mrp2 specific 
primers (Table S3). As a control for gDNA contamination, PCRs were carried out on cDNAs synthesized in the 
presence (+) or absence (-) of reverse transcriptase. WT gDNA and cDNA show amplicons of the expected size 
whereas no products were amplified in the mutant parasites. No cDNA (-D) and WT gDNA (G) were used as 
negative and positive controls, respectively. 
Manuscript_SR_DEF.indd   76 21-04-16   07:57
77
Multidrug ABC transporters are essential for hepatic development of Plasmodium sporozoites
Figure S2. Generation and genotype analysis of P. falciparum PfΔmrp1, PfΔmrp2, and PfΔmrp1Δmrp2 
parasites.
A Schematic representation of the genomic loci of mrp1 (PF3D7_0112200), and mrp2 (PF3D7_1229100) genes 
of wild-type (WT), PfΔmrp1 and PfΔmrp2 gene deletion mutants before (Δmrp1gfp and PfΔmrp2gfp) and after 
the FLPe mediated removal of the hdhfr::gfp resistance marker (PfΔmrp1 and PfΔmrp2 clones) respectively. 
The constructs for the targeted deletion of mrp genes (pHHT-FRTGFP mrp) contain two FRT sequences (red 
triangles) that are recognized by FLPe. P1, P2 and P3, P4 primer pairs for (LR-)PCR analysis of mrp loci respectively 
(see B, C); cam: calmodulin; hrp: histidine rich protein; hsp: heatshock protein; fcu: cytosine deaminase/uracil 
phosphoribosyl-transferase; hdhfr::gfp: human dihydrofolate reductase fusion with green fluorescent protein; 
pbdt: P.berghei dhfr terminator. 
B Long range PCR analysis of genomic DNA from WT, PfΔmrp1, PfΔmrp2 and PfΔmrp1Δmrp2 parasites confirms 
the mrp gene deletions in the different mutants and subsequent removal of the hdhfr::gfp resistance marker. 
The PCR products are generated using primers P1 and P2 (see a for their location and Table S3 for the sequences). 
A PCR product for WT mrp1 and mrp2 of 7937 and 8595 bp was obtained, whereas amplification of PfΔmrp1 and 
PfΔmrp2 genomic DNA resulted in product sizes of 2257 and 2380 bp. For the PfΔmrp1Δmrp2 double gene 
deletion mutant, a PCR product of 5353 bp was obtained upon Pfmrp1 amplification, as the selectable marker 
at this site was not removed. Specific products were obtained upon restriction with ScaI and XmnI for wild type 
mrp1 and mrp2 PCR products respectively; AvaI restriction of both amplicons obtained from the PfΔmrp1 and 
PfΔmrp2 single gene deletion mutants and SacI and AvaI restriction of the PCR product obtained after mrp1 
and mrp2 amplification in the PfΔmrp1Δmrp2 line. C PCR analysis of genomic DNA from WT, PfΔmrp1, PfΔmrp2 
and PfΔmrp1Δmrp2 parasites confirms the mrp gene deletions in the different mutants. The PCR products are 
generated using primers P3 and P4 (see A for their location and Table S3 for the sequences). 
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Figure S3. Sensitivity of WT and mutant parasites to antimalarial drugs 
Dose-response curves of blood stages of WT, PfΔmrp1, PfΔmrp2 and PfΔmrp1Δmrp2 cultured in the presence of 
the following antimalarials: chloroquine, artemisinin, dihydroartemisinin, atovaquone, lumefantrine, quinine 
and mefloquine. No significant differences in IC50 concentrations were observed when the IC50 values of the 
different mutants were compared with those of WT, except for mefloquine (see Table S1).
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Figure S4. Localisation of MRP2 in liver stages of P. berghei Pbmrp::cmyc by fluorescence microscopy, and 
localisation of MRP1 and MRP2 in liver stages of P. falciparum NF54 WT parasites
Standard (A) and confocal (B) fluorescence microscopy  images of Pbmrp::cmyc liver stages at different time points 
(hours; h) after invading cultured hepatocytes. Pbmrp::cmyc liver stages were stained with antibodies recognizing 
cmyc (red) and the parasite vacuole membrane protein EXP1 (green). Circumferential staining with the cmyc 
antibodies which does not co-localise with EXP1 staining indicates a location of MRP2::cmyc at the plasma lemma 
membrane of the parasite. Nuclei are stained with Hoechst-33342. Images were acquired with confocal microscope 
Leica TCS SP8 X with white light laser (WLL) and DM RA Leica fluorescence microscope. Scale bar 10μm. C Confocal 
microscopy was used for localization of MRP1 and MRP2 in NF54 WT liver stage parasites at day 6 using antibodies 
recognizing MRP1 (green or red) and MRP2 (red) and cytosolic HSP70 shows a honeycomb-like pattern for MRP 
proteins, indicating localization of these proteins on the plasma lemma membrane of the parasite.
Manuscript_SR_DEF.indd   79 21-04-16   07:57
80
CHAPTER 4
Figure S5.  Liver stage development of Pbcmyc::mrp2.
 A Immunofluorescence analysis of liver stages at different time points post infection (p.i.) of cultured hepatocytes 
(upper panel). Parasites are stained with anti-cmyc and anti Exp1 antibodies and nuclei with Hoechst. At 40 and 
54 hour dividing liver stages are detected inside the PVM. Infection of mice by intravenous injection of 104 
Pbcmyc::mrp2 sporozoites results in a prepatent period similar to mice infected with wild type parasites (lower 
panel). B Genotyping by Southern analysis of PFG-separated chromosomes (chr) of Pbcmyc::mrp2 blood stage 
parasites after mosquito infection shows the same genotype as before mosquito transmission (see Figure S1). 
The probe (3’UTR dhfr/ts) hybridizes to the endogenous dhfr/ts gene on chromosome 7, the GFP-Luciferase 
expression cassette in chromosome 3 and the Pbcmyc::mrp2 tagging construct in chromosome 14.  
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Figure S6. Protection against liver stage parasitemia after vaccination with low-dose gene deletion 
parasites 
BALB/c mice were vaccinated with saline, 400, 800 or 1200 gene-deletion sporozoites, and after 21 days they 
were challenged with luminescence-expressing sporozoites. A Development of liver stage parasitemia after 
48 hours is displayed. B Luminescence intensity was measured for each mouse. C Appearance of blood stage 
parasitaemia was monitored.
Manuscript_SR_DEF.indd   81 21-04-16   07:57
82
CHAPTER 4
Manuscript_SR_DEF.indd   82 21-04-16   07:57
83
Vital and dispensable roles of Plasmodium multidrug resistance 
transporters during blood- and mosquito-stage development
CHAPTER 5
Vital and dispensable roles of Plasmodium 
multidrug resistance transporters during blood- 
and mosquito-stage development
Mol Microbiol. 2016 Mar 15
Sanna R. Rijpma1*, Maarten van der Velden1*, Takeshi Annoura2, Joachim M. Matz3, Sanketha 
Kenthirapalan4, Taco W.A. Kooij3,5, Kai Matuschewski4,6, Geert-Jan van Gemert3, Marga van de 
Vegte-Bolmer3, Rianne Siebelink-Stoter3, Wouter Graumans3, Jai Ramesar7, Onny Klop7, Frans G.M. 
Russel1, Robert W. Sauerwein3, Chris J. Janse7, Blandine M. Franke-Fayard7, Jan B. Koenderink1.
1 Department of Pharmacology and Toxicology, Radboud University Medical Center, 
Geert-Grooteplein 28, 6525 GA Nijmegen, The Netherlands
2 Department of Tropical Medicine, The Jikei University School of Medicine, 
Post code 105-8461 Nishi-shinbashi 3-25-8, Minato-ku, Tokyo, Japan 
3 Department of Medical Microbiology, Radboud University Medical Center, 
Geert-Grooteplein 28, 6525 GA Nijmegen, The Netherlands
4 Parasitology Unit, Max Planck Institute for Infection Biology, Charitéplatz 1, 10117 Berlin, Germany.
5 Centre for Molecular and Biomolecular Informatics, Radboud University Medical Center, 
Geert-Grooteplein 28, 6525 GA Nijmegen, The Netherlands
6 Institute of Biology, Humboldt University, 10117 Berlin, Germany.
7 Leiden Malaria Research Group, Parasitology, Center of Infectious Diseases, 
Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands
* These authors contributed equally to this study
Manuscript_SR_DEF.indd   83 21-04-16   07:57
84
CHAPTER 5
ABSTRACT
Multidrug resistance (MDR) proteins belong to the B subfamily of the ATP Binding Cassette (ABC) 
transporters, which export a wide range of compounds including pharmaceuticals. In this study we 
used reverse genetics to study the role of all seven Plasmodium MDR proteins during the life cycle 
of malaria parasites. Four P. berghei genes (encoding MDR1, 4, 6 and 7) were refractory to deletion, 
indicating a vital role during blood stage multiplication and validating them as potential targets for 
antimalarial drugs. Mutants lacking expression of MDR2, MDR3 and MDR5 were generated in both 
P. berghei and P. falciparum, indicating a dispensable role for blood stage development. Whereas P. 
berghei mutants lacking MDR3 and MDR5 had a reduced blood stage multiplication in vivo, blood 
stage growth of P. falciparum mutants in vitro was not significantly different. Oocyst maturation 
and sporozoite formation in Plasmodium mutants lacking MDR2 or MDR5 was reduced. Sporozoites 
of these P. berghei mutants were capable of infecting mice and life cycle completion, indicating 
the absence of vital roles during liver stage development. Our results demonstrate vital and 
dispensable roles of MDR proteins during blood stages and an important function in sporogony 
for MDR2 and MDR5 in both Plasmodium species.
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INTRODUCTION
ATP Binding Cassette (ABC) transporters are membrane proteins that translocate diverse 
compounds at the expense of ATP and have been well conserved in many organisms. They are 
organized into either two domains (half-transporter), consisting of a transmembrane domain 
(TMD) and a nucleotide-binding domain (NBD) required for ATP-hydrolysis or into four domains 
(full-transporter), consisting of two TMDs alternated with two NBDs (Figure 1A). Half-transporters 
require homo- or hetero-dimerization to become functional20.
In humans, ABC-transport proteins are well known for their involvement in multidrug resistance 
against antiviral, antimicrobial or anti-cancer drugs255. Especially transporters of the ABCB, ABCC 
and ABCG subfamilies play important roles in resistance, of which the most studied multidrug 
resistance (MDR) protein is MDR1. This protein belongs to the ABCB subfamily, which contains both 
half- and full-transporters255. Amplification of the MDR1 encoding gene has been shown to confer 
resistance of cancer cells to chemotherapeutic drugs through increased excretion256. However, 
these transporters also play important roles in physiological cellular processes such as membrane 
biogenesis, autocrine pathways and homeostasis, as their substrates may vary from lipids and 
sterols to heavy metals and amphipathic or conjugated xenobiotic compound 87.
In the human malaria parasite P. falciparum, 16 ABC genes have been identified148. Based on 
phylogenetic analysis of the conserved nucleotide binding domains, seven are recognized as members 
of the B family of ABC transporters. Pfmdr1 (PF3D7_0523000) has been most intensively studied for its 
involvement in antimalarial drug resistance. Amplifications and polymorphisms of Pfmdr1 have been 
associated with decreased sensitivity towards multiple antimalarial drugs, including chloroquine 
and artemisinin12,24,59. Its primary localization on the membrane of the digestive vacuole may indicate 
involvement in drug accumulation, where several antimalarial compounds interfere with polymerization 
of reactive free heme released upon hemoglobin digestion257. Hence, Pfmdr1 polymorphisms have 
been shown to reduce drug accumulation resulting in antimalarial resistance12. Furthermore, a single 
nucleotide polymorphism (SNP) in Pfmdr2 (PF3D7_1447900), a heavy metal transporter48, is associated 
with in vitro resistance to pyrimethamine 50. Recently, another SNP in Pfmdr2 showed a statistically 
significant association (p = 2 x 10-10) with artemisinin resistance258. Moreover, varying indels in 
the Pfmdr6 gene (PF3D7_1352100) have been associated with altered artesunate and piperaquine 
Manuscript_SR_DEF.indd   85 21-04-16   07:57
86
CHAPTER 5
sensitivity11,51-53, although transfection-based confirmation of that association is lacking. Apart from a 
role in drug resistance, the physiological function as well as substrate specificity of the Plasmodium MDR 
proteins remains largely unknown, also for PfMDR5 (PF3D7_1339900), which is localized at the plasma 
membrane of intra-erythrocytic parasites17. 
To gain insight into the function of these proteins and their role in the Plasmodium life cycle, we first 
systematically targeted the seven MDR proteins by experimental genetics in the murine malaria model 
parasite Plasmodium berghei. We found that four out of seven ABCB encoding genes (mdr1, mdr4, mdr6 
and mdr7) are refractory to gene deletion. We were able to select P. berghei mutants lacking mdr2, mdr3 
and mdr5, which is indicative of a dispensable role for the encoded proteins during asexual blood stage 
growth in vivo. We subsequently targeted mdr2, mdr3 and mdr5 for deletion in P. falciparum and were 
able to select mutants in vitro, confirming a non-essential role for blood stage development. Both P. 
berghei and P. falciparum mutants lacking expression of MDR2 and MDR5 showed reduced oocyst 
formation. Additionally, the mutants lacking Pbmdr2, Pbmdr5 and Pfmdr2 showed reduced sporozoite 
production. Furthermore, PbMDR2::mCherry expression was observed during blood- and mosquito 
stage development. Combined, our results provide evidence that Plasmodium express several MDR 
proteins that have specific functions during sporogony. 
MATERIALS AND METHODS
Experimental animals and P. berghei ANKA reference lines
Animal experiments were conducted in female C57BL/6, BALB/c and Swiss OF1 mice (6-8 weeks; 
Charles River) and approved by the Animal Experiments Committee of the Leiden University 
Medical Center (DEC; 12042; 12111), or in C57BL/6 mice as approved by the ethics committee of the 
Berlin state authority (Landesamt für Gesundheit und Soziales Berlin, permit number G0469/09. 
Both the Dutch Experiments on Animal Act and the German ‘Tierschutzgesetz in der Fassung vom 
22. Juli 2009’ are established under European guidelines (EU directive no. 86/609/EEC regarding the 
Protection of Animals used for Experimental and Other Scientific Purposes).
Two different P. berghei ANKA parasite lines were used to generate gene-deletion mutants: 
676m1cl1 (PbGFP-LUCcon; mutant RMgm-29; www.pberghei.eu) and 1037cl1 (PbGFP-Lucschiz; 
mutant RMgm-32; www.pberghei.eu), originating from the cl15cy1 wild type (WT)204 which was 
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used to generate the Pbmdr2::mCherry tagged parasites. In both reporter lines, a gfp-luc expression 
cassette is stably integrated into the Pb230p locus in absence of a drug-selectable marker207,214. These 
lines thus express the GFP-Luciferase fusion protein under the control of either the constitutively 
active eef1α promoter (676m1cl1) or the schizont-specific ama1 promoter (1037cl1).
Generation of P. berghei ABC transporter gene deletion and tagged mutants 
Genes encoding ABC transporters were deleted using a double cross-over strategy based on 
homologous recombination of targeting constructs into the genome of the parasite. Targeting 
sequences were PCR amplified from P. berghei ANKA (cl15cy1) genomic DNA using primers specific 
for the 5’UTR or 3’UTR regions of the different ABC transporter genes (Table S3). These targeting 
regions (TR) were cloned into the pL0001 plasmid (www.mr4.com), flanking the pyrimethamine 
resistant Toxoplasma gondii (Tg) dihydrofolate reductase-thymidylate synthase (dhfr/ts) as a 
selectable marker (SM) under control of the P. berghei dhfr/ts promoter. Tagging of mdr4 was 
performed using a similar double crossover recombination strategy as described above. A DNA 
construct containing an 3xHA tag was used to target mdr4. This construct was obtained from the 
Sanger Institute (PbGEM-084058; http://plasmogem.sanger.ac.uk/designs/final_vector/84058; 
named in this study plasmid pL1995)259. This construct aims at integration at the 3’ end of mdr4, 
replacing the stop codon with an HA tag and contains the pyrimethamine resistant human 
dihydrofolate reductase-thymidylate synthase (hdhfr). Transfection and pyrimethamine selection 
of mutant parasites with was performed as described for generation of the gene deletion mutants. 
For the Pbmdr2::mCherry tagging construct, fragments at the 3’ region and the carboxy-terminal end of the 
coding sequence were amplified using specific primers (Table S3). These fragments were cloned into the 
pBAT-SIL6 vector260 using the indicated restriction enzymes (Table S3). The carboxy-terminus was cloned 
in frame with the mCherry-3xMyc tag. Gene-deletion and tagging constructs were verified by Sanger 
sequencing and linearized with the appropriate restriction enzymes (Table S3). Transfection and selection 
of transformed parasites with pyrimethamine was performed using the high efficiency transfection and 
selection technology for genetic modification of P. berghei 204. Clonal lines of all gene-deletion mutants 
were generated through limiting dilution of the parasites in mice. Deletion of the targeted genes or mdr2 
tagging by correct integration of the DNA constructs was verified by diagnostic PCR analysis covering the 
5’TR and 3’TR integration using gene-specific primers (Table S4) and Southern analysis of pulsed-field gel 
electrophoresis separated chromosomes that were hybridized with a 3’pbdhfr/ts probe (FIGE) (Table S4). 
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Transcription of the mdr genes was determined by Northern analysis of RNA obtained from WT and 
gene-deletion mutant blood stages of asynchronous in vivo infections or from synchronous blood 
infections of WT parasites 208. Northern blots were hybridized with a 5’-UTR fragment of the mdr 
genes, PCR amplified from genomic WT DNA using the appropriate primer pairs (Table S3) and 
with the a/b-large subunit rRNA probe as control (primer 644) 11. 
In vivo multiplication rate of asexual P. berghei blood stage parasites
During the cloning procedure of the gene-deletion mutants, the multiplication rate of asexual 
blood stage parasites in mice was determined as described before214. Parasitemias in percentages 
in Swiss OF1 mice injected with a single parasite are determined at day 8 to 11 in Giemsa-stained 
blood films. Per mouse, an estimated number of 1.2 x 1010 erythrocytes is used to calculate the 24-
hour multiplication rate. The percentage of infected erythrocytes in mice infected with reference 
lines of the P. berghei ANKA strain consistently ranges between 0.5-2% at day 8 post infection, 
resulting in a mean multiplication rate of 10 per 24h261. 
In vivo P. berghei gametocyte production and in vitro ookinete production 
The gametocyte conversion rate was determined as the percentage of ring forms that develop into 
mature gametocytes in synchronized infections in mice that are pre-treated with phenylhydrazine-
HCl208. Ookinete production was analyzed by standard in vitro fertilization and ookinete maturation 
assays262. Gametocytes for these assays were obtained from infected mice that had been pre-
treated with phenylhydrazine-HCl to increase gametocyte numbers. The ookinete conversion 
rate is defined by the percentage of female gametes that develop into mature ookinetes under 
standardized in vitro culture conditions for activation of gametocytes, fertilization and ookinete 
maturation. The percentage of females that developed into ookinetes was determined by counting 
female gametes and mature ookinetes in Giemsa-stained blood smears, made at 16-18 h post 
activation. 
P. berghei oocyst and sporozoite production in Anopheles stephensi mosquitoes
For mosquito transmission experiments, female A. stephensi mosquitoes were fed on mice infected with WT 
parasites or gene-deletion mutants. Oocyst development, oocyst production and sporozoite production 
was monitored in infected mosquitoes as described263. Oocyst numbers were counted and measured in 
midguts of infected mosquitoes at 9, 12, 14, 16, 19, 21, and 23 days post infection, while sporozoite numbers 
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were counted at day 21-22. Salivary gland sporozoites were isolated and counted as described215. Mean 
differential oocyst (± SEM) and sporozoite numbers between WT and mutant lines were determined using 
a one-way ANOVA with Dunnett’s post-test.
Localization of HA-tagged PbMDR4 and mCherry-tagged PbMDR2
Detection of the HA-MDR4 protein was performed after fixing asexual parasites with 4% para-
formaldehyde (PFA), quenching with 0.1 M glycine, blocking with 10% FCS and permeabilization 
with 1% Triton-X-100. Localization of was performed using specific antibodies against HA raised in 
rat (Roche, 1:1000), visualized with anti-rat ALEXA488 (green). Nuclei were stained with DAPI (red). 
Live protein localization of the PbMDR2::mCherry tagged protein was performed only minutes 
after sample collection and Hoechst 33342 DNA staining, using either conventional slides and 
coverslips or concanavalin A-coated ibidi µ-Dishes (35 mm, low; Grid500) with pre-warmed RPMI 
1640 medium containing 20% fetal calf serum. Images for live protein localization were recorded 
on a Zeiss AxioObserver Z1 epifluorescence microscope, equipped with a Zeiss AxioCam MRm 
camera, and processed minimally with FIJI264. 
P. berghei sporozoite infectivity and liver stage development
P. berghei sporozoites were collected at day 21-22 post infection by hand-dissection of the salivary 
glands. Salivary glands were collected in DMEM (Dulbecco’s Modified Eagle Medium from GIBCO) 
and homogenized in a home-made glass grinder. The number of sporozoites was determined by 
counting these in 10 salivary glands in duplicate in a Bürker-Türk counting chamber using phase-
contrast microscopy. 
To determine in vivo infectivity of sporozoites, Swiss OF1 mice were infected with 104 salivary 
gland sporozoites by intravenous injection, as previously described263. Blood stage infections 
were monitored by analysis of Giemsa-stained thin smears of tail blood collected on day 4–8 after 
inoculation of sporozoites. The prepatent phase (measured in days post sporozoite infection) ends 
at the day that blood stage infection with 0.5-2% parasitemia is observed. 
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P. falciparum reference lines and culture conditions
Plasmodium falciparum wild type (NF54) and mutant parasites were maintained in a semi-
automated culture system and gametocyte formation was induced as reported previously153,205,210. 
Briefly, in vitro parasites were grown in RPMI medium supplemented with human serum (complete 
medium) and 5% hematocrit. Medium was changed twice daily and fresh human red blood cells 
were obtained weekly from the Dutch national blood bank (Sanquin).
Generation and genotyping of P. falciparum mdr2, mdr3 and mdr5 gene deletion mutants 
For phenotype analysis, we used the previously generated P. falciparum mdr2 and mdr5 gene 
deletion lines lacking the hdhfr::gfp selectable marker265. In addition, for the parasite development 
within mosquitoes, we used two independetly generated additional PfΔmdr2 and PfΔmdr5 clones 
in which the selectable marker was not removed. For deletion of the P. falciparum mdr3 and mdr6 
genes, we followed a homologous double crossover strategy as described151,266. The deletion 
construct was made by replacing the Pf52 homologous regions in the pHHT-FRT-(GFP)-Pf52 
construct (kindly provided by Ben van Schaijk) with mdr3 and mdr6 target regions (TR) (Figure 
S1)152. These regions were amplified from P. falciparum NF54 genomic DNA (gDNA) using PfuUltra II 
Fusion HS DNA Polymerase (Agilent Technologies) with primer pairs for the 5’ and 3’ target regions 
of mdr3, respectively (Table S3), and a similar approach was applied to amplify the mdr6 target 
regions. The 5’ and 3’ target regions were cloned into the pHHT-FRT-(GFP)-Pf52 construct using 
BssHII plus BsiWI and XmaI plus NheI restriction enzymes after TOPO TA subcloning (Invitrogen) 
and sequence validation. This resulted in the deletion constructs pHHT-FRT-(GFP)-Pfmdr3 and 
pHHT-FRT-(GFP)-Pfmdr6. Transfection and selection procedures we performed as described 
previously151,266, and clonal lines were obtained by limiting dilution.
Genotyping of the PfΔmdr3 mutant was performed by diagnostic PCR using Expand Long Range 
dNTPack (Roche) PCR (LR-PCR). Mixed asexual blood stage gDNA from NF54 wild type (WT) 
and PfΔmdr3 was isolated using the QIAamp DNA Blood Mini Kit (Qiagen). Primers flanking the 
5’ and 3’ TR of mdr3 were used to amplify WT and mutant DNA using LR-PCR to validate correct 
double homologous crossover integration (Table S4). The LR-PCR was performed as described 
previously265, with an annealing temperature of 43.5°C. An additional diagnostic PCR was 
performed as reported265 on gDNA using primers designed within the open reading frame (ORF) 
of mdr3 (Table S4).
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P. falciparum in vitro multiplication rate of asexual blood stages
Asexual growth of P. falciparum WT and two clones from each of the mutant lines PfΔmdr2, PfΔmdr3 
and PfΔmdr5 was monitored in three consecutive experiments during 7 days. Briefly, parasites were 
inoculated in triplicate at 0.1% parasitemia in complete medium (at 2.5% hematocrit) and were 
incubated in 96-wells plates at 37°C under candle jar culture conditions267. After sedimentation of 
RBC, complete medium was refreshed daily. Each day, a subset of iRBC samples was resuspended 
and transferred to black-side clear-bottom 96-wells cell culture plates (Greiner Bio-One) and frozen 
at -20°C until readout using a modified Plasmodium lactate dehydrogenase (pLDH) method154. 
In this assay, pLDH activity was determined by adding 70 µL fresh reaction mixture (286 mM 
3-acetyl pyridine adenine dinucleotide (Sigma-Aldrich), 5.66 U/mL diaphorase (Worthington), 
357.5 µM resazurin (Sigma-Aldrich), 286 mM sodium L-lactate (Sigma-Aldrich), 20 mM Tris-HCl pH 
8.0) to all plates of three independent experiments. After incubation in the dark for 30-60 min 
following excitation at 530 nm, absorbance was measured at 590 nm using a Synergy 2 Multi-Mode 
Microplate Reader (Bio-Tek). Uninfected red blood cells served as background and growth rate 
was measured in relative fluorescent units (RFU) and plotted using GraphPad Prism version 5.03 
(GraphPad Software). Difference in growth rate of all mutant lines (two independently transfected 
clones per mutant line were pooled) was compared to WT values at all time points using 2-way 
ANOVA with Bonferroni’s post-test.
P. falciparum oocyst and sporozoite production in Anopheles stephensi mosquitoes
To study parasite mosquito development of the PfΔmdr2, PfΔmdr3 and PfΔmdr5 mutant lines, 
standard membrane feeding assays using female A. stephensi mosquitoes were performed as 
described153,219. Midgut oocysts were counted at day 7 post infection in wild type NF54, PfΔmdr2, 
PfΔmdr3 and PfΔmdr5 parasites from 7, 6, 1, and 4 independent experiments containing a total of 
120, 120, 20 and 60 mosquitoes, respectively. Salivary gland sporozoites were determined at day 14-
16 or 18 post infection in 10 mosquitoes per experiment (of which the means are represented in the 
graph) in 6, 3, 3, and 3 independent assays for NF54, PfΔmdr2, PfΔmdr3 and PfΔmdr5, respectively. 
For PfΔmdr2 and PfΔmdr5, two independent clones were used and the resulting oocyst and 
sporozoite data was plotted using GraphPad Prism version 5.03 (GraphPad Software). We only 
included experiments in which at least 70% of the mosquitoes were infected. Mean differential 
oocyst and sporozoite numbers (± SEM) between WT and mutant lines were determined using a 
one-way ANOVA with Dunnett’s post-test.
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RESULTS
Dispensable roles of P. berghei MDR2, MDR3 and MDR5 for blood stage development
We systematically targeted all seven mdr genes by experimental genetics in the rodent malaria 
parasite Plasmodium berghei. Multiple attempts to disrupt Pbmdr1, 4, 6, and 7 by DNA constructs 
that integrate through homologous double cross-over integration (Figure 1A) using standard 
methods for genetic modification of P. berghei 204 were unsuccessful (Table S1). Mutant parasites 
lacking these MDR encoding genes could not be isolated, indicating an essential role of these 
proteins for blood stage multiplication. Evidence for expression of these genes in blood stages 
has previously been reported (Table S2). We successfully targeted the Pbmdr4 gene with a DNA-
construct for C-terminal tagging with an HA-tag (Figure S2A and B), indicating that the failure to 
delete the gene from blood stages is not due to inaccessibility of the locus for genetic modification. 
However, we were unable to detect expression of the HA-tagged MDR4 by immunofluorescence 
using anti-HA antibodies, possibly due to low expression levels in blood stages (Figure S2C). 
We were successful in obtaining mutant parasites lacking Pbmdr2, Pbmdr3 and Pbmdr5, in which 
correct deletion was demonstrated by Southern analysis of separated chromosomes and diagnostic 
PCR for 5’ and 3’ TR integration (Figure 1B). We also generated a mutant expressing PbMDR2 tagged 
at the C-terminus with an mCherry-3xMyc tag (Pbmdr2::mCherry; Figure 1A). Correct tagging was 
shown by diagnostic PCR for 5’ and 3’ TR integration of the tagging construct (Figure 1B). 
Northern analysis of transcription in blood stages indicates that all three genes are transcribed in blood 
stages (Figure 1C). Also RNAseq analyses of synchronized P. berghei blood stages showed expression 
in asexual trophozoites/schizonts (Table S2). No transcript could be detected in PbΔmdr3 and PbΔmdr5 
blood stage parasites (Figure 1C). We did observe a small transcript of 1.2kb in PbΔmdr2 parasites, 
which encodes for the first 85 amino acids of MDR2, while the full size transcript of 4.5kb was present in 
WT parasites, which encodes for the protein of 948 amino acids (Figure 1C). 
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Figure 1. MDR transporters targeted for deletion in P. berghei and P. falciparum. 
A Schematic overview of ABC transporter structure (top), double crossover deletion mechanism (middle) and 
mdr tagging strategy (bottom). B Southern analysis of separated chromosomes and diagnostic PCR confirms 
correct disruption of the mdr genes in Δmdr2, Δmdr3 and Δmdr5 (left panel). Separated chromosomes were 
hybridized using a 3’UTR pbdhfr probe that recognizes the DNA‐construct integrated into the mdr2, mdr3, and 
mdr5 loci on chromosome 13, 9 and 11 respectively and the endogenous dhfr/ts on chromosome 7. In addition 
in Δmdr2 and Δmdr5 it recognizes the GFP‐luciferase reporter cassette in the 230p locus on chromosome 3 
of the parent line. Diagnostic PCR analysis showing correct integration of the gene targeting construct using 
primers (see Table S4 for the primer sequences) that amplify both the 5’ and 3’ side of the integration regions 
after targeting Pbmdr2 both for deletion and mCherry-3xMyc tagging as well as Pbmdr3 and Pbmdr5 for 
deletion(right panel). C Northern analysis showing the presence of transcripts of all three mdr genes in blood 
stages of WT parasites. In blood stages of both the Δmdr3 and Δmdr5 transcripts are absent. In Δmdr2 a small 
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transcript of 1.2kb is observed, which encodes for the first 85 amino acids of MDR2, while the full size transcript 
of 4.5kb is present in WT. D Diagnostic PCR using either Long Range (left panel) or intra-ORF (right panel) PCR 
amplification of genomic DNA from both wild type (NF54) and PfΔmdr3 lines confirming deletion of Pfmdr3 
using specific primers (Table S4), respectively. The Long Range PCR shows an increased product size in the 
PfΔmdr3 line resulting from integration of the selectable marker cassette. The intra-ORF PCR amplifies the 
expected fragment of 340 bp in WT, whereas this fragment is absent in the mutant PCR as a result of Pfmdr3 
gene excision.
For PbΔmdr5 parasites, asexual growth was significantly decreased resulting in a multiplication rate of 
6.8 per 24 hr (SD 0.8; n = 5), which is 10 per 24 hr in WT (SD 0, n = 10)261. For PbΔmdr2 the multiplication rate 
of was comparable to WT (Table 1). For PbΔmdr3 we have only been able to select mutants in a single 
transfection experiment. Both clones from this experiment showed a strongly reduced growth rate of 
asexual blood stages (mean multiplication rate of 4.2x per 24 hr (SD 0.6; n=2). In all other transfection 
experiments (n=9) targeting Pbmdr3 we were unable to select for parasites with a disrupted mdr3 locus, 
probably due to the strong reduction in growth rate. Because of the failure to select an independent 
secondary mutant we decided to discontinue further analysis of the PbΔmdr3 phenotype.
Combined, these results show that PbMDR2, 3 and 5 are dispensable for blood stage development of P. 
berghei, although the lack of both MDR3 and MDR5 appears to affect the growth rate of blood stage parasites. 
Lines 
WT
Asexual 
multipli-
cation rate1 
(SD) 
Gametocyte 
production2 
% (SD) 
Ookinete 
production3 
% (SD) 
Oocyst 
production 
day 12-134 
(SD) 
Oocyst 
production 
day 16-174 
(SD) 
Sporozoite 
production5 
X 103 (SD) 
Oocyst 
size day 
126 μM 
(SD) 
Oocyst 
size day 
166 μM 
(SD) 
WT
1037m1f 
1m0c1 (a)
10 (0) n=10 15-256 50-906 375 (228) 266 (117) 35 (12.4)
676m1cl1    
(b)
10 (0) n=10 15-256 50-906 224 (134) 151 (242) 58.8 (7.8) 33 (3) 33 (6)
Mutants
∆mdr2-a 10 (0) n= 4 ND ND 152 (89.0) 17.8 (20.9) 1.2 (0.5)
∆mdr2-b 10 (0) n= 2 16.9 (1.0) 80.7 (9.1) 145 (151) 20.6(10.9) 3.5 (1.0) 19 (5) 27 (6)
∆mdr5-a 6.8 (0.8) n=2 18.2 (1.4) 71.7 (6.5) 147 (102) 50.2 (29.1) 4.5 (1.3)
∆mdr5-b 6.7 (0.7) n=3 ND ND 168 (169) 94.5 (26.0) 9.8 (2.9) 21 (2) 33 (3)
Table 1: Phenotypes of P. berghei mutants lacking expression of MDR proteins
1 The multiplication rate per 24 hour of blood stage parasites in mice infected with a single parasite; 
2 The percentage of blood stage parasites developing into gametocytes in vivo; 
3 The percentage of female gametes developing into mature ookinetes in vitro; 
4 The mean number of oocysts per mosquito 
5 The mean number of salivary gland sporozoites per mosquito (day 19–22); 
6  The developmental data for wild type parasites are shown as the range of mean values of > 10 experiments. 
ND, not determined.
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Dispensable roles of P. falciparum MDR2, MDR3, and MDR5 for blood stage development
We have previously generated P. falciparum mutants lacking expression of MDR2 and MDR5265. Generation 
of these mutants indicate that both MDR2 and MDR5 are dispensable for blood stages and confirms the 
observations in P. berghei. In this study we additionally targeted mdr3 and mdr6 for deletion with the pHHT-
FRT-(GFP)-Pfmdr3 and pHHT-FRT-(GFP)-Pfmdr6 deletion constructs (Figure S1) 151,266. In agreement with 
our findings in P. berghei, we were unable to isolate P. falciparum parasite mutants lacking mdr6 in three 
transfection experiments (data not shown), which indicates an essential role of the MDR6 protein for blood 
stage development. In contrast, we were able to readily select mutants lacking expression of MDR3. Correct 
deletion of Pfmdr3 was validated using a diagnostic LR-PCR in which the expected larger amplification 
product (including selectable marker cassette) was obtained for parasites lacking this gene compared to 
WT (Figure 1D). In addition, an intra-exonic PCR confirmed absence of the Pfmdr3 gene in the mutant line 
(Figure 1D). 
Our ability to generate P. falciparum mdr2, mdr3, and mdr5 mutants indicates dispensable roles during 
blood stage development. We next analyzed the in vitro growth rate of P. falciparum blood stages over 
a period of 7 days using a modified pLDH method268. In this assay, mutants lacking MDR2, MDR3 and 
MDR5 showed a normal growth rate, whereas the maximal parasitemia that was reached in cultures of 
PfΔmdr2 parasites was significantly lower at day 7 compared to WT parasites of the NF54 strain (Figure 2). 
 
Figure 2. Reduced maximal parasitemia in PfΔmdr2 parasites. 
Growth of asexual blood stages of WT and two clonal lines for PfΔmdr2, PfΔmdr3 and PfΔmdr5 (data of two clones per 
mutant was pooled) was monitored over a 7-day period in the in vitro multiplication assay. In vitro parasite cultures 
were started at 0.1% parasitemia and growth was determined by measuring relative fluorescence units (RFU) in 
three independent experiments (triplicate samples per time point) using a modified pLDH method268. Asexual 
multiplication was comparable for mdr3 and mdr5, however, maximal parasitemia of PfΔmdr2 was significantly 
reduced at day 7.
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MDR2 and MDR5 of P. berghei play a role during mosquito stage sporogony
We explored the phenotypes of PbΔmdr2 and PbΔmdr5 during sexual, mosquito and liver stages. The 
gametocyte and ookinete conversion rate resembled that of WT parasites (Table 1). Whereas oocysts 
were readily detected in mosquito midguts that were fed on mice infected with P. berghei parasites 
lacking expression of MDR2 or MDR5, the subsequent sporogonic development was significantly 
affected. The mean number of PbΔmdr2-b and PbΔmdr5-b GFP-positive oocysts was 48 ± 13 and 63 ± 
16, respectively, between day 9-23 after mosquito feeding (Figure 3A) and was significantly reduced 
compared to WT (128 ± 24; p < 0.05). Moreover, this effect was increased in time as at later time points 
(day 16-17) fewer oocysts could be detected for both lines when compared to earlier time points (day 
12-13) (Table 1). Many of the MDR2 and MDR5 deficient oocysts appeared immature (Figure 3E) and 
their average size was significantly smaller at day 12 compared to WT (Table 1). However, at day 16, 
mutant oocysts measured similar sizes as WT oocysts, suggesting that the lack of the MDR2 or MDR5 
protein resulted in a delayed growth (Table 1). Maturation of oocysts could be specifically monitored in 
the 1037m1f1m0cl1 parent line. This reference line expresses the reporter fusion protein GFP-Luciferase 
under the control of the ama-1 promoter. In mosquito stages, this promoter is only active in mature 
oocysts when sporozoites are formed. We therefore counted GFP-positive oocysts in mutant and WT-
infected mosquitoes at day 17 after infection. Developmental retardation was evident and significant 
for the PbΔmdr2-a and PbΔmdr5-a gene deleted parasites as only 1.0% (SD 1.6%) and 23% (SD 11%) of 
the oocysts in the respective deletion mutants reached full maturation as shown by GFP expression, 
compared to 82% (SD 9.7%) in WT (Figure 3F). This also resulted in strongly reduced numbers of 
sporozoites. Only 3.4% - 6.0% and 13 - 17% of WT sporozoite numbers could be isolated from salivary 
glands of PbΔmdr2 and PbΔmdr5 infected mosquitoes, respectively (Table 1; Figure 3B). 
These results indicate that both MDR2 and MDR5 play a role during sporogony. No published data 
is available on expression of these proteins in P. berghei oocysts or sporozoites, although evidence 
has been reported for transcription of MDR5 in sporozoites (Table S1). Moreover, P. falciparum 
MDR5 has been found in proteomes of sporozoites. MDR2 has only been detected in proteomes of 
P. falciparum asexual blood stages and gametocytes. We analysed expression of PbMDR2 in blood 
stages, oocysts and sporozoites of the mutant Pbmdr2::mCherry by fluorescence microscopy. 
In both asexual blood stages and gametocytes fluorescence signals were detected, which is in 
agreement with MDR2 detection in the P. falciparum proteomes of these stages. The fluorescence 
signals are mainly associated with hemozoin granules (in both asexual stages and gametocyte; 
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Figure 3. Altered mosquito stage development of mutants lacking expression of MDR2 and MDR5. 
A Oocyst production in A. stephensi mosquitoes of P. berghei parasites lacking MDR2 and MDR5 is significantly 
reduced (p < 0.05). B Sporozoite production in A. stephensi mosquitoes of P. berghei parasites lacking MDR2 
and MDR5 is significantly reduced (p < 0.0001) C Following P. falciparum standard membrane feeding assays 
using female A. stephensi mosquitoes, oocysts were counted at day 7 post infection in wild type NF54, 
PfΔmdr2, PfΔmdr3 and PfΔmdr5 parasites. Oocyst production of parasites lacking MDR2 and MDR5 expression 
was significantly reduced (p < 0.0001), however, oocyst production of PfΔmdr3 was unaffected (p > 0.05). D 
The number of sporozoites that could be isolated from the salivary glands of the infected mosquitoes was 
decreased for PfΔmdr2 (p < 0.05) and PfΔmdr5 (p = 0.05), but not for PfΔmdr3 (p > 0.05) parasites isolated at day 
14-16 or 18 post infection. Each data point represents the average number of sporozoites from 10 dissected 
mosquitoes in an experiment. E Oocyst number and maturity was substantially decreased at day 16 in P. berghei 
gene deletion lines compared to WT, as shown by GFP positivity in whole midguts and sporogony per oocyst 
in phase-contrast microscopy. F Strongly decreased formation of mature oocysts in PbΔmdr2 and PbΔmdr5 as 
visualized by mature GFP-expressing oocyst. Both WT and mutant parasites express GFP under control of the 
ama1 promotor that is only active in mature oocysts that undergo sporogony.
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Figure 4A), which may suggest that this protein is located on the food vacuole membrane as P. berghei 
trophozoites and gametocytes have many small food vacuoles. In mature schizonts these food vacuoles 
merge into one or two large vesicles containing hemozoin, and it is in these vesicles that we also observe 
fluorescent signal; Figure 4A). In addition, we found fluorescence signals associated with the plasma 
lemma of blood stages, which is especially clear in merozoites of mature schizonts.
We also observed fluorescence signals during oocyst development (Figure 4B). From day 10 onwards, 
before sporozoite formation, we observe a highly structured fluorescence pattern within the oocyst 
possibly associated with early sporoblast formation269 In more mature oocysts, when sporozoite 
formation is observed, the fluorescence signal becomes more diffuse but it is only associated with the 
areas within the oocyst where sporozoites are present and are budding from the sporoblasts. 
Figure 4. Localization of PbMDR2::mCherry
Expression of MDR2::mCherry during P. berghei blood (A) and mosquito (B) stage development. Upper 
row represents mCherry expression, middle row is combined expression of cytoplasmic GFP (green) and 
MDR2::mCherry (red), lower row shows phase-contrast and nuclear Hoechst33342 (blue) staining. A Shown 
are parasites during ring, trophozoite, merozoite and male as well as female gametocyte stages. B Shown are 
oocysts 10, 14, 17 and 18 days after the mosquito bloodmeal and a salivary gland-associated sporozoite.
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Infectivity of PbΔmdr2 or PbΔmdr5 salivary gland sporozoites was tested by intravenous injection of 
10,000 parasites into mice. All mice (n=3) developed blood stage infection after a prepatent period 
of 5-6 days which is comparable to the prepatent period of WT sporozoites215.
In conclusion, PbMDR2 and PbMDR5 play an important role in both oocyst formation and 
maturation as well as sporozoite development. In the mutants lacking these proteins, lower total 
numbers of oocysts were observed, and in addition to a lower percentage of fully mature oocysts, 
this resulted in strongly reduced sporozoite formation. No evidence was found that sporozoites 
that were produced in parasites lacking MDR2 or MDR5 expression had a lower infectivity to mice.
P. falciparum MDR2 and MDR5 play a role during mosquito stage sporogony
Oocyst and sporozoite formation was also analyzed in the P. falciparum mutants PfΔmdr2, PfΔmdr3, 
and PfΔmdr5. Gametocytes of these parasites were fed to Anopheles stephensi mosquitoes using a 
standard membrane feeding assay153. First, oocysts in mosquito midguts were quantified 7 days 
post infection in 1 to 7 independent feeding experiments. Oocyst production in PfΔmdr3-infected 
mosquitoes (50 ± 6 oocysts; n=1, 20 mosquitoes) was not significantly different (p > 0.05) from wild 
type infected mosquitoes (75 ± 7 oocysts; n=7, 120 mosquitoes). This is in contrast with PbΔmdr2 
and PbΔmdr5 infected mosquitoes, where the number of oocysts was significantly reduced (both 
p < 0.0001) to only 18 ± 2 oocysts (n=6, 120 mosquitoes) and 11 ± 2 oocysts (n=4, 60 mosquitoes), 
respectively (Figure 3C). Sporozoite formation was analyzed by determining the mean in 10 
mosquitoes per experiment by salivary gland dissection at 14-16 or 18 days post infection. In 
infected mosquitoes, the number of salivary gland sporozoites was significantly reduced to only 
17.2% (p < 0.05) for PfΔmdr2 (n=3) and borderline significant (p = 0.05) to 30.3% for PfΔmdr5 (n=3) 
compared to NF54 WT (n=6) (Figure 3D). In contrast, mosquitoes fed on PfΔmdr3 (n=3) had wild 
type levels of salivary gland sporozoites (Figure 3D). 
 
DISCUSSION
In this study, we analyzed the role of seven MDR proteins during the life cycle of P. berghei and 
P. falciparum malaria parasites using reverse genetic methods. As a first screen, all seven genes 
were targeted for deletion in the P. berghei rodent model since for this parasite highly efficient and 
standardized methods exist for deletion of genes by double cross-over homologous constructs 
using linear DNA constructs. Despite multiple attempts to delete the mdr1, mdr4, mdr6 and mdr7 
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genes from the P. berghei genome, we could not select gene deletion mutant parasites. These results 
suggest that these genes are essential for blood stage multiplication. In addition, the unsuccessful 
attempts to delete the genes encoding for MDR1270 and MDR6 (this study) in P. falciparum supports 
our findings in P. berghei that these proteins are essential for blood stage development of malaria 
parasites. We therefore focused on the function of the mdr2, mdr3, and mdr5 genes that could be 
deleted from the P. berghei genome and generated equivalent mutants in P. falciparum. 
Mdr2, mdr3, and mdr5 were successfully deleted in P. berghei and P. falciparum. In P. berghei, data from 
Northern analysis (this paper) and RNAseq analysis 271 indicated that these three genes are transcribed 
in blood stages, suggesting that they play a role during blood stage development. Also by analyzing a 
mutant expressing a mCherry-tagged version of MDR2 we found expression in asexual blood stages 
and in gametocytes. The fluorescence signals were associated both with hemozoin crystals and with 
the surface of parasites suggesting a location in both the membrane of food vacuoles surrounding the 
hemozoin crystals and in the plasma lemma membrane.  Although the ability to delete these genes may 
indicate that other proteins compensate for the loss MDR transporter function, the reduced growth we 
observed for P. berghei blood stages lacking expression of MDR3 and MDR5 does suggest a role of these 
proteins in these stages. The lack of a growth phenotype in blood stages of the P. berghei mutant lacking 
MDR2 suggests either the absence of a function in blood stages or complete compensation of its role by 
other proteins. Also for the P. falciparum genes evidence is present for blood stage expression, both at 
the transcript and protein level (Table S2). However, and in contrast to the P. berghei results, we did not 
find evidence for a decreased growth rate for the Pfmdr3 and Pfmdr5 gene deletion mutants, whereas 
the maximal parasitemia that was reached in cultures of PfΔmdr2 parasites was significantly lower at day 
7 compared to WT parasites. This may indicate that the function of the orthologous MDR proteins differ 
between blood stages of P. berghei and P. falciparum or that in P. falciparum blood stages the loss of the 
MDR3 and MDR5 proteins can be completely compensated by other proteins, whereas in P. berghei 
blood stages only the function of MDR2 can be fully compensated by (an)other protein(s). However, 
these discrepancies may also be due to different assays used for analysis of blood stage growth. For 
P. berghei, blood stage growth was determined in vivo whereas P. falciparum growth was analyzed 
under in vitro conditions. Although here we describe Pfmdr2 as a dispensable gene in vitro, the T484I 
polymorphism is identified as a genetic background marker for kelch13 mutations258, highlighting the 
possible importance of this gene for parasite survival within artemisinin-treated hosts. 
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Further analysis of the mutants lacking expression of MDR2 and MDR5 demonstrated that these 
proteins play a role in the formation of oocysts and sporozoites in both P. berghei and P. falciparum. 
Whereas P. falciparum MDR5 expression has been shown previously by analysing proteomes of 
sporozoites (Table S2), MDR2 expression had not been reported in mosquito stages. MDR2 had only 
been detected in proteomes of P. falciparum asexual blood stages and gametocytes. By analyzing 
the Pbmdr2::mCherry mutant, we show here for the first time expression of MDR2 in oocysts and in 
sporozoites. Expression in these stages is in agreement with our observations of reduced sporogony in 
mutants lacking expression of MDR2. Absence of these proteins results in strongly reduced oocyst and 
sporozoite (except for PfΔmdr5) formation compared to WT parasites. Whereas in P. berghei we found 
a more pronounced reduction of PbΔmdr2 compared to PbΔmdr5 oocyst numbers, in P. falciparum the 
effect was more severe in mutants lacking MDR5 expression. The effect of MDR2 or MDR5 absence on P. 
berghei maturation was most clearly visualized in the parasite mutants where only fully mature oocysts 
express GFP, as a strong and significant reduction in GFP-positive oocysts was observed compared to 
the parent line. In both P. berghei and P. falciparum, the absence of MDR2 and MDR5 did not result in a 
complete block of sporozoite formation. We demonstrated that P. berghei sporozoites lacking either 
MDR2 or MDR5 were infectious to mice, resulting in blood stage infections with prepatent periods that 
were comparable to WT sporozoites. These observations suggest that these proteins have no function 
during sporozoite invasion of hepatocytes or during subsequent liver stage development. 
ABC transport proteins play an important role in maintaining homeostasis in many organisms, 
and could be of special importance for parasites interacting with their host cell environment from 
which they require essential nutrients and where they dispose toxic waste products. Identification 
of the vital role of these transporters in different stages of the parasite life cycle may reveal novel 
drug targets for inhibition of parasite development and transmission prevention. In this study, we 
present evidence that P. berghei mdr1, 4, 6, 7, and P. falciparum mdr6 are likely to be essential for 
asexual multiplication, highlighting the potential of these transporters or their substrates as drug 
targets for treating blood stage malaria. Furthermore, mdr2 and 5 play a significant role in mosquito-
stage development in both species. Further unraveling their involvement in physiological pathways 
could lead to novel strategies to target parasite transmission, and the determination of substrate 
specificity of these transporters is therefore an essential next step.
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Unsuccessful 
attempts
Gene ID P. falciparum 
orthologue
DNA 
construct 
name
Experiment 
No1
Parent line2 RMgmDB ID3
mdr1 PBANKA_123780 PF3D7_0523000 pL1617 1624, 1656, 
1724
1037m1f1cl1 
676m1cl1
RMgm-1158
mdr4 PBANKA_040120 PF3D7_0302600 pL1725 1820, 1881, 
1929, 2040
1037m1f1cl1 RMgm-1159
mdr6 PBANKA_136480 PF3D7_1352100 pL1923 2128, 2144, 
2145, 2160
1037m1f1cl1 
676m1cl1
RMgm-1160
mdr7 PBANKA_060830 PF3D7_1209900 pL1629 1665, 2103, 
1728
1037m1f1cl1 
676m1cl1
RMgm-1161
Mutants Gene ID P. falciparum 
orthologue
DNA 
construct 
name
Experiment 
No1
Parent line2 RMgmDB ID3
∆mdr2-a PBANKA_131170 PF3D7_1447900 pL1724 1928cl3 1037m1f1cl1 RMgm-1165
∆mdr2-b 2135cl1 676m1cl1 RMgm-1166
∆mdr5-a PBANKA_135330 PF3D7_1339900 pL1726  2041cl1 1037m1f1cl1 RMgm-1168
∆mdr5-b 2137cl1 676m1cl1 RMgm-1169
∆mdr3 PBANKA_090350 PF3D7_1145500 pL1985 2308cl1 1037m1f1cl1 RMgm-1167
Table S1: Targeting P. berghei MDR  genes for deletion: unsuccessful attempts and mutants generated
1  Experiment number for independent transfection experiments: the unsuccessful attempts and the experiment number/
clone of the gene deletion mutants
2 Parent P. berghei ANKA  line in which the genes were targetted for deletion
3  The ID number of the mutants (or of the unsuccessful attempts for gene deletion) in the RMgm database (www.pberghei.eu) 
of genetically modified rodent malaria parasites
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Protein Gene ID mRNA               Protein
P. berghei As1 Gct1 Ook2 Sp2 As3 Gct4
MDR1 PBANKA_123780 ++ ++ + - + ++
MDR2 PBANKA_131170 + - - - +/- -
MDR3 PBANKA_090350 + - - - - -
MDR4 PBANKA_040120 + - - - - -
MDR5 PBANKA_135330 + + - +/- - -
MDR6 PBANKA_136480 + - + +/- - -
MDR7 PBANKA_060830 + + - - - -
P. falciparum As5 Gct5 Sp6 As3 Gct3 Ooc3 Sp3
MDR1 PF3D7_0523000 ++ ++ +/- ++ ++ - -
MDR2 PF3D7_1447900 +/- +/- +/- ++ ++ - -
MDR3 PF3D7_1145500 +/- +/- +/- +/- - - -
MDR4 PF3D7_0302600 +/- +/- +/- +/- +/- - +/-
MDR5 PF3D7_1339900 +/- +/- +/- +/- + - ++
MDR6 PF3D7_1352100 + +/- +/- - +/- - -
MDR7 PF3D7_1209900 + +/- +/- - + - -
Table S2. Expression profile of Plasmodium mdr genes 
AS, asexual stages; Gct, gametocytes; Ook, ookinetes; Ooc, oocysts; Sp, sporozoites
1 Rodent malaria gene expression (+ = 21-100 ; ++ >100)272 
2 PlasmoDB EST data (+/- = 1-5 ESTs)
3 PlasmoDB proteome data (+/- = 1-2; + = 3-10; ++ > 10)
4 PbANKA Male vs female gametocyte proteome 273
5 PlasmoDB RNAseq (FPKM) data (+/- < 10; + = 10-20; ++ > 20)
6 PlasmoDB oligo array (+/- = 1-10) RMA value (log2)
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Construct Basic 
construct
# Sequences Restriction 
sites
Description
Gene deletion constructs
Pbmdr1 pL1617 pL0001 1 GGGGGTACCATTTTTT-
GAATGGTGCTTCC
Asp718I 5’- mdr1 
targeting 
region F
2 GGGAAGCTTCTCTTTC-
TCAACTTCATGTTTG
HindIII 5’- mdr1 
targeting 
region R
3 GGGGAATTCCTGTTTAC-
AAAAATAGTGGC
EcorI 3’-mdr1 
targeting 
region F
4 GGGTCTAGACGGGGTAT-
GTATCTGTAAATTTTC
XbaI 3’- mdr1 
targeting 
region R
Pbmdr2 pL1724 pL0001 5 GGGGGTACCGGGTATA-
ATATATATTCGTC
Asp718I 5’- mdr2 
targeting 
region F
6 GGGAAGCTTCCGAAA-
GTGTTGTATATCC
HindIII 5’- mdr2 
targeting 
region R
7 GGGGAATTCGTACTAT-
ATCCTCAGCAGAATC
EcorI 3’- mdr2 
targeting 
region F
   8 GGGTCTAGACGGTACG-
CATATACTCAGG
XbaI 3’- mdr2 
targeting 
region R
Pbmdr3 pL1985 pL0001 9 GGGGGTACCCTTTTTG-
TGCAATTATAATGGG
Asp718I 5’- mdr3 
targeting 
region F
10 GGGAAGCTTCCTCATA-
TTCAATGCTACAACC
HindIII 5’- mdr3 
targeting 
region R
11 GGGGAATTCCTTTACA-
GATGGGTATTTG
EcorI 3’- mdr3 
targeting 
region F
   12 GGGTCTAGACCAAAAT-
TCGATCATAACAC
XbaI 3’- mdr3 
targeting 
region R
Pbmdr4 pL1725 pL0001 13 GGGGGTACCGTTGCTTAT-
CGTATTATGGG
Asp718I 5’- mdr4 
targeting 
region F
14 GGGAAGCTTCCCAG-
CAGTTTCATGTTTC
HindIII 5’- mdr4  
targeting 
region R
15 GGGGAATTCCCACA-
ATTAAGCATTGTG
EcorI 3’- mdr4  
targeting 
region F
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Construct Basic 
construct
# Sequences Restriction 
sites
Description
   16 GGGTCTAGAGCATAT-
GTACACACATACATGTG
XbaI 3’- Mmdr4 
targeting 
region R
Pbmdr5 pL1726 pL0001 17 GGGGGTACCATGTC-
TCTCATTTTTGAG
Asp718I 5’- mdr5 
targeting 
region F
18 GGGAAGCTTCTTAC-
AAAGGTTATTCCC
HindIII 5’- mdr5 
targeting 
region R
19 GGGGAATTCCAATG-
TCTTCTGGACAGAAAC
EcorI 3’- mdr5 
targeting 
region F
   20 GGGTCTAGAGTGGAT-
GTTGCATATGTATGG
XbaI 3’- mdr5 
targeting 
region R
Pbmdr6 pL1923 pL0001 21 GGGGGTACCATTTTT-
TGAATGGTGCTTCC
Asp718I 5’- mdr6 
targeting 
region F
22 GGGAAGCTTGGTGT-
GATATTTTTGAAC
HindIII 5’- mdr6 
targeting 
region R
23 GGGGAATTCGCAAA-
CATATTTCATAAATTATCC
EcorI 3’- mdr6 
targeting 
region F
   24 GGGTCTAGACACAAA-
AAATATGGAATGCTCG
XbaI 3’- mdr6 
targeting 
region R
Pbmdr7 pL1629 pL0001 25 Asp718I 5’- mdr7 
targeting 
region F
26 GGGAAGCTTGCTAC-
TAAGCATGCGAAGC
HindIII 5’- mdr7 
targeting 
region R
27 GGGGAATTCGGATCA-
TTTTTATCGGGTGGTC
EcorI 3’- mdr7 
targeting 
region F
   28 GGGTCTAGAGTGC-
ATATATACATGTACAC
XbaI 3’- mdr7 
targeting 
region R
Pfmdr3 pHHT-
FRT-(GFP)-
Pfmdr3
pHHT-FRT-
(GFP)-Pf52
29 GGGGCGCGCCTTT-
TCATGAATTTAAAGCC
BssHII 5’- mdr3 
targeting 
region F
pHHT-
FRT-(GFP)-
Pfmdr3
pHHT-FRT-
(GFP)-Pf52
30 GGGCGTACGTCTC-
TTAAAAGGATGAGG
BsiWI 5’- mdr3 
targeting 
region R
pHHT-
FRT-(GFP)-
Pfmdr3
pHHT-FRT-
(GFP)-Pf52
31 GGGCCCGGGTCGA-
ATGGATTAACAAATG
XmaI 3’- mdr3 
targeting 
region F
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 pHHT-
FRT-(GFP)-
Pfmdr3
pHHT-FRT-
(GFP)-Pf52
32 GGGGCTAGCGTCT-
CGTTAAATAACCATC
NheI 3’- mdr3 
targeting 
region R
Pfmdr6 pHHT-
FRT-(GFP)-
Pfmdr6
pHHT-FRT-
(GFP)-Pf52
33 GGGGCGCGCTTTCC-
AATGAGCCAACG
BssHII 5’- mdr6 
targeting 
region F
pHHT-
FRT-(GFP)-
Pfmdr6
pHHT-FRT-
(GFP)-Pf52
34 GGGCGTACGCATTT-
ATTATAAAAACTGCGC
BsiWI 5’- mdr6 
targeting 
region R
pHHT-
FRT-(GFP)-
Pfmdr6
pHHT-FRT-
(GFP)-Pf52
35 GGGCCCGGGCGTCC-
TAGATGAACATGCAAG
XmaI 3’- mdr6 
targeting 
region F
 pHHT-
FRT-(GFP)-
Pfmdr6
pHHT-FRT-
(GFP)-Pf52
36 GGGGCTAGCGAAATG-
ATATGTACATTATACAGG
NheI 3’- mdr6 
targeting 
region R
     
Construct Basic 
construct
# Sequences Restriction  
sites
Description
Gene tagging constructs
Pbmdr2 pMTP-IM-
Pbmdr2
pBAT-SIL6 37 AATCCTAGGTTTGGAAAGT-
AATCCAAATACTAATCG
AvrII 3’- Mdr2 
insert F
38 ATAGGTACCATAATTGCTTT-
ATTTCATATATCGATGG
KpnI 3’- Mdr2 
insert R
39 AATCCGCGGCTCAAGATAC-
TATATTATTTAATGAAACG
SacII C terminus 
insert F
   40 AAAGAATTCAATATCGTTAT-
TACCAGATTGCATATT
EcoRI C terminus 
insert R
Table S3 Targeting constructs and primers
Gene No. Sequences Description
Pb diagnostic primers
Pbmdr1 41 CCTATACATGTATAACTAC Mdr1 5’- in F
42 TAGTCAGAATTCAAGGGTG Mdr1 3’- in R
Pbmdr2 43 GGTTGATATATAAAGGTAGAG Mdr2 5’- in F
 44 GGATACAATGCTGTATCTTC Mdr2 3’- in R
Pbmdr2::mCherry-3xMyc 45 CTGAAGGAGATATTAAAATAGGAGG Mdr2 5’ F
46 CCCTCCATGTGAACCTTGAAG mCherry R
47 ATGAAATACCGCTCCATTTTTCC 5’ DHFR F
48 CAAAAAATCTGGATATATTATTTATACATGC Mdr2 3’ R
Pbmdr3 49 GAAGGGATGTTATACACG Mdr3 5’- in F
 50 CTGTACCTGTATTTGGAG Mdr3 3’- in R
Pbmdr4 51 GTATATTACATACATGCAC MDR4 5’- in F
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Gene No. Sequences Description
 52 GTATTATTTGCGCAGGCATG MDR4 3’- in R
Pbmdr5 53 GTGCATGATATATATAAGTGTG Mdr5 5’- in F
 54 GTTGAAAAGGGAAAGATGAG Mdr5 3’- in R
Pbmdr6 55 GCATATGTAGAAGCTTGC Mdr6 5’- in F
 56 GATGTGATCGGAAGGCCATC Mdr6 3’- in R
Pbmdr7 57 GGGTGGAGGTTTTAAAGAGG Mdr7 5’- in F
 58 TGCTCATAATGTGTTTATCC Mdr7 3’- in R
Pb SM primers
5’ in R 59 TTGACCTGCAGGCATGCAAGC Mdr1 ORF, F
3’ in F 60 GATTCATAAATAGTTGGAC Mdr1 ORF, R
 Pf diagnostic primers
Pfmdr3 61 CTTTTCATGAATTTAAAGCC Mdr3 5’-  long range F
Pfmdr3 62 AAGAAGACTTATCCGATATG Mdr3 3’- long range R
Pfmdr3 63 TGTATAGTACCGAATTACATGAATG Mdr3 ORF F
Pfmdr3 64 CTCGTAAATCTGCCGCTTATATG Mdr3 ORF R
 
Table S4 Analytical primers 
 
Figure S1. Schematic of the strategy of Pfmdr3 deletion and genotyping of the PfΔmdr3 mutant. 
Upon transfection of the HHT-FRT-(GFP)-Pfmdr3 construct and positive selection with WR99210, mutants 
are selected in which the construct integrates into either the 5’ or 3’ target region (TR) in the wild type 
locus. Subsequent negative selection on 5-fluorocytosine selects for mdr gene replacement by the positive 
selectable marker cassette harboring the hdhfr::gfp fusion gene flanked by FRT sites (blue triangles). This 
results in selection of parasites with the Pfmdr3 gene deleted (PfΔmdr3). cam: calmodulin; hdhfr::gfp: human 
dihydrofolate reductase fused to green fluorescent protein; hrp: histidine rich protein; hsp: heat shock protein; 
mdr: multidrug resistance; Scfcu: Saccharomyces cerevisiae cytosine deaminase/uracil phosphoribosyl-
transferase; Pbdt: P. berghei dhfr terminator; FRT: flippase recognition target; p: primer; TR: target region.
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Figure S2. Pbmdr4 tagging and lo calization
A The mrp gene was C-terminally tagged with a 3xHA-tag using a PlasmoGem DNA construct (PbGEM-084058; 
pL1995) that integrates by double cross-over integration and contains the hdhfr/yfcu selectable marker (sm). 
B Genotyping of mdr4::3xHA by Southern analysis of separated chromosomes (chr.) and diagnostic PCR. 
Hybridisation with the 3’-UTR dhfr/ts probe recognizes the endogenous P. berghei dhfr/ts gene on chr. 7 and the 
integrated DNA construct in the mdr4 locus on chr. 4. C Expression of MDR4::3xHA was shown by IFA analysis of 
blood stage parasites using anti-HA antibodies and Alexa488 (green) and DAPI nuclear staining (red). 
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INTRODUCTION
ATP-binding cassette (ABC) transporters are evolutionary well-conserved membrane proteins that 
are involved in cellular multidrug resistance. They actively extrude xenobiotics, which results in 
decreased drug concentrations at target sites in many organisms, including the malaria parasite 
Plasmodium falciparum. As their function in Plasmodium species remained a rather unexplored 
territory, we aimed to study all ABC transport proteins in P. falciparum as well as the rodent model 
organism P. berghei. In the latter we targeted all 9 ABC transport genes148 for deletion and obtained 
mutant parasites for Pbmdr2, Pbmdr3, Pbmdr5 and Pbabcg1. After multiple ineffectual attempts to 
obtain viable parasites after removal of Pbmdr1, Pbmdr4, Pbmdr6 and Pbmdr7, we concluded that 
these genes are essential for blood stage multiplication and parasite survival. The deletion of Pbmrp 
orthologues Pfmrp1 and Pfmrp2 was subsequently performed in P. falciparum. As the parasite has to 
undergo complete transformation more than once during its life cycle, adaptations of Plasmodium 
to very diverse environments is required. Therefore, we did not only study the phenotype in asexual 
stages, but also during mosquito- and liver-stage development. 
Interaction of antimalarial compounds with human ABC transporters
Human ABC transport proteins may affect antimalarial drug effectivity through alterations of 
local drug concentrations and drug-drug interactions with co-medication at the transporter site. 
Therefore we studied the interaction of chloroquine, quinine, artemisinin, mefloquine, lumefantrine, 
atovaquone, dihydroartemisinin and proguanil with transport activity of P-glycoprotein (P-
gp/MDR1), breast cancer resistance protein (BCRP/ABCG2), bile salt export pump (BSEP/ABCB) 
and multidrug resistance-associated proteins (MRP/ABCC) 1–4 was assessed in Chapter 2, 
using a vesicular transporter overexpression assay. The strong inhibitory effect of quinine and 
mefloquine on P-gp-mediated transport and of mefloquine, atovaquone and proguanil on that 
of BCRP indicate that indeed these export proteins may be involved in drug-drug interaction with 
substrates of these transporters. For both atovaquone and quinine, significant inhibition of BCRP 
and P-gp, respectively, was observed at concentrations that are pharmacologically relevant during 
drug treatment regimens. Indeed, reports of suspected clinical interactions with atovaquone 
included azithromycin, etravirine, saquinavir, efavirenz, lopinavir/ritonavir and atazinavir/ritonavir 
co-mediaction111,112,121. Other compounds that are known to interact with BCRP-mediated transport 
are fluoroquinolone antibiotics, kinase inhibitors, cytostatics, antifolates, and statins123-129. These 
Manuscript_SR_DEF.indd   112 21-04-16   07:57
113
General Discussion
drugs are not widely used in malaria-endemic areas, however, interactions with prophylactic doses 
of atovaquone used by travelers can be anticipated. Interactions with quinine have been described 
for ritonavir/lopinavir combination therapy as well as ritonavir monotherapy, and for nevirapine, 
rifampicin, lopinavir, cyclosporine, and digoxin134-136,139-141. Although quinine is not used any more 
in first-line treatment strategies, its use has increased as it is often applied as an alternative 
treatment after artemisinin-based combination therapy (ACT) stock-outs145 and for treatment of 
malaria infections in pregnant women146. Adherence to this compound is known to be low due to 
frequently occurring side effects, which are often plasma concentration-dependent147. For these 
reasons, establishing effective but non-toxic plasma concentrations is essential, and interaction 
with co-administered compounds that mediate P-gp transport should be monitored. Especially 
the interaction of both atovaquone and quinine with antiretroviral medication could have severe 
implications on treatment strategies for both infections, as HIV is another major health issue in 
sub-Saharan regions of Africa99. Many different antiretroviral compounds are being prescribed, 
depending on personal characteristics and resistance status, and interactions with BCRP have 
been described for many of these compounds. Drug-drug interactions of atovaquone and quinine 
with antiretroviral medication could have severe implications on treatment strategies; unperceived 
decreased concentrations due to alterations in transport efficiency can lead to earlier antiretroviral 
therapy treatment failure or parasite recrudescence, and could have a large impact on morbidity.
The contribution of ABC transporters to Plasmodium drug sensitivity
In order to study the contribution of ABC transport proteins of Plasmodium parasites to drug 
sensitivity, we deleted the encoding genes in P. berghei. Drug sensitivity assays on these transporter 
knockout lines gave no phenotype with conventional anti-malarial compounds (unpublished 
results)274. Multiple factors potentially influenced this outcome, such as the short duration of the 
assays (24 hours), the quality of the parasites at inoculation and the improved development of P. 
berghei parasites in reticulocytes, which are scarce in peripheral blood samples used for culturing 
in these assays274. P. falciparum drug sensitivity assays were performed on the mrp1 and mrp2 
gene deletion mutants, and similarly show  no effect for the selected drugs, except for a small 
decrease in mefloquine sensitivity (Chapter 4).  Raj et al. did find an increase in sensitivity of MRP1-
deficient mutants to chloroquine, quinine, artemisinin, piperaquine and primaquine, resulting in 
a decreased IC50 concentration in the chloroquine-resistant W2 strain
64. We, however, deleted the 
MRP-encoding genes in a sensitive parasite background, NF54, and the generally low transport 
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capacity of endogenously expressed ABC transport proteins further reduced the chance of 
detection of differential sensitivity. Moreover, we removed the selectable marker though enhanced 
flippase (FLPe)-mediated recombination, whereas the deletion of mrp1 by Raj et al. was exerted in 
a single crossover fashion, and heterologous DNA including the selectable marker was maintained. 
These discrepancies in the model organisms may (partially) explain the differential outcomes in 
antimalarial sensitivity.
Plasmodium ABC transporter substrate identification
The identification of specific Plasmodium ABC transporter substrates is of critical importance to explore 
their physiological roles in (fundamental) cellular processes, such as homeostasis and signaling. A 
recently described untargeted metabolomic approach by Jansen et al.155, has been developed for the 
crude detection of differentially distributed physiological substrates in extracellular compartments 
of wild type versus mrp-deleted cells. In this way, differential export of metabolites can be detected 
in the extracellular matrix, a technique we applied on our mrp-deleted P. falciparum parasites as 
described in Chapter 3. We did indeed detect decreased folate concentrations in the red blood cell 
compartment of PfΔmrp1 schizont-infected erythrocytes, which was confirmed with targeted liquid 
chromatography/tandem mass spectrometry (LC/MS-MS). As folate is a known substrate of human 
MRP transport proteins, it is likely that it is exported by PfMRP1192.
A role of MRP protein expression in folate homeostasis, rather than involvement in autocrine or 
signaling pathways, has been suggested in humans166. The conservation of de novo synthesis enzymes 
in Plasmodium species167,168 underlines the high demand for folate during specific life cycle stages in 
which proliferation is unparalleled169. Although folate is involved in multiple processes including DNA 
translation initiation and methylation of DNA and proteins, its function as one-carbon donor in purine 
synthesis is most fundamental and explains its high consumption during cellular replication170,171. The 
extent to which folate is exported in other proliferative life cycle stages such as the oocyst- and liver 
stages, still needs to be explored. Furthermore, alternative substrates may be more abundant in these 
life cycle stages. However, obtaining large quantities of purified mosquito and liver stage parasites 
required for such metabolomic studies has proven to be a great challenge.
We observed a significantly reduced sensitivity of mrp1-deleted parasites for the antifolate 
methotrexate. Because of reduced export, folate concentrations are presumably increased, which 
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could have effectively antagonized the improved affinity of methotrexate for dihydrofolate 
reductase (DHFR), resulting in decreased methotrexate sensitivity. The beneficial effect of 
an increased folate concentration on survival of antifolate treatment has been observed 
previously184,186. However, the anti-folates pyrimethamine, WR99210 and trimethoprim did not 
show a differential effect. Antifolates inhibit folate synthesis at two levels; (1) during de novo 
synthesis, where the para-aminobenzoic acid (pABA) and hydroxymethyl dihydropteridine 
pyrophosphate components are joined into dihydrofolate by the hydroxymethyl dihydropteridine 
pyrophosphokinase – dihydropteroate synthase enzyme complex, or (2) during conversion of 
dihydrofolate to tetrahydrofolate by the DHFR enzyme. Sulfadoxine, sulfalene, sulfamethoxazole 
and dapsone are structural analogues of pABA. The sulfa-adducts that are incorporated with 
these compounds lead to inhibition of enzyme activity downstream in folate metabolism. DHFR 
is the target of a second set of anti-malarial antifolates: pyrimethamine, proguanil, methotrexate, 
trimethoprim and WR99210. These compounds in general bind to DHFR with increased affinity, 
thereby inhibiting its function. Methotrexate is the only structural analogue of folate, and the 
resistance towards this compound of mrp1-deleted parasites may therefore be explained by direct 
competition at the DHFR binding pocket. 
Other more fundamental questions regarding the characteristics of substrate-transporter 
interaction, such as type of enzyme kinetics and the effect of amino acid substitutions on 
substrate specificity, cannot be answered using this metabolomics approach. Therefore, functional 
expression and direct measurement of vesicular transport of potential substrates in a heterologous 
overexpression system would be the method of choice, by using either radiolabelled compounds 
or LC/MS-MS detection100,275. Alternative options to identify substrates include the application of 
specific inhibitors and/or cellular accumulation assays to evaluate reduced translocation that can 
be attributed to the function of specific ABC transporters276,277. However, Plasmodium studies are 
faced with multiple obstacles. The selectivity of currently available inhibitors for ABC transport 
proteins is poor, while heterologous overexpression remains a technical challenge as P. falciparum 
DNA is extremely AT rich typically constituting 70-80% of the open reading frame. Mutation-free 
PCR amplification of the large ABC transporter coding genes37 is another stumble block as codon 
usage is very atypical in Plasmodium species. This hampers effective translation in heterologous 
organisms where truncation has been observed162. Functional expression of P. falciparum MDR1 
has been reported in Pichia pastoris and Xenopus laevis oocytes41,43. In our hands, however, 
Manuscript_SR_DEF.indd   115 21-04-16   07:57
116
CHAPTER 6 General Discussion
expression of PfMRP1 and PfMRP2 has remained unsuccessful278. Future attempts might work with 
larger availability of custom-designed DNA sequences in which codon-usage can be optimized 
or harmonized. Since heterologous overexpression failed in E. coli, Xenopus laevis oocytes, Sf9 
insect cells and Dyctiostelium discoideum, expression in Toxoplasma gondii might be an attractive 
alternative. This apicomplexan parasite is closely related to Plasmodium species and shares distinct 
biological properties, such as the presence of an apicoplast as well as a high content of A and T 
bases in genomic DNA with distinct codon usage279. Toxoplasma gondii can be easily manipulated, 
which would aid the introduction of P. falciparum genes. Different types of yeast could be also tried 
for functional PfABC transporter expression, as these cells can sometimes be optimized for proteins 
that are difficult to express280. Endogenous overexpression in Plasmodium species could also be 
attempted through epigenetic expression or promoter swapping. Major disadvantages of this 
strategy are the difficulties in Plasmodium manipulation, especially when large constructs need to 
be transduced, and the large-scale cultures that need to be processed in order to obtain substantial 
parasite specific membrane fractions, as we experienced ourselves (unpublished results).
Essential role of MRP2 for hepatic development
While MRP transporters of the ABCC subfamily could be stably deleted in both P. berghei and P. 
falciparum, MRP2 appeared to be essential for liver-stage development, as described in Chapter 4. Mrp2-
deficient parasites readily invade hepatocytes at WT rates and establish a parasitophorous vacuole (PV) 
as shown by the expression and correct localization of exported protein 1 (EXP1), but are unable to 
form mature liver schizonts as shown by the reduced size, annihilated nuclear multiplication and the 
absence of MSP1, a marker for merozoite formation239.  In fact, the lack of mrp2 alone results in complete 
developmental arrest of liver stages, while the phenotype of the mrp1 gene deletion mutant does not 
alter in any of the P. falciparum life cycle stages. This indicates that MRP2 transports essential substrates 
during liver-stage development, a function that apparently cannot be compensated for by MRP1 or 
other (ABC) transporters. Rodent Plasmodium species encode only a single MRP protein, whereas in 
human parasites two members have been identified. The single copy abcc gene of P. berghei seems 
to be the syntenic ortholog of Pfmrp2 as it shows a higher sequence similarity to Pfmrp2, suggestive 
for functional orthology of the P. berghei MRP protein and PfMRP2. Indeed, upon the deletion of the P. 
berghei mrp gene, we observed a phenotype of aborted liver-stage development comparable to Pfmrp2 
deletion. 
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This important finding creates exciting opportunities for clinical development of drug leads 
specifically targeting pre-erythrocytic stages and/or whole sporozoite-based vaccines. As 
treatment of malaria infections is threatened by the emergence and spread of drug resistance 
including artemisinins8,281, and with a renewed impulse for malaria elimination, measures 
preventing clinical episodes of malaria are urgently required. Interventions during liver stage 
infection are an elected opportunity to battle infection before symptoms arise; for instance by 
targeting the parasite using pharmaceuticals. The demand for effective liver-stage drugs is 
specifically high, because the only effective pre-erythrocytic drug that is currently available is 
primaquine282. This compound unfortunately causes hemolysis in individuals carrying glucose-6-
phosphate dehydrogenase (G6PD) deficiency283, common in malaria endemic regions, which is also 
compromising the effective treatment of hypnozoites and thus malaria relapse in P. vivax-infected 
individuals. As MRP2 is essential for hepatocytic-stage development of the parasite, targeting this 
protein or its substrates could be a valuable novel strategy.
Vaccination against pre-erythrocytic stages would be a powerful tool to control or even eliminate 
malaria. Subunit vaccination strategies have proven notoriously difficult. The only subunit 
vaccine candidate that is currently completing phase three of clinical trials, RTS,S284, is based on 
circumsporozoite surface protein (CSP), and unfortunately does not show efficacy exceeding 36,3%, 
which is likely insufficient for elimination strategies285. Pre-erythrocytic stage immunizations with 
attenuated whole sporozoites have proven their superior potential285, as sterile protection can be 
achieved using the different strategies. These include radiation-attenuated sporozoites (RAS)286, or 
under cover of chemo-prophylaxis (CPS)287. However, for mass administration both strategies are 
suboptimal, as irradiated sporozoites represent a genetically diverse population and adherence 
and efficiency of prophylactic strategies in chemical attenuation is essential to prevent episodes 
of vaccine-induced malaria. Another strategy comprehends of the application of genetically 
attenuated sporozoites (GAS), which constitute of a genetically homogenous population without 
the need for application of pharmaceuticals to prevent breakthrough to blood stage infection240.
A number of rodent GAS have previously been reported to arrest at early time points during 
development in the liver240,242. These include GAPs based on genes essential for the formation 
and maintenance of a PV (b9, p52, p36, uis3 and uis4; 243-245), type II fatty acid synthesis (i.e. fabb/f, 
fabz, pdh e1α;246,247), and regulation of gene expression (sap1/slarp248-250). However, many of these 
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deletion mutants show leaky phenotypes, resulting in blood stage infections. Incomplete liver 
stage arrest obviously disqualifies GAPs for further clinical development for safety reasons. The 
PbΔmrp2 gene deletion mutant, however, showed no breakthrough to blood-stage infection upon 
injection with a high doses (300.000) sporozoites in C57bl/6 mice, the most sensitive mouse model. 
The only alternative GAP candidate that arrests completely during liver stage is lacking the sap1/
slarp gene3,249,250,252. This GAP arrests early after hepatocyte invasion, as these parasites do not 
construct a functional PV249,250. Immunization with Slarp deleted parasites, however, does not result 
in consistent protection250,288. Moreover, there is evidence that GAP immunizations with a later 
arresting phenotype induce superior immune responses resulting in higher protection in mice, 
presumably through the prolonged presentation of a larger repertoire of antigens 253,254. Parasites 
lacking MRP2 develop to a further extent compared to the safe and early arresting GAP, as nuclear 
division is observed with formation of a PV maintained and they persist minimally for the duration 
of a normal liver stage infection in hepatocytes. The presumed prolonged presentation of a larger 
repertoire of antigens, including PV-associated proteins such as EXP1, may be a benefit for efficient 
induction of protective immunity. In preliminary experiments, we have immunized BALB/c mice 
with low dose PbΔmrp2 sporozoites, indeed resulting in protection against a WT challenge. Further 
experiments are needed in the more stringent C57BL/6 mouse model to characterize the protective 
potential of this GAP, including long-term protection. Comparing multiple GAP candidates should 
give a final verdict on the benefit of these later arresting sporozoites.
For the application of safe GAP vaccination strategies, it has been previously suggested that a minimum 
of two essential genes have to be deleted in order to ensure parasite stability and minimize the risk of 
reversion to a vital phenotype during liver stage development215. Vaccine candidates that are currently 
being evaluated for human administration, however, lack two essential genes that are involved in similar 
pathways of membrane biogenesis, resulting in absence of a PV during liver stage development. The 
deletion of two genes in unrelated pathways that play vital roles in parasite development during liver 
stage would be a more ideal safety measure, minimizing the chance that adaptation of the parasite 
could lead to an effective completion of the liver stage and consequent blood stage infection upon 
vaccination. As MRPs are a different class of proteins with functions in alternative cellular processes, a 
tandem deletion with mrp2 would be an attractive safety measure. So far, additional proteins known 
to play a vital role during the later stages of intra-hepatic parasite development are not identified yet, 
which for now restricts the opportunity to take advantage of PfΔmrp2 as a late stage arrester.
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Plasmodium falciparum liver stage assay
Improvement of the liver stage assay for human Plasmodium parasites is of essential importance, 
as currently, in vitro options are scarce and notoriously result in very limited numbers of infected 
hepatocytes. Not only the production of large numbers of liver stage parasites could hold the key 
to the characterization of parasite biology during this stage, including the identification of MRP2 
substrates and essential pathways they are involved in using metabolomics, but also sensitive 
assays are needed for detection of trace parasites that escape liver stage developmental arrest. 
Furthermore, studying P. vivax hynozoite biology for the development of drugs targeting these 
exo-erythrocytic forms (EEF) would stimulate another field that is currently under-represented. 
The only immortalized cell line supporting liver-stage development for P. falciparum are HCO4, 
indeed resulting in very low infection rates289. Furthermore, fresh primary human hepatocytes have 
been used290.  Sporozoite infection rates in these cultures (around 0,5-1% in our hands) are higher as 
compared to HCO4 cells (around 0,05% in our hands)291. The use of freshly isolated human material 
comes with significant disadvantages, as it is a labor-intense process, cells can be cultured for only 
approximately 14 days, the availability of human liver tissue is unpredictable, there is large variation 
in cell viability upon extraction and inter-donor differences in infection rates limits standardization 
of the assays.  
Novel assays should ideally fulfill the following requirements; 1) High recovery and viability after 
cryopreservation. 2) Inducible high multiplication rates to produce sufficient cells in a short amount 
of time to accommodate all required experimental conditions. 3) High sporozoite infection rates. 
Expression of CD81 is the only marker that is currently associated with parasite invasion and can 
be evaluated292, however, multiple factors are most likely involved in invasion and establishment of 
hepatocytic infection. 4) Parasites develop into fully matured schizonts. 5) Cells do not multiply during 
the infection with P. falciparum, as this would dilute the number of parasites. 
Currently, many strategies for optimization of primary human hepatocyte cultures are being 
evaluated, such as efficient cryopreservation and co-culturing of micropatterned hypatocytes with 
supportive stromal cells, which contribute beneficially to the longevity of cryopreserved primary 
hepatocytes in vitro291,293. Furthermore, growing primary human hepatocytes under hypoxic 
conditions has shown some efficacy on the increase of parasite infectivity and support in hepatic-
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stage development294 and the use of extracellular matrix mimics, including matrigel and structured 
surfaces or flowcells are being explored. For development of a routinely used in vitro hepatic-stage 
assay, the use of either human hepatocyte stem cells or immortalizing primary hepatocytic (stem)
cells that can either proliferate or differentiate in a static culture depending on temperature using 
both the temperature-sensitive mutant U19tsA58 of SV40 large T antigen (SV40T) and the essential 
catalytic subunit of human telomerase (hTERT) system295,296 might be novel strategies holding 
potential of studying hepatocyte-related processes for many purposes.
Vital and dispensable roles of Plasmodium MDR transporters
In Chapter 5, we revealed another physiological role of ABC transporters in P. berghei. The majority 
of MDR encoding genes (mdr1, mdr4, mdr6 and mdr7) could not be deleted and are apparently 
essential for blood-stage multiplication. Mdr2, mdr3, and mdr5 have been successfully deleted in 
both P. berghei and P. falciparum. These three genes are transcribed in blood stages (www.plasmodb.
org)271, suggesting that they play a role during this developmental phase. Although the ability to 
delete these genes may indicate that other proteins compensate for the loss of MDR transporter 
function, the reduced growth we observed for P. berghei blood stages lacking expression of MDR5 
strongly suggest a role in these stages. However, and in contrast to the P. berghei results, we did 
not observe a decreased growth rate for the Pfmdr3 and Pfmdr5 gene deletion mutants, whereas 
maximal parasitaemia was inhibited in Pfmdr2 deletion mutants. This may indicate that the function 
of the orthologous MDR proteins differs between blood stages of P. berghei and P. falciparum or that 
in P. falciparum the loss of these MDR proteins can be compensated by other proteins. However, 
these discrepancies may also be due to different assays used for analysis of blood stage growth. For 
P. berghei, blood stage growth was determined in vivo, whereas P. falciparum growth was analyzed 
under in vitro conditions.
Mdr2 and mdr5 knockout parasites showed compromised formation of oocysts and maturation 
of sporozoites in P. berghei and strongly reduced oocyst and sporozoite numbers in P. falciparum. The 
effect of mdr2 or mdr5 deletion on P. berghei maturation was most clearly visualized in the parasite 
mutants where only fully mature oocysts express GFP, as a strong and significant reduction in GFP-
positive oocysts was observed. In both P. berghei and P. falciparum, the absence of MDR2 and MDR5 
did not result in a complete block of sporozoite formation. These proteins apparently play a role, 
although non-essential, in oocyst maturation, and more detailed investigation of the substrates and 
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pathways that are involved in this mechanism may provide valuable information on oocyst biology and 
opportunities to interfere with parasite development during transmission stages. 
Options for P. falciparum gene manipulation
ABC transport proteins play an important role in maintaining homeostasis in many organisms, and 
could be of special importance for parasites interacting with their host cell environment from which 
they require essential nutrients and to where they dispose of toxic waste products. For example, 
MDR transport proteins are known to play a role in lipid metabolism and phosphatidylcholine 
transport in many organisms, and as membrane biogenesis peaks during sporozoite formation 
this might be one of the factors contributing to the observed phenotype in mosquito stage 
development297. Elucidation of the vital role of these transporters in different stages of the parasite 
life cycle may reveal novel drug targets for inhibition of parasite development and transmission 
prevention.
P. berghei mdr1, 4, 6, 7, and P. falciparum mdr6 are essential for asexual multiplication, however, we 
have not been able to study ABC transporter genes that are essential during blood stage as parasite 
transfection and selection is executed in these stages. From a biological and drug development 
perspective, these genes are of particular interest. Specific targeting of transport function of these 
Plasmodium ABC proteins could potentially lead to a novel group of anti-malarial compounds. For 
that purpose, expression regulation, conditional deletion and the introduction of single nucleotide 
mutations will be essential. Molecular techniques that can be applied to study gene function in 
other (model) organisms are unfortunately not available in P. falciparum. One example is RNA 
interference (RNAi), where short inhibitory RNA (siRNA) or short hairpin RNA (shRNA) is transfected 
into cells and accounts for mRNA degradation and consequently downregulation of protein 
expression, abusing cellular antiviral defense mechanims298. Because the encoding genes for the 
RNAi machinery are not present in Plasmodium species, manipulation at this level is not possible299. 
P. berghei parasites can be transformed during merozoite stage, because under these conditions 
only the parasite and nucleic membrane have to be crossed to target DNA. This higher transfection 
efficiency enables direct selection of double crossover parasites, into which linearized targeting 
constructs are stably integrated204. In P. falciparum, this process is much less efficient as early 
ring stage parasites can only incorporate circular DNA constructs upon electroporation, and this 
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DNA has to pass four membrane barriers; the erythrocyte, parasitophorous vacuole, plasma, and 
nucleotide membrane211,300. Furthermore, transfection efficiency declines with increasing construct 
size, implying difficulties in the introduction of large genes, such as the >6kB constructs encoding 
ABC transporter proteins204.  
Despite of these drawbacks, remarkable progression in molecular manipulation of P. falciparum 
parasites has been made in recent years. Successful application of the FLP-FRT and the Cre-loxP 
recombination systems has been reported upon optimization for P. falciparum152,301. These systems 
enable the excision of DNA sequences intermediary of two FRT or loxP sites, a technique which 
we also used for the removal of the positive selection marker and the subsequent deletion of a 
second mrp gene in order to delete the entire MRP family in P. falciparum. Besides the possibility to 
remove multiple genes with this technique, it has also been used for conditional deletions in many 
organisms by placing Cre or FLP encoding genes under control of a differentially active promoter302. 
This application has also been reported in P. berghei, where conditional deletion of genes was 
achieved by placing FLPe expression under control of a sporozoite-specific promotor241,303-305. 
However, for application in P. falciparum, the impossibility of introducing linearized DNA is 
interfering with correct integration of the FRT sites as well as practical feasibility due to prolonged 
culturing requirements. Conditional deletion of loxP-flanked sites was achieved in P. falciparum 
using a DiCre system, where Cre recombinase is expressed in two separate units containing 
rapamycin binding domains that combine and become functional upon the addition of rapamycin 
to the culture306,307. Again, the introduction of the loxP sites at the correct positions in the genome 
is challenging and time-consuming in P. falciparum. 
Another relatively new application in P. falciparum forward genetics, aiming at the identification 
of genes involved in specific phenotypes, is the piggyBac transposon system. Insertion of this 
transposon resulted in random integration into the parasite genome, however, integration into P. 
berghei genomic DNA was more efficient, most likely due to the higher transfection efficiency308,309. 
Furthermore, tagging with a destabilization domain (DD) has been attempted with some success, 
in order to target the protein for proteosomal degradation upon withdrawal of stabilizing 
compounds310-313. However, the DD tag should not affect protein function and trafficking towards 
the proteasome should not be compromised in order to achieve efficient knockdown. Recently, 
another type of post-translational regulation in the form of an auxin-based degron system has 
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been successfully applied in P. falciparum314. Although the advantage of this system is that protein 
expression can be reversed, the applicability for all targets and the effect on protein function still 
needs to be investigated. 
A leap forward in genome editing of P. falciparum was achieved in 2012 through the successful 
application of zinc finger nucleases for site-specific rearrangement of genomic DNA315. As zinc 
fingers are targeted against specific sequences and introduce double strand breaks at this site, 
insertion of large homologous regions for plasmid integration is not required. There are, however, 
limitations concerning the availability for all required sequences and the specificity for the excision 
site, as well as the time-consuming and expensive commercial design of sufficiently specific zinc 
finger combinations. These drawbacks are reflected in the lack of publications yet on applying zinc 
finger technology for genome editing. 
The successful application of a novel and exciting genome editing technique, the CRISPR/Cas9 
system, has been reported in P. falciparum316,317. In this system, the Cas9 enzyme is guided to the 
specific DNA strand using a single guide RNA, after which a double strand break is introduced. 
Template DNA is presented for double strand break repair, by which mutations can be introduced, 
and genes deleted or inserted. Major advantages of this technique are that it only requires the 
introduction of DNA plasmids and even linearized DNA was shown to be integrated, possibly due 
to the high integration efficiency.
Applying these novel techniques to study the function of essential ABC proteins could be of help 
in identifying their contribution to specific genotypes more rapidly through forward genetics. 
Especially conditional gene deletion holds the potential of identifying the exact erythrocytic 
stage at which these genes are essential and evaluate the effect of their absence in mosquito- 
and liver-stage parasites. Furthermore, the application of CRISPR/Cas9 technology can contribute 
to our knowledge of the effect of single base pair substitutions in ABC proteins on parasite drug 
sensitivity and thus transporter characteristics. As it is clear from deletion experiments that many 
ABC transporter genes are essential during different life cycle stages, applying these techniques to 
identify their substrates and physiological functions could aid in unraveling parasite biology and 
revealing specific vulnerabilities.
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Conclusion
The association of ABC transporters with drug sensitivity has been the main focus of research in 
Plasmodium species during previous years (Chapter 1). Whereas single nucleotide polymorphisms 
and variation in expression had been associated with altered drug sensitivity of the parasite, 
limited functional data were available. This thesis has given a first indication of substrates under 
physiological conditions and has underlined the vital roles of ABC transport proteins in Plasmodium 
parasite development during different life cycle stages. Next steps would be to elucidate additional 
specific substrates and identifying pathways in which these transport proteins are involved 
in different life cycle stages through over-expression and genome editing by applying novel 
techniques for conditional gene deletion and mutagenesis. Exploitation of this knowledge, either 
by drug targeting of asexuals, transmission blocking opportunities, or by using gene-deleted 
parasites in hepatic stage vaccine strategies, might provide an alternative contribution to the 
toolbox for malaria eradication.
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SUMMARY
Malaria tropica remains one of the largest threats to global health, as it results in a fatal outcome 
in approximately 600.000 cases annually. Especially children under five in countries with limited 
resources in sub-Sahara Africa are affected by the causative parasite, Plasmodium falciparum. 
An effective vaccine is not available despite of the many challenging research initiatives, and 
moreover, effective treatment is threatened by the emergence and spread of parasite resistance 
against the first-line drug class of artemisinins. ATP-binding cassette (ABC) proteins are known 
for their involvement in multidrug resistance in many organisms, as these transporters located at 
membranes can export a wide variety of compounds including drugs away from their target site. 
Also in Plasmodium falciparum, single nucleotide polymorphisms, genomic duplication or altered 
expression of these transporters has been associated with decreased drug resistance. 
In Chapter 1 we described the general structure of all ABC transporters in Plasmodium species, 
including a phylogenetic analysis. Furthermore, we provided an overview of the current knowledge 
on the association of specific mutations and expression variation of Plasmodium ABC transport 
with antimalarial sensitivity. 
Next, we explored the interaction of commonly used antimalarial compounds with human 
ABC transport proteins in Chapter 2. Vesicular transporter overexpression assays identified a 
strong inhibitory effect of quinine and mefloquine on P-glycoptorein-mediated transport and 
of mefloquine, atovaquone and proguanil on that of breast cancer resistance protein (BCRP); 
indicating that these compounds may be involved in drug-drug interaction with substrates of 
these transporters. 
In Chapter 3 we set out to identify physiological substrates of MRP1 and MRP2 transporters, which 
were stably deleted from the P. falciparum genome through double crossover recombination. 
Using an untargeted metabolomic approach and applying LC-MS/MS analysis, we identified a 
decreased concentration of folate in the red blood cell compartment of PfΔmrp1 schizont-infected 
erythrocytes. Furthermore, we performed drug sensitivity assays for a number of antifolate 
compounds, and observed a significantly reduced sensitivity of mrp1-deleted parasites for the 
antifolate methotrexate. Both results and the fact that folate is a known substrate of human MRP 
transport proteins suggest that indeed folate is exported by PfMRP1.
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Phenotype analysis of mrp-deleted parasites in different life cycle stages of P. berghei and P. 
falciparum was described in Chapter 4. Although these parasites developed normally during blood- 
and mosquito stages, MRP2 had an essential function during liver stage maturation. A fluorescently 
tagged MRP2 orthologue in P. berghei shows localization of the protein at the plasma lemma of 
the liver-stage parasite, which is confirmed for both MRP1 and MRP2 using immunofluorescence 
in P. falciparum. For both species, hepatocyte traversal and invasion of mrp2-deleted parasites was 
not affected, and also the construction of a parasitophorous vacuole was successful, as shown by 
the presence of EXP1 expression. However, nuclear multiplication was significantly inhibited, and 
parasite size and survival rates are reduced most strongly in P. falciparum. Furthermore, expression 
of MSP1, a marker for liver stage maturation, is not present in both species. Mrp2-deleted 
sporozoites could not induce blood stage infection; indicating complete liver stage attenuation. 
This represents an important novel finding, stressing the essential functions of ABC transporters 
in Plasmodium species, which can be exploited in pre-erythrocytic drug development and/or 
genetically attenuated whole sporozoite vaccination strategies.
In Chapter 5 we targeted the complete multidrug resistance (MDR) ABC transporter subfamily in 
P. berghei, and successfully deleted mdr2, mdr3 and mdr5. Despite of multiple attempts, parasites 
lacking expression of MDR1, MDR4, MDR6 and MDR7 could not be obtained, indicating that these 
proteins have essential functions during blood stage development. These results were confirmed 
in P. falciparum as attempts to delete mdr6 were unsuccessful, whereas mdr2, mdr3 and mdr5 could 
be removed. Phenotypic evaluation of mdr deleted parasites showed a reduced blood stage 
multiplication rate of PbΔmdr5 and a reduced maximal parasitemia for PfΔmdr2. More strikingly, in 
both P. berghei and P. falciparum, development of mdr2 and mdr5 deleted parasites during mosquito 
stages resulted in decreased numbers of oocysts and sporozoites. Evaluation of mdr-deletion in P. 
berghei parasites expressing GFP only in mature oocysts showed a specific effect on this stage.
The combined data showed that ABC transport proteins may play important roles in Plasmodium 
drug interactions and sensitivity, and have both essential and otherwise important functions 
during different parasite stages. Identification of specific substrates of these transporters and 
further exploration of the pathways will aid in targeting these parasites at different key point of 
their life cycle.
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SAMENVATTING
 
Malaria tropica blijft één van de grootste bedreigingen van de wereldgezondheid, aangezien het 
jaarlijks tot ongeveer 600.000 sterfgevallen leidt. Vooral kinderen jonger dan vijf jaar in de arme landen 
ten zuiden van de Sahara zijn het slachtoffer van Plasmodium falciparum, de parasiet die deze ziekte 
veroorzaakt. Ondanks jarenlang onderzoek is een zeer effectief vaccin nog niet beschikbaar, en daarbij 
wordt de huidige behandeling met artemisinine in combinatie met andere antimalariamiddelen 
bedreigd doordat resistente parasieten zijn opgedoken en zich verspreiden. ATP-binding-cassette 
(ABC)-eiwitten staan bekend om hun aandeel in het veroorzaken van resistentie tegen een groot aantal 
geneesmiddelen in verschillende organismen. Het zijn membraantransporteiwitten die een breed scala 
aan stoffen actief uit de cel kunnen pompen en daarmee wegtransporteren van hun aangrijpingspunten. 
In Plasmodium falciparum spelen mutaties of verhoogde expressie van deze transporters een rol bij een 
verlaagde gevoeligheid voor antimalariamiddelen. 
In Hoofdstuk 1 hebben we de structuur van ABC-transporters die in het genoom van Plasmodium-
parasieten gecodeerd zijn beschreven, inclusief een phylogenetische analyse. Wij hebben een 
samenvatting gegeven van de huidige kennis op het gebied van specifieke mutaties en variatie in 
expressie van Plasmodium ABC-transporters en hoe dit in verband staat met de gevoeligheid van de 
parasiet voor antimalariamiddelen.
Vervolgens hebben we in Hoofdstuk 2 de interactie onderzocht van veelgebruikte antimalariamiddelen 
met humane ABC-transporters. Experimenten met membraanvesicles waarin transporter-eiwitten tot 
over-expressie zijn gebracht lieten een sterk remmend effect zien van quinine en mefloquine op de 
transportactiviteit van P-glycoproteine, alsmede een vergelijkbaar effect van mefloquine, atovaquone 
en proguanil op transport door breast-cancer-resistance-protein (BCRP). De resultaten suggeerden 
dat deze antimalariamiddelen betrokken kunnen zijn bij interacties met andere geneesmiddelen die 
substraten zijn van deze transporters.
In Hoofdstuk 3 hebben we getracht de fysiologische substraten te identificeren van multidrug-
resistance-associated-protein MRP1- en MRP2-transporters na genetische verwijdering uit het genoom 
van P. falciparum. In een ‘non targeted’-metabolomicsstudie en LC-MS/MS-analyse hebben wij een 
verlaagde concentratie van folaat gevonden in het cytosol van erythrocyten geïnfecteerd door 
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schizonten met een Pfmrp1-deletie. Verder hebben we in sensitiviteitstesten voor een aantal antifolaten 
aangetoond dat de gevoeligheid van parasieten met een mrp1-deletie voor methotrexaat significant 
is afgenomen. Gezien het feit dat folaat een bekend substraat van humane MRP-transporters is, 
suggereerden de gecombineerde resultaten dat folaat getransporteerd wordt door PfMRP1.
Het fenotype van parasieten met een mrp-deletie is in Hoofdstuk 4 geëvalueerd in verschillende 
stadia van de levenscyclus van zowel P. berghei als P. falciparum. Hoewel beide parasieten zich 
gedurende de bloed- en muggenstadia normaal ontwikkelen, bleek MRP2 een essentiële functie te 
hebben gedurende de rijping in het leverstadium. De ortholoog van MRP2 in P. berghei lokaliseerde 
op de plasmamembraan gedurende het leverstadium wat ook geldt voor zowel MRP1 als MRP2 in 
P. falciparum. In beide speciës was de hepatocyt-passage en -invasie van parasieten met een mrp2-
deletie niet aangedaan, en bleek ook de vorming van de parasitofore vacuole onveranderd.  De 
nucleaire multiplicatie was echter wel sterk verminderd en ook overleving en groei van met name 
de P. falciparum-parasieten is sterk gereduceerd. Expressie van MSP1, een marker voor uitrijping 
in het leverstadium, was in beide speciës afwezig. P. berghei- mrp2-deletie mutanten gaven 
geen bloedstadium infectie waarmee voor het eerst een essentiële rol van ABC-transporters in 
Plasmodium werd aangetoond. Dit biedt mogelijkheden voor ontwikkeling van vaccins en nieuwe 
geneesmiddelen. 
In Hoofdstuk 5 hebben we geprobeerd alle genen van de multidrug-resistance (MDR) ABC-
transportersubfamilie te verwijderen uit het genoom van P. berghei, wat is gelukt voor mdr2, mdr3 
en mdr5, maar niet voor mdr1, mdr4, mdr6 en mdr7. Dit wijst erop dat deze eiwitten waarschijnlijk 
een essentiële functie hebben gedurende de ontwikkeling van de parasiet in het bloedstadium. 
Vergelijkbare resultaten werden verkregen in P. falciparum, waarin het ook onmogelijk is gebleken 
mdr6 te verwijderen, terwijl parasieten met een mdr2-, mdr3- en mdr5-deletie wel geproduceerd 
konden worden. Fenotypische analysen van parasieten met een deletie van één van deze genen 
lieten zien dat er een verminderde groei gedurende het bloedstadium was voor P. berghei-
parasieten zonder expressie van MDR5, en dat de maximale parasitemie lager was voor P. falciparum-
parasieten zonder MDR2-expressie. Nog opvallender was dat in zowel P. berghei en P. falciparum 
de ontwikkeling van parasieten met een mdr2- of mdr5-deletie gedurende het muggenstadium 
resulteerde in verminderde aantallen oöcysten en sporozoïten. Nadere bestudering van P. berghei 
parasieten met een mdr-deletie waarbij alleen volledig uitgerijpte oöcysten een fluorescent signaal 
gaven, liet zien dat specifiek deze uitrijping was verstoord.
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Concluderend laten deze resultaten een belangrijke rol van humane ABC-transporters zien bij 
geneesmiddeleninteracties met antimalariamiddelen. Voorts vervullen deze transporters essentiële 
functies gedurende de verschillende ontwikkelingsstadia van de parasiet. De identificatie van 
specifieke endogene substraten van deze transporters en verder onderzoek naar de biologische 
mechanismen bieden nieuwe mogelijkheden om de parasiet te bestrijden gedurende belangrijke 
fases in de levenscyclus.
Manuscript_SR_DEF.indd   157 21-04-16   07:57
158
CHAPTER 7 Epilogue
LIST OF PUBLICATIONS
Rijpma SR*, van der Velden M*, Annoura T, Matz JM, Kentirapalan S, Kooij TWA, Matuschewski 
K, van Gemert GJ, van der Vegte-Bolmer M, Siebelink-Stoter R, Graumans W, Ramesar J, Klop O, 
Russel FGM, Sauerwein RW, Janse CJ, Franke-Fayard BM, Koenderink JB Vital and dispensable 
roles of Plasmodium multidrug resistance transporters during blood- and mosquito-stage 
development Mol Microbiol, 2016 Mar 15
*Authors contributed equally to this study
Rijpma SR, van der Velden M, Bilos A, Jansen RS, Mahakena S, Russel FGM, Sauerwein RW, van 
de Wetering K, Koenderink JB MRP1 mediates folate transport and antifolate sensitivity in 
Plasmodium falciparum FEBS letters. 2016 Feb;590(4):482-92.
Stone WJR, Dantzler KW, Nilsson SK, Drakeley CJ, Marti M, Bousema T, Rijpma SR Naturally 
acquired immunity to sexual stage P. falciparum parasites Parasitology. 2016 Feb;143(2):187-98.
Rijpma SR, van der Velden M, González-Pons M, Annoura T, van Schaijk BCL, van Gemert GJ, 
van den Heuvel JMW, Ramesar J, Chevalley-Maurel S, Ploemen IH, Khan SM, Franetich JF, Mazier 
D, de Wilt JHW, Serrano AE, Russel FGM, Janse CJ, Sauerwein RW*, Koenderink JB*, Franke-Fayard 
BM* Multidrug ABC transporters are essential for hepatic development of Plasmodium 
sporozoites Cell Microbiol. 2016 Mar;18(3):369-83.
*Authors contributed equally to this study
van der Velden M, Rijpma SR, Russel FG, Sauerwein RW, Koenderink JB PfMDR2 and PfMDR5 are 
dispensable for Plasmodium falciparum asexual parasite multiplication but change in vitro 
susceptibility to anti-malarial drugs. Malar J. 2015 Feb 14;14:76.
Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB 
Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. 
Malar J.  Sep 13;13:359.
Manuscript_SR_DEF.indd   158 21-04-16   07:57
159
Epilogue
Annoura T, van Schaijk BC, Ploemen IH, Sajid M, Lin JW, Vos MW, Dinmohamed AG, Inaoka DK, 
Rijpma SR, van Gemert GJ, Chevalley-Maurel S, Kiełbasa SM, Scheltinga F, Franke-Fayard BM, Klop 
O, Hermsen CC, Kita K, Gego A, Franetich JF, Mazier D, Hoffman SL, Janse CJ, Sauerwein RW, Khan 
SM Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage 
development. FASEB J. 2014 May;28(5):2158-70.
Koenderink JB, Kavishe RA, Rijpma SR & Russel FG The ABCs of multidrug resistance in malaria. 
Trends Parasitol. 2010 Sep;26(9):440-6.
Patents:
Sauerwein RW, Rijpma SR, Janse CJ, Fayard BM, Kahn SM, Russel FGM, Koenderink JB A genetically 
attenuated, live organism of the Plasmodium genus. World Intellectual Property Organization, 
WO2015/132338, 11 September 2015
Manuscript_SR_DEF.indd   159 21-04-16   07:57
160
CHAPTER 7 Epilogue
CURRICULUM VITAE
Sanna Rijpma was born in 1985 in Dunedin, New-
Zealand, as the daughter of a Frisian father and Dutch 
mother. After almost four years, her family moved back 
to the Netherlands and she spent her youth with her two 
younger sisters in Silvolde. There she went to the Almende 
College, Isala site high school, where she was educated in 
the Nature and Technical as well as the Nature and Health 
profile, with additional subjects economy and geography. 
She graduated cum laude, and spent a semester at 
the RijksUniversiteit Groningen, where she studied 
international relations and international organizations. Then, she started her bachelor biomedical 
sciences at the Radboud University Nijmegen, during which she was a representative for monitoring 
quality of education, and did an internship at the department of Pharmacology and Toxicology, 
entitled “Cloning and expression of ABC-transporters from Plasmodium falciparum”. For this work, 
she was awarded the Dr. J. Bex prize in 2007 for best bachelor’s thesis in biomedical sciences. During 
her master’s studies she completed a research profile in toxicology and pathobiology and did an 
internship at the RIVM National Institute for Public Health and the Environment in the Laboratory 
of Health Protection Research on “Reproductive toxicity of Selective Serotonin Reuptake Inhibitors 
antidepressants in the Embryonic Stem cell Test”. Furthermore, she did an internship at the NKI, the 
Dutch Cancer Institute, at the Division of Molecular Biology, entitled “Characterization of cell cycle 
checkpoints in cisplatin-surviving Brca-1; p53-deficient mouse mammary cancer cells”, for which 
she was awarded the Faculty prize of the Radboud University for best master’s thesis in biomedical 
sciences.  She obtained an UMC St. Radboud personal grant for her PhD project, which she set out 
to do on ABC transport proteins in Plasmodium falciparum, resulting in this dissertation. Currently, 
she is working at the department of Medical Microbiology at the Radboudumc in the group of Teun 
Bousema on molecular and immonological mechanisms of malaria transmission.
Manuscript_SR_DEF.indd   160 21-04-16   07:57
161
Epilogue
ACKNOWLEDGEMENTS
I have been in a fortunate position during my PhD as I was surrounded by numerous talented, 
inspiring, sympathetic and humorous people. It would have been impossible to complete this 
thesis without your help, and although I want to address you specifically in this chapter, I sincerely 
hope you know who you are and I have expressed my gratitude throughout this journey.
Dear Frans Russel, you have offered me the opportunity to write my own PhD proposal. You have 
supported my work throughout the project, and especially at difficult decision point and during 
harsh times I have experienced this as a steady drive. Robert Sauerwein, I am grateful for your 
critical broader view, as well as the fact that you created the conditions that enabled the molecular 
work on ABC transport proteins. Jan Koenderink, although this project has proven to be a bumpy 
road, we did ride it together. Thank you for seeing me through.
Chris Janse, your contribution to two main chapters of this thesis has been invaluable. Thank you for 
your intellectual input, experience and the fact that you would always make time to discuss experiments 
and rebuttals. Also Blandine Franke-Fayard, it has been an enormous pleasure to collaborate with 
you, thank you for your hospitality and determinedness into transporter related work. 
Maarten, I have been extremely fortunate to be able to team up with you, as one of the most 
sympathetic and critical people I know. I wish you the brightest future after your PhD, although I 
believe science would have hugely benefited from your contribution. Ben, you have introduced 
me to molecular malaria, although advising me, on my first day, never to do a PhD in malaria :-). 
I have enjoyed your sparkling personality and mentoring talks. As well as our trips to Paris with 
Martijn, who has been the steady factor that I could always ask for hands-on advise, for instance in 
seemingly impossible cloning issues.
The Pharm/Tox department is widely known for its atmosphere, which is solely contributable to 
the people whom I got to work with. Reginald, thank you for introducing me into malaria research 
with great patience and thoroughness. Kim, Rick M, Alwin, Bas, Frank, Jeroen, Janny, Ab, 
Hanneke, Anita, Rachel, Karl, Elnaz, Julien, Rick G, Martijn, Tom, Pedro, Jitske, Lindsey,  Bas, 
Daniëlle, Saloua, Petra, Lillibeth and Wendy; only you understand the full meaning of frozen 
Manuscript_SR_DEF.indd   161 21-04-16   07:57
162
CHAPTER 7 Epilogue
confetti, alu-wrapping-tastic and Christmas-rocking-dinner. Although our projects diverted, cross-
contamination with research ideas has been of significant importance. Also thanks to my students; 
Patty, Monique, Harm and Jasper, who taught met equally much. Special thanks to Paul Smits, 
as you have inspired me to write my own research proposal, leading to this project. Furthermore to 
Roos Masereeuw, as female role model in a heavily male-dominated research environment.
At the department of Medical Microbiology, I have always felt extremely welcome, enjoyed the 
work discussions and extra-curricular activities. Thanks for your interest in a typical topic, the ABC 
transport proteins, and all the technical and theoretical input I have received; Ivo, Krystelle, Anja, 
Anne, Marije, Maarten, Joachim, Theo, Will, Rob, Taco, Karina, Annemieke, Guido, Else, Jona 
and Isaïe. For some people, simple genetics is insufficiently fulfilling; thanks Richard, Wieteke, 
Sabine, Christa and Rob for adding that additional layer of epi-complexity. Furthermore, thanks 
to the people of TropIQ, Koen, Karin, Judith and Martijn T.
At the malaria unit, many people have supported my projects, for which I am very grateful. From a 
mosquito point-of-view, the help and in-depth advise of Geert-Jan, with his lovely ladies Jolanda, 
Laura, Astrid and Jacqueline has been fundamental. For advise on parasite, and especially 
gametocyte, culturing, the contribution of Marga, Rianne and Wouter has been of great 
importance. Thank you for welcoming and supporting me in the malaria unit!
In Leiden, I was always welcomed by Onny, Saj, Shahid, Severine, Catherin, Jay and Hans, and 
loved the molecular discussions. At the institute Pitié-Salpêtrière we were able to do the first liver 
experiments, for which I am gratefull Dominique Mazier. Thanks for the investment of multiple 
evenings, nights and weekend days; Jean-Francois and Valérie. Many thanks to Hans de Wilt 
for your enthusiasm and cooperation; without your help, chapter 4 would have been virtually 
impossible. Many thanks to Koen van de Wetering, Robert en Sunny for applying their novel 
transportomic tactics on a novel target; the malaria parasite. 
For introducing me into the next chapter of malaria research, I would like to thank Teun Bousema. I 
am grateful for your trust, inspiring guidance and contagious enthousiasm and greatly enjoy doing 
multiple projects with multiple research groups. Team members Kjerstin, Will, Fitsum, Helmi, 
Lisette, Amrish and Joshua; it’s an utmost pleasure working with you.
Manuscript_SR_DEF.indd   162 21-04-16   07:57
163
Epilogue
For watching over my mental sanity; thanks to Lieke, Rosa, Noortje, Sietske and Janneke, as I 
couldn’t have wished for better friends. Thanks to the people of Musical Productions Gelderland, 
for providing the opportunity to lose my normal self once in a while. My in-law family Leon, Jos, 
Julia, Ine, Henny, Daan, Sabine, Ghijs, who have always been interested and supportive. To my 
sisters, Simone and Myrthe, for whom a few words suffice for understanding. To my mother Corry, 
who taught me I could achieve anything if I tried, and my father Yde, from whom I inherited my 
beta-oriented brain. To Coen, the love in my life; Rosemijn and Florens, the light in my life.
Alea iacta est
Sanna
Manuscript_SR_DEF.indd   163 21-04-16   07:57
164
CHAPTER 7 Epilogue
Manuscript_SR_DEF.indd   164 21-04-16   07:57
